


=>

Uploading C:\Program Files\Common Files\System\Mapi\1033\NT\09773736.str



chain nodes :

20 71 72 73 74 75 76 77 81

ring nodes :

1 2 3 4 5 6 7 8 9 10 13 14 15 16 17 18 21 22 23 24 25 26 27
 28 29 30 31 32 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 60
 61 62 63 64

ring/chain nodes :

82 83

chain bonds :

20-71 71-81 72-74 73-75 73-83 74-76 74-82 75-77

ring bonds :

1-2 1-5 2-3 3-4 4-5 6-7 6-10 7-8 8-9 9-10 13-14 13-18 14-15 15-16
 16-17 17-18 21-22 21-26 22-23 23-24 24-25 25-26 27-28 27-32 28-29 29-30
 30-31 31-32 39-40 39-43 40-41 41-42 42-43 44-45 44-48 45-46 46-47 47-48
 49-50 49-53 50-51 51-52 52-53 60-61 60-64 61-62 62-63 63-64

exact/norm bonds :

1-2 2-3 3-4 6-7 7-8 8-9 20-71 71-81 72-74 73-75 73-83 74-76 74-82
 75-77

exact bonds :

1-5 4-5 6-10 9-10 39-40 39-43 40-41 41-42 42-43 44-45 44-48 45-46 46-47
 47-48 49-50 49-53 50-51 51-52 52-53 60-61 60-64 61-62 62-63 63-64

normalized bonds :

13-14 13-18 14-15 15-16 16-17 17-18 21-22 21-26 22-23 23-24 24-25 25-26
 27-28 27-32 28-29 29-30 30-31 31-32

isolated ring systems :

containing 1 : 6 : 13 : 21 : 27 : 39 : 44 : 49 : 60 :

G1:[*1],[*2]

G2:[*3-*4],[*5-*6],[*7-*8],[*9-*10],[*11-*12],[*13-*14],[*15-*16]

G3:[*17],[*18]

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 20:CLASS 21:Atom 22:Atom
 23:Atom 24:Atom 25:Atom 26:Atom 27:Atom 28:Atom 29:Atom 30:Atom 31:Atom
 32:Atom 39:Atom 40:Atom 41:Atom 42:Atom 43:Atom 44:Atom 45:Atom 46:Atom
 47:Atom 48:Atom 49:Atom 50:Atom 51:Atom 52:Atom 53:Atom 60:Atom 61:Atom
 62:Atom 63:Atom 64:Atom 71:CLASS 72:CLASS 73:CLASS 74:CLASS 75:CLASS
 76:CLASS 77:CLASS 81:CLASS 82:CLASS 83:CLASS

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

=> s l1 sss sam

SAMPLE SEARCH INITIATED 07:04:40 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 7035 TO ITERATE

14.2% PROCESSED 1000 ITERATIONS
 INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
 SEARCH TIME: 00.00.01

0 ANSWERS

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
 BATCH **COMPLETE**

PROJECTED ITERATIONS: 135673 TO 145727
 PROJECTED ANSWERS: 0 TO 0

L2 0 SEA SSS SAM L1

=> s l1 sss ful

FULL SEARCH INITIATED 07:05:15 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 138334 TO ITERATE


100.0% PROCESSED 138334 ITERATIONS
 SEARCH TIME: 00.00.02

0 ANSWERS

L3 0 SEA SSS FUL L1

=>

Uploading C:\Program Files\Common Files\System\Mapi\1033\NT\09773736 (a).str



chain nodes :

20 71 72 73 74 75 76 77 81

ring nodes :

1 2 3 4 5 6 7 8 9 10 13 14 15 16 17 18 21 22 23 24 25 26 27
28 29 30 31 32 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 60
61 62 63 64

ring/chain nodes :

82 83

chain bonds :

20-71 71-81 72-74 73-75 73-83 74-76 74-82 75-77

ring bonds :

1-2 1-5 2-3 3-4 4-5 6-7 6-10 7-8 8-9 9-10 13-14 13-18 14-15 15-16
16-17 17-18 21-22 21-26 22-23 23-24 24-25 25-26 27-28 27-32 28-29 29-30
30-31 31-32 39-40 39-43 40-41 41-42 42-43 44-45 44-48 45-46 46-47 47-48
49-50 49-53 50-51 51-52 52-53 60-61 60-64 61-62 62-63 63-64

exact/norm bonds :

1-2 1-5 2-3 3-4 4-5 6-7 6-10 7-8 8-9 9-10 20-71 71-81 72-74 73-75
73-83 74-76 74-82 75-77

exact bonds :

39-40 39-43 40-41 41-42 42-43 44-45 44-48 45-46 46-47 47-48 49-50 49-53
50-51 51-52 52-53 60-61 60-64 61-62 62-63 63-64

normalized bonds :

13-14 13-18 14-15 15-16 16-17 17-18 21-22 21-26 22-23 23-24 24-25 25-26
27-28 27-32 28-29 29-30 30-31 31-32

isolated ring systems :

containing 1 : 6 : 13 : 21 : 27 : 39 : 44 : 49 : 60 :

G1:[*1],[*2]

G2:[*3-*4],[*5-*6],[*7-*8],[*9-*10],[*11-*12],[*13-*14],[*15-*16]

G3:[*17],[*18]

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 20:CLASS 21:Atom 22:Atom
 23:Atom 24:Atom 25:Atom 26:Atom 27:Atom 28:Atom 29:Atom 30:Atom 31:Atom
 32:Atom 39:Atom 40:Atom 41:Atom 42:Atom 43:Atom 44:Atom 45:Atom 46:Atom
 47:Atom 48:Atom 49:Atom 50:Atom 51:Atom 52:Atom 53:Atom 60:Atom 61:Atom
 62:Atom 63:Atom 64:Atom 71:CLASS 72:CLASS 73:CLASS 74:CLASS 75:CLASS
 76:CLASS 77:CLASS 81:CLASS 82:CLASS 83:CLASS

L4 STRUCTURE UPLOADED

=> d l4

L4 HAS NO ANSWERS

L4 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

=> s l4 sss sam

SAMPLE SEARCH INITIATED 07:07:05 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 7035 TO ITERATE

14.2% PROCESSED 1000 ITERATIONS 37 ANSWERS
 INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
 SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
 BATCH **COMPLETE**

PROJECTED ITERATIONS: 135673 TO 145727
 PROJECTED ANSWERS: 4238 TO 6172

L5 37 SEA SSS SAM L4

=> =>Testing the current file.... screen

ENTER SCREEN EXPRESSION OR (END):end

=> screen 1839


L6 SCREEN CREATED

=> screen 2016 OR 2026 OR 2039 OR 2040 OR 2045 OR 2047

L7 SCREEN CREATED

=>

Uploading C:\Program Files\Common Files\System\Mapi\1033\NT\09773736 (b).str



chain nodes :

20 71 72 73 74 75 76 77 81 84 85 86 87 88 89 90 91 92 93 94 95
96 97 98 99 100 101 102 103

ring nodes :

1 2 3 4 5 6 7 8 9 10 13 14 15 16 17 18 21 22 23 24 25 26 27
28 29 30 31 32 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 60
61 62 63 64

ring/chain nodes :

82 83

chain bonds :

13-86 15-84 16-85 18-87 20-71 21-91 23-88 25-89 26-90 27-95 30-92 31-93
32-94 41-96 42-97 46-98 48-99 52-100 53-101 61-102 64-103 71-81 72-74
73-75 73-83 74-76 74-82 75-77

ring bonds :

1-2 1-5 2-3 3-4 4-5 6-7 6-10 7-8 8-9 9-10 13-14 13-18 14-15 15-16
16-17 17-18 21-22 21-26 22-23 23-24 24-25 25-26 27-28 27-32 28-29 29-30
30-31 31-32 39-40 39-43 40-41 41-42 42-43 44-45 44-48 45-46 46-47 47-48
49-50 49-53 50-51 51-52 52-53 60-61 60-64 61-62 62-63 63-64

exact/norm bonds :

1-2 1-5 2-3 3-4 4-5 6-7 6-10 7-8 8-9 9-10 20-71 71-81 72-74 73-75
73-83 74-76 74-82 75-77

exact bonds :

13-86 15-84 16-85 18-87 21-91 23-88 25-89 26-90 27-95 30-92 31-93 32-94
39-40 39-43 40-41 41-42 41-96 42-43 42-97 44-45 44-48 45-46 46-47 46-98
47-48 48-99 49-50 49-53 50-51 51-52 52-53 52-100 53-101 60-61 60-64
61-62 61-102 62-63 63-64 64-103

normalized bonds :

13-14 13-18 14-15 15-16 16-17 17-18 21-22 21-26 22-23 23-24 24-25 25-26
 27-28 27-32 28-29 29-30 30-31 31-32
 isolated ring systems :
 containing 1 : 6 : 13 : 21 : 27 : 39 : 44 : 49 : 60 :

G1:[*1],[*2]

G2:[*3-*4],[*5-*6],[*7-*8],[*9-*10],[*11-*12],[*13-*14],[*15-*16]

G3:[*17],[*18]

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 20:CLASS 21:Atom 22:Atom
 23:Atom 24:Atom 25:Atom 26:Atom 27:Atom 28:Atom 29:Atom 30:Atom 31:Atom
 32:Atom 39:Atom 40:Atom 41:Atom 42:Atom 43:Atom 44:Atom 45:Atom 46:Atom
 47:Atom 48:Atom 49:Atom 50:Atom 51:Atom 52:Atom 53:Atom 60:Atom 61:Atom
 62:Atom 63:Atom 64:Atom 71:CLASS 72:CLASS 73:CLASS 74:CLASS 75:CLASS
 76:CLASS 77:CLASS 81:CLASS 82:CLASS 83:CLASS 84:CLASS 85:CLASS 86:CLASS
 87:CLASS 88:CLASS 89:CLASS 90:CLASS 91:CLASS 92:CLASS 93:CLASS 94:CLASS
 95:CLASS 96:CLASS 97:CLASS 98:CLASS 99:CLASS 100:CLASS 101:CLASS 102:CLASS
 103:CLASS

L8 STRUCTURE UPLOADED

=> que L8 AND L6 NOT L7

L9 QUE L8 AND L6 NOT L7

=> d l9

L9 HAS NO ANSWERS

L6 SCR 1839

L7 SCR 2016 OR 2026 OR 2039 OR 2040 OR 2045 OR 2047

L8 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

L9 QUE L8 AND L6 NOT L7

=> s l9 sss sam

SAMPLE SEARCH INITIATED 07:12:54 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 6918 TO ITERATE

14.5% PROCESSED 1000 ITERATIONS
 INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
 SEARCH TIME: 00.00.01

14 ANSWERS

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
 BATCH **COMPLETE**

PROJECTED ITERATIONS: 133375 TO 143345

PROJECTED ANSWERS: 1347 TO 2527

ENTER SCREEN EXPRESSION OR (END):end

=> screen 1839


L11 SCREEN CREATED

=> screen 2016 OR 2026 OR 2039 OR 2040 OR 2045 OR 2047

L12 SCREEN CREATED

 \Rightarrow

Uploading C:\Program Files\Common Files\System\Mapi\1033\NT\09773736 (c).str



chain nodes :

20	71	72	73	74	75	76	77	81	84	85	86	87	88	89	90	91	92	93	94	95
96	97	98	99	100	101	102	103	104	106											

ring nodes :

[illegible]

ring/chain nodes :

82 83

chain bonds :

13-86 15-84 16-85 18-87 20-71 21-91 23-88 25-89 26-90 27-95 30-92 31-93
32-94 41-96 42-97 46-98 48-99 52-100 53-101 61-102 64-103 71-81 72-74
73-75 73-83 74-76 74-82 75-77

ring bonds :

1-2 1-5 2-3 3-4 4-5 6-7 6-10 7-8 8-9 9-10 13-14 13-18 14-15 15-16
16-17 17-18 21-22 21-26 22-23 23-24 24-25 25-26 27-28 27-32 28-29 29-30
30-31 31-32 39-40 39-43 40-41 41-42 42-43 44-45 44-48 45-46 46-47 47-48
49-50 49-53 50-51 51-52 52-53 60-61 60-64 61-62 62-63 63-64

exact/norm bonds :

1-2 1-5 2-3 3-4 4-5 6-7 6-10 7-8 8-9 9-10 20-71 71-81 72-74 73-75
73-83 74-76 74-82 75-77

exact bonds :

13-86 15-84 16-85 18-87 21-91 23-88 25-89 26-90 27-95 30-92 31-93 32-94
39-40 39-43 40-41 41-42 41-96 42-43 42-97 44-45 44-48 45-46 46-47 46-98
47-48 48-99 49-50 49-53 50-51 51-52 52-53 52-100 53-101 60-61 60-64
61-62 61-102 62-63 63-64 64-103

normalized bonds :

13-14 13-18 14-15 15-16 16-17 17-18 21-22 21-26 22-23 23-24 24-25 25-26
27-28 27-32 28-29 29-30 30-31 31-32

isolated ring systems :

containing 1 : 6 : 13 : 21 : 27 : 39 : 44 : 49 : 60 :

G1:[*1],[*2]

G2:[*3-*4],[*5-*6],[*7-*8],[*9-*10],[*11-*12],[*13-*14],[*15-*16]

G3:[*17],[*18]

G4:[*19],[*20]

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 20:CLASS 21:Atom 22:Atom
23:Atom 24:Atom 25:Atom 26:Atom 27:Atom 28:Atom 29:Atom 30:Atom 31:Atom
32:Atom 39:Atom 40:Atom 41:Atom 42:Atom 43:Atom 44:Atom 45:Atom 46:Atom
47:Atom 48:Atom 49:Atom 50:Atom 51:Atom 52:Atom 53:Atom 60:Atom 61:Atom
62:Atom 63:Atom 64:Atom 71:CLASS 72:CLASS 73:CLASS 74:CLASS 75:CLASS
76:CLASS 77:CLASS 81:CLASS 82:CLASS 83:CLASS 84:CLASS 85:CLASS 86:CLASS
87:CLASS 88:CLASS 89:CLASS 90:CLASS 91:CLASS 92:CLASS 93:CLASS 94:CLASS
95:CLASS 96:CLASS 97:CLASS 98:CLASS 99:CLASS 100:CLASS 101:CLASS 102:CLASS
103:CLASS 104:Atom 106:CLASS

Generic attributes :

104:

Saturation : Unsaturated

106:

Saturation : Saturated

Element Count :

Node 106: Limited

C,C1-8

L13 STRUCTURE UPLOADED

=> que L13 AND L11 NOT L12

L14 QUE L13 AND L11 NOT L12

=> d l14

L14 HAS NO ANSWERS

L11 SCR 1839

L12 SCR 2016 OR 2026 OR 2039 OR 2040 OR 2045 OR 2047

L13 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

L14 QUE L13 AND L11 NOT L12

=> s l14 sss sam

SAMPLE SEARCH INITIATED 07:21:18 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 6918 TO ITERATE

14.5% PROCESSED 1000 ITERATIONS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

9 ANSWERS

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
 BATCH **COMPLETE**

PROJECTED ITERATIONS: 133375 TO 143345
PROJECTED ANSWERS: 772 TO 1718

L15 9 SEA SSS SAM L13 AND L11 NOT L12

=> => s l14 sss ful

FULL SEARCH INITIATED 07:22:35 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 135685 TO ITERATE



100.0% PROCESSED 135685 ITERATIONS
SEARCH TIME: 00.00.03

1072 ANSWERS

L16 1072 SEA SSS FUL L13 AND L11 NOT L12

=>

Uploading C:\Program Files\Common Files\System\Mapi\1033\NT\09773736 (sub1).str



ring nodes :

1 2 3 4 5 6 7 8 9 10 11

chain bonds :

4-6

ring bonds :

1-2 1-5 2-3 3-4 4-5 6-7 6-11 7-8 8-9 9-10 10-11

exact/norm bonds :

1-2 1-5 2-3 3-4 4-5 4-6

normalized bonds :

6-7 6-11 7-8 8-9 9-10 10-11

Match level :


1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom

L17 STRUCTURE UPLOADED

=> d 117

L17 HAS NO ANSWERS

L17 STR



Structure attributes must be viewed using STN Express query preparation.

=> s 117 sub=116 sss sam

SAMPLE SUBSET SEARCH INITIATED 07:24:10 FILE 'REGISTRY'

SAMPLE SUBSET SCREEN SEARCH COMPLETED - 21 TO ITERATE

100.0% PROCESSED 21 ITERATIONS

21 ANSWERS

SEARCH TIME: 00.00.01

PROJECTIONS (WITHIN SPECIFIED SUBSET):

ONLINE **COMPLETE**

PROJECTED ITERATIONS (WITHIN SPECIFIED SUBSET):

146 TO 694

PROJECTED ANSWERS (WITHIN SPECIFIED SUBSET):

146 TO 694

L18 21 SEA SUB=L16 SSS SAM L17

=> s 117 sub=116 sss ful

FULL SUBSET SEARCH INITIATED 07:24:17 FILE 'REGISTRY'

FULL SUBSET SCREEN SEARCH COMPLETED - 456 TO ITERATE

100.0% PROCESSED 456 ITERATIONS

452 ANSWERS



SEARCH TIME: 00.00.01

L19 452 SEA SUB=L16 SSS FUL L17

=>

Uploading C:\Program Files\Common Files\System\Mapi\1033\NT\09773736 (sub2).str

Hy^{*1} 6^{*1}



chain nodes :

6 9

ring nodes :

1 2 3 4 5

ring bonds :

1-2 1-5 2-3 3-4 4-5

exact/norm bonds :

1-2 1-5 2-3 3-4 4-5

G1:N, [*1]

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 9:CLASS 10:CLASS

Generic attributes :

6:

Type of Ring System : Polycyclic


L20 STRUCTURE UPLOADED

=> d l20

L20 HAS NO ANSWERS

L20 STR

Hy¹



G1 N, [C1]

Structure attributes must be viewed using STN Express query preparation.

=> s l20 sub=l16 sss sam

SAMPLE SUBSET SEARCH INITIATED 07:26:44 FILE 'REGISTRY'

SAMPLE SUBSET SCREEN SEARCH COMPLETED - 51 TO ITERATE

100.0% PROCESSED 51 ITERATIONS

15 ANSWERS

SEARCH TIME: 00.00.01

PROJECTIONS (WITHIN SPECIFIED SUBSET):

ONLINE **COMPLETE**

PROJECTED ITERATIONS (WITHIN SPECIFIED SUBSET):

592 TO 1448

PROJECTED ANSWERS (WITHIN SPECIFIED SUBSET):

68 TO 532

L21 15 SEA SUB=L16 SSS SAM L20

=> s l20 sub=l16 sss ful

FULL SUBSET SEARCH INITIATED 07:26:50 FILE 'REGISTRY'

FULL SUBSET SCREEN SEARCH COMPLETED - 1072 TO ITERATE

100.0% PROCESSED 1072 ITERATIONS
SEARCH TIME: 00.00.01

350 ANSWERS

L22 350 SEA SUB=L16 SSS FUL L20

=> s 119 or 122

L23 767 L19 OR L22

=> s 116 not 123

L24 305 L16 NOT L23

=> => s 124

L25 88 L24

=> d 125 1-88 bib,ab,hitstr

L25 ANSWER 1 OF 88 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 2004:311011 CAPLUS
 DN 140:321649
 TI Preparation of pyrazolyl glycoside derivatives as inhibitors of
 1,5-anhydroglucitol/fructose/mannose transporters
 IN Fujikura, Hideki; Kikuchi, Norihiko; Tazawa, Shigeki; Yamato, Tokuhisa;
 Isaji, Masayuki
 PA Kissei Pharmaceutical Co., Ltd., Japan
 SO PCT Int. Appl., 159 pp.
 CODEN: PIXXD2
 DT Patent
 LA Japanese
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004031203	A1	20040415	WO 2003-JP12477	20030930
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRAI	JP 2002-293090	A	20021004		
	JP 2002-330694	A	20021114		
	JP 2002-378959	A	20021227		
AB	The title compds. [I; R = each (un)substituted C3-8 cycloalkyl, C6-10 aryl, C2-9 heterocycloalkyl, or C1-9 heteroaryl; R1 = H, each (un)substituted C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-8 cycloalkyl, C6-10 aryl, C2-9 heterocycloalkyl, or C1-9 heteroaryl; one of Q0 and T0 = α - or β -D-glucopyranosyloxy or -mannopyranosyloxy or β -D-deoxyglucopyranosyloxy- and the other = (CH ₂) _n Ar; wherein Ar = each (un)substituted C6-10 aryl or C1-9 heteroaryl; n = an integer of 0-2] or pharmacol. acceptable salts or prodrugs thereof are prepared Also disclosed are medicinal composition containing the compound I, medicinal use thereof, and intermediates in producing the same. These compds. exerts an excellent effect of inhibiting human 1,5-anhydroglucitol/fructose/mannose transporters and inhibit reabsorption or cellular uptake of glucose, fructose, and mannose in kidney or absorption of these saccharide small intestine and inhibit the increase in blood sugar. Therefore, they are useful as preventives, progress inhibitors or remedies for a disease caused by the over intake of at least one saccharide selected from among glucose, fructose, and mannose or a disease caused by hyperglycemia (diabetic complication, diabetes, or diabetic nephropathy). Thus, glycosidation of 1-isopropyl-5-(4-methoxyphenyl)-4-[(4- methoxyphenyl)methyl]-1,2-dihydro-3H-pyrazol-3-one by acetobromo- α -D- glucose in the presence of benzyltributylammonium bromide in a mixture of CH ₂ Cl ₂ and 5 N aqueous NaOH at room temperature for 1.5 h followed by treatment of the product with NaOMe in MeOH gave 3-(β -D-glucopyranosyloxy)-1- isopropyl-5-(4-methoxyphenyl)-4-[(4-methoxyphenyl)methyl]-1H-pyrazole (II). II in vitro inhibited the uptake of [14C]methyl α -D-glucopyranoside in COS-7 cells transfected with human				

SMINT/PME18S-FL expression plasmid with IC50 of 92 nM.

IT **678994-67-7P**


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyrazolyl glycoside derivs. as inhibitors of 1,5-anhydroglucitol/fructose/mannose transporters and preventives, progress inhibitors or remedies for diabetic complication, diabetes, or diabetic nephropathy)

RN 678994-67-7 CAPLUS

CN Benzamide, 4-[4-[(2,4-dimethoxyphenyl)methyl]-3-(β-D-glucopyranosyloxy)-1-(1-methylethyl)-1H-pyrazol-5-yl]-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 42 THERE ARE 42 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L25 ANSWER 2 OF 88 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 2004:290461 CAPLUS
 DN 140:303664
 TI Process of making phenylpyrazoles useful as selective 5HT2A modulators and intermediates thereof
 IN Horns, Stefan; Ray, Max; Teegarden, Bradley; Drouet, Keith; Feichtinger, Konrad; Elwell, Katie
 PA Arena Pharmaceuticals, Inc., USA
 SO PCT Int. Appl., 70 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004028450	A2	20040408	WO 2003-US29736	20030922
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRAI US 2002-413299P P 20020924

OS CASREACT 140:303664; MARPAT 140:303664

AB The present invention relates to a process for making certain selective 5HT2A modulators of formula (I; wherein R1 = C1-2 alkyl; R2 = C1, Br; R3-R7 = H, halo, haloalkyl; provided that at least one is not H) by hydrolyzing a compound of formula (II; R1, R2, = same as above; R = R10CO; wherein R10 = C1-6 alkyl) and carbamoylation of the resulting amine II (R = H) and the intermediates thereof. The compds. I are useful in the prophylaxis or treatment of 5HT2A mediated diseases, such as, 5HT2A mediated platelet aggregation, asthma, agitation, degenerative diseases of the CNS and the like (no data). Thus, 3-acetamidoacetophenone was condensed with N,N-dimethylformamide di-Me acetal in ethanol under refluxing for 9 h to give 80% 3-dimethylamino-1-(3-acetamidophenyl)-2-propen-1-one which was cyclocondensed with methylhydrazine in a mixture of MeOH and 37% aqueous HCl solution at 0 to -10° for 45-75 min and 10-15° for 2.5-3 h and then treated with aqueous NH3 to give 86% 5-(3-acetamidophenyl)-1-methylpyrazole (III). III was brominated by N-bromosuccinimide in DMF at 20-30° for 40-80 min and 50-60° for 30-60 min and treated with water at 50-60° over 30-60 min to give 5-(3-acetamidophenyl)-4-bromo-1-methylpyrazole which was hydrolyzed in a mixture of 30% aqueous NaOH solution and ethanol under reflux for 17 h to give 61% 5-(3-aminophenyl)-4-bromo-1-methylpyrazole (IV). IV underwent carbamoylation with 4-chlorophenyl isocyanate in CH2Cl2 at 20-25° for .apprx.5 h to give 77% N-(4-chlorophenyl)-N'-[3-(1-methyl-4-bromo-1H-pyrazol-5-yl)phenyl]urea.


IT **676463-88-0P**, 5-(3-Acetamidophenyl)-1-methyl-1H-pyrazole
676463-91-5P, 5-(3-Acetamidophenyl)-4-bromo-1-methylpyrazole
676463-94-8P, 5-(3-Acetylaminophenyl)-4-chloro-1-methyl-1H-pyrazole

RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic

preparation); PREP (Preparation); RACT (Reactant or reagent)
 (intermediate; method for preparation of phenylpyrazoles as selective 5HT2A
 modulators for treating 5HT2A mediated diseases and intermediates
 thereof)


RN 676463-88-0 CAPLUS

CN Acetamide, N-[3-(1-methyl-1H-pyrazol-5-yl)phenyl]- (9CI) (CA INDEX NAME)




RN 676463-91-5 CAPLUS

CN Acetamide, N-[3-(4-bromo-1-methyl-1H-pyrazol-5-yl)phenyl]- (9CI) (CA
 INDEX NAME)



RN 676463-94-8 CAPLUS

CN Acetamide, N-[3-(4-chloro-1-methyl-1H-pyrazol-5-yl)phenyl]- (9CI) (CA
 INDEX NAME)




IT **676464-06-5P**, 5-(3-Acetamidophenyl)-4-bromo-1-methylpyrazole
 hydrobromide

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)

(intermediate; method for preparation of phenylpyrazoles as selective 5HT2A
 modulators for treating 5HT2A mediated diseases and intermediates
 thereof)

RN 676464-06-5 CAPLUS

CN Acetamide, N-[3-(4-bromo-1-methyl-1H-pyrazol-5-yl)phenyl]-,
 monohydrobromide (9CI) (CA INDEX NAME)



● HBr


IT **676463-89-1P**, 5-(3-Acetamidophenyl)-2-methyl-2H-pyrazole

RL: BYP (Byproduct); PREP (Preparation)

(method for preparation of phenylpyrazoles as selective 5HT_{2A} modulators for treating 5HT_{2A} mediated diseases and intermediates thereof)

RN 676463-89-1 CAPLUS

CN Acetamide, N-[3-(1-methyl-1H-pyrazol-3-yl)phenyl]- (9CI) (CA INDEX NAME)



L25 ANSWER 3 OF 88 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 2004:80450 CAPLUS
 DN 140:145835
 TI Preparation of dibenzofused bicyclo[2.2.2]octane-derived amides as
 modulators of the glucocorticoid receptor
 IN Vaccaro, Wayne; Yang, Bingwei Vera; Kim, Soong-hoon; Huynh, Tram;
 Tortolani, David R.; Leavitt, Kenneth J.; Li, Wenying; Doweiko, Arthur M.;
 Chen, Xiao-tao; Doweiko, Lidia
 PA Bristol-Myers Squibb Company, USA; et al.
 SO PCT Int. Appl., 265 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004009017	A2	20040129	WO 2003-US22300	20030717
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRAI US 2002-396877P P 20020718

OS MARPAT 140:145835

AB Title compds. I [R-R4 = H, alk(en/yn)yl, alkoxy, aryl, etc.; Z =
 carboxamido, alkylamino, etc.] are prepared For instance,
 2-amino-4,5-dimethylthiazole is coupled to the acid derived from the
 cycloaddn. of methacrylic acid and anthracene (CH3CN, EDCI, Et3N, HOAt, 18
 h) to give II. I are glucocorticoid receptor modulators which are useful
 in treating diseases requiring glucocorticoid receptor agonist or
 antagonist therapy such as obesity, diabetes, inflammatory and immune
 disorders.


IT 651035-91-5P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)

(preparation of dibenzofused bicyclo[2.2.2]octane-derived amides as
 modulators of glucocorticoid receptor)

RN 651035-91-5 CAPLUS

CN 9,10-Ethanoanthracene-11-carboxamide, N-[4-(4-bromo-1-methyl-1H-pyrazol-3-
 yl)phenyl]-9,10-dihydro- (9CI) (CA INDEX NAME)



L25 ANSWER 4 OF 88 CAPLUS COPYRIGHT 2004 ACS on STN

AN 2003:1006988 CAPLUS

DN 140:59632

TI Preparation of benzofused heteroaryl amide derivatives of thienopyridines as tyrosine kinase inhibitors useful against hyperproliferative disorders

IN Romines, William Henry, III; Kania, Robert Steven; Lou, Jihong; Collins, Michael Raymond; Cripps, Stephan James; He, Mingying; Zhou, Ru; Palmer, Cynthia Louise; Deal, Judith Gail

PA Pfizer Inc., USA

SO PCT Int. Appl., 194 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003106462	A1	20031224	WO 2003-IB2393	20030604
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2004009965	A1	20040115	US 2003-460010	20030611

PRAI US 2002-389110P P 20020614

OS MARPAT 140:59632

AB The invention relates to benzofused heteroaryl amide derivs. of thienopyridines (shown as I; variables defined below; e.g. II) and to prodrugs or metabolites thereof, or pharmaceutically acceptable salts or solvates of said compds., prodrugs, and metabolites. The invention also relates to pharmaceutical compns. containing I and to methods of treating hyperproliferative disorders in a mammal by administering I. Inhibitory activities of >200 examples of I are tabulated for a number of tyrosine kinases. Also, pharmacokinetics of 19 examples of I in mice and metabolism in human liver microsomes were analyzed. Although the methods of preparation are not claimed, 140 example preps. are included. For example, II was prepared in 5 steps starting from 3-methoxybenzenethiol and bromoacetaldehyde di-Et acetal and involving intermediates 1-[(2,2-diethoxyethyl)sulfanyl]-3-methoxybenzene, 6-methoxy-2-methylbenzo[b]thiophene, 6-methoxy-2-methylbenzo[b]thiophene-3-carboxylic acid methylamide, and 6-hydroxy-2-methylbenzo[b]thiophene-3-carboxylic acid methylamide; the last step comprises reaction of 7-chloro-2-(1-methyl-1H-imidazol-2-yl)thieno[3,2-b]pyridine and 6-hydroxy-2-methylbenzo[b]thiophene-3-carboxylic acid methylamide (40 %). For I: Y is NH, O, S, or CH₂; Z is O, S, or N; R₁₄ is a C₁-C₆ alkyl, C₁-C₆ alkylamino, C₁-C₆ alkylhydroxy, C₃-C₁₀ cycloalkylamino, or methylureido group; R₁₅ and R₁₇ = H, halo, or a C₁-C₆ alkyl group (un)substituted by ≥1 R₅ groups. R₁₆ is H or a C₁-C₆ alkyl group when Z is N, and R₁₆ is absent when Z is O or S; R₁₁ is H, C₁-C₆ alkyl, C₃-C₁₀ cycloalkyl, C(O)NR₁₂R₃, C(O)(C₆-C₁₀ aryl), (CH₂)t(C₆-C₁₀ aryl), (CH₂)t(5 to 10 membered heterocyclic), (CH₂)tNR₁₂R₁₃, SO₂NR₁₂R₁₃ or CO₂R₁₂. Each R₅ = halo, cyano, nitro, trifluoromethoxy, trifluoromethyl, azido, C(O)R₈, C(O)OR₈, OC(O)OR₈, NR₆C(O)R₇, C(O)NR₆R₇, NR₆R₇, OR₉, SO₂NR₆R₇, C₁-C₆ alkyl, C₃-C₁₀ cycloalkyl, C₁-C₆

alkylamino, (CH₂)_jO(CH₂)_qNR₆R₇, (CH₂)_tO(CH₂)_qOR₉, (CH₂)_tOR₉, S(O)_j(C₁-C₆ alkyl), (CH₂)_t(C₆-C₁₀ aryl), (CH₂)_t(5 to 10 membered heterocyclic), C(O)(CH₂)_t(C₆-C₁₀ aryl), (CH₂)_tO(CH₂)_j(C₆-C₁₀ aryl), (CH₂)_tO(CH₂)_q(5 to 10 membered heterocyclic), C(O)(CH₂)_t(5 to 10 membered heterocyclic), (CH₂)_jNR₇(CH₂)_qN R₆R₇, (CH₂)_jNR₇CH₂C(O)NR₆R₇, (CH₂)_jNR₇(CH₂)_qNR₉C(O)R₈, (CH₂)_jNR₇(CH₂)_tO(CH₂)_qOR₉, (CH₂)_jNR₇(CH₂)_qS(O)_j(C₁-C₆ alkyl), (CH₂)_jNR₇(CH₂)_tR₆, SO₂(CH₂)_t(C₆-C₁₀ aryl), and SO₂(CH₂)_t(5 to 10 membered heterocyclic). Each R₆ and R₇ = H, OH, C₁-C₆ alkyl, C₃-C₁₀ cycloalkyl, (CH₂)_t(C₆-C₁₀ aryl), (CH₂)_t(5 to 10 membered heterocyclic), (CH₂)_tO(CH₂)_qOR₉, (CH₂)_tCN(CH₂)_tOR₉, (CH₂)_tCN(CH₂)_tR₉ and (CH₂)_tOR₉; each R₈ = H, C₁-C₁₀ alkyl, C₃-C₁₀ cycloalkyl, (CH₂)_t(C₆-C₁₀ aryl), and (CH₂)_t(5 to 10 membered heterocyclic); t = 0-6; j = 0-2; q = 2-6; each R₉ and R₁₀ = H, OR₆, C₁-C₆ alkyl, and C₃-C₁₀ cycloalkyl. Each R₁₂ and R₁₃ = H, C₁-C₆ alkyl, C₃-C₁₀ cycloalkyl, (CH₂)_t(C₃-C₁₀ cycloalkyl), (CH₂)_t(C₆-C₁₀ aryl), (CH₂)_t(5 to 10 membered heterocyclic), (CH₂)_tO(CH₂)_qOR₉, and (CH₂)_tOR₉; addnl. details including provisos are given in the claims.


IT 638221-65-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of benzofused heteroaryl amide derivs. of thienopyridines as tyrosine kinase inhibitors useful against hyperproliferative disorders)

RN 638221-65-5 CAPLUS

CN 3-Benzofurancarboxamide, 2-methyl-N-[3-(1H-pyrazol-3-yl)phenyl]-6-(thieno[3,2-b]pyridin-7-yloxy)- (9CI) (CA INDEX NAME)



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L25 ANSWER 5 OF 88 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 2003:868109 CAPLUS
 DN 139:350729
 TI Preparation of 4,4-difluoro-3-butenyl-substituted heterocycles and their insecticidal and acaricidal compositions
 IN Manabe, Hiroshi; Takahashi, Nobuyoshi; Endo, Yasuhiro; Sasama, Yasuhiro; Ishii, Naoki
 PA Otsuka Chemical Holdings Co., Ltd., Japan
 SO Jpn. Kokai Tokkyo Koho, 63 pp.
 CODEN: JKXXAF
 DT Patent
 LA Japanese
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 2003313169	A2	20031106	JP 2002-117310	20020419
PRAI	JP 2002-117310		20020419		
OS	MARPAT 139:350729				

AB QCH₂CH₂CH:CF₂ [Q = (un)substituted N-containing heterocyclyl; Q is bonded to the C via the N; Q ≠ phthalimido], which are not toxic to mammals, are prepared. Thus, refluxing 4-(2,4-dichlorophenyl)-1,3-thiazolin-2-one with 4-bromo-1,1-difluoro-1-butene and K₂CO₃ in MeCN overnight gave the corresponding thiazolinone derivative, which showed 100% insecticidal activity against *Nephotettix cincticeps*.


IT **618433-45-7P 618433-57-1P**

RL: AGR (Agricultural use); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of difluorobutenyl-substituted heterocycles as insecticides and acaricides)


RN 618433-45-7 CAPLUS

CN 1H-Pyrazole-5-carboxylic acid, 1-(4,4-difluoro-3-butenyl)-3-[4-[(ethylamino)carbonyl]phenyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 618433-57-1 CAPLUS


CN 1H-Pyrazole-5-carboxylic acid, 3-[3-(acetylamino)phenyl]-1-(4,4-difluoro-3-butenyl)-, ethyl ester (9CI) (CA INDEX NAME)



L25 ANSWER 6 OF 88 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 2003:865842 CAPLUS
 DN 140:42078
 TI Synthesis of multi-substituted pyrazoles utilizing the N-alkylated
 3-hydroxy-3-propargyl- or allenylisoindolines
 AU Choi, Yong Hyun; Kim, Kyung Soon; Lee, Sangku; Jeong, Tae-Sook; Lee,
 Hee-Yoon; Kim, Yong Hae; Lee, Woo Song
 CS Department of Chemistry and School of Molecular Science (BK21), Korea
 Advanced Inst. of Science and Technology, Daejeon, 307-701, S. Korea
 SO Heterocycles (2003), 60(11), 2499-2510
 CODEN: HTCYAM; ISSN: 0385-5414
 PB Japan Institute of Heterocyclic Chemistry
 DT Journal
 LA English
 AB N-Alkyl-substituted phthalimides I (R1 = Me, Et, Me2CH, Me3C) were easily
 converted to di-, tri-, and tetra-substituted pyrazoles II (R2 = H, Me,
 Ph, 4-FC6H4, 4-O2NC6H4; R3 = H, Me) via a one-pot addition-ring
 opening-cyclocondensation process. The structure and regiochem. of II
 were confirmed by X-ray crystallog. anal. and 1H-nOe expts.
 IT **637010-59-4P 637010-60-7P 637010-61-8P**
637010-62-9P 637010-63-0P 637010-67-4P
637010-68-5P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of polysubstituted carbamoylphenyl pyrazoles via one-pot
 ring-opening/ cyclocondensation of N-alkyl phthalimides with Grignard
 reagents and hydrazines)
 RN 637010-59-4 CAPLUS
 CN Benzamide, N-methyl-2-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)




RN 637010-60-7 CAPLUS
 CN Benzamide, N-ethyl-2-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)




RN 637010-61-8 CAPLUS
 CN Benzamide, N-(1-methylethyl)-2-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA

INDEX NAME)




RN 637010-62-9 CAPLUS

CN Benzamide, N-(1,1-dimethylethyl)-2-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)




RN 637010-63-0 CAPLUS

CN Benzamide, N-(1,1-dimethylethyl)-2-(1,5-dimethyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)




RN 637010-67-4 CAPLUS

CN Benzamide, N-(1,1-dimethylethyl)-2-(4,5-dimethyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



RN 637010-68-5 CAPLUS

CN Benzamide, N-(1,1-dimethylethyl)-2-(1,4,5-trimethyl-1H-pyrazol-3-yl)-
(9CI) (CA INDEX NAME)



RE.CNT 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L25 ANSWER 7 OF 88 CAPLUS COPYRIGHT 2004 ACS on STN

AN 2003:826823 CAPLUS

DN 139:317441

TI 2-(3-Hydroxyanilino)-2-oxoacetamide derivatives and interleukin 12 production inhibitors containing them

IN Sato, Masakazu; Matsunaga, Yuiko; Ushiki, Yasunobu; Ito, Nobumasa; Nishimura, Koji

PA Taisho Pharmaceutical Co., Ltd., Japan

SO Jpn. Kokai Tokkyo Koho, 27 pp.

CODEN: JKXXAF

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 2003300875	A2	20031021	JP 2002-106023	20020409
PRAI	JP 2002-106023		20020409		
OS	MARPAT 139:317441				

AB 3-(HOC6H4)NHC(=O)NHR [I; R = (un)substituted Ph, (un)substituted naphthyl, (un)substituted pyridyl, quinolinyl, (alkyl)benzothiazolyl, (un)substituted thienyl, (un)substituted pyrazolyl; substituents are given] and their pharmaceutically acceptable salts and interleukin 12 production inhibitors containing I or their salts are claimed. I [R = C₆H₃(OMe)_{2-3,4}] at 30 μ m showed 89.7% inhibition on INF- γ -stimulated production of interleukin 12 by human peripheral blood monocytes.


IT **614721-58-3**

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(preparation of 3-hydroxyanilide derivs. [N-(hetero)aryl-N'-(hydroxyphenyl)oxalamides] as 12 production inhibitors)

RN 614721-58-3 CAPLUS

CN Ethanediame, N-[3-(4-bromo-1-methyl-1H-pyrazol-3-yl)phenyl]-N'-(3-hydroxyphenyl)- (9CI) (CA INDEX NAME)



L25 ANSWER 8 OF 88 CAPLUS COPYRIGHT 2004 ACS on STN

AN 2003:777523 CAPLUS

DN 139:307756

TI 4,5-Dihydro-1H-pyrazole derivatives useful as mitotic kinesin inhibitors, and their pharmaceutical compositions and use in the treatment of cancer

IN Breslin, Michael J.; Coleman, Paul J.; Cox, Christopher D.; Culberson, J. Christopher; Hartman, George D.; Mariano, Brenda J.; Torrent, Maricel

PA Merck & Co., Inc., USA

SO PCT Int. Appl., 159 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003079973	A2	20031002	WO 2003-US6403	20030304
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRAI US 2002-362922P P 20020308

OS MARPAT 139:307756

AB The invention relates to dihydropyrazole compds. that are useful for treating cellular proliferative diseases, for treating disorders associated with KSP kinesin activity, and for inhibiting KSP kinesin. The invention also related to compns. which comprise these compds., and methods of using them to treat cancer in mammals. The compds. are disclosed as pyrazole derivs. I [R1 = various (un)substituted acyl and thioacyl, sulfonyl, alkyl, (hetero)aryl, etc.; R2 = (un)substituted alk(en/yn)yl, aryl, perfluoroalkyl, (hetero)aralkyl, cycloalkyl, or heterocyclyl; R3, R4, R5, R6 = H, (un)substituted alk(en/yn)yl, cycloalkyl, (hetero)aralkyl, or heterocyclyl; or R3R4 or R5R6 (when W and Z are bonds) = atoms to form (CH2)1-5 with one optional replacement of a CH2 by O, S, SO, SO2, NHCO or NH or derivs.; Y, W, Z = bond, CO, C:S, S, SO, SO2, CH(OH), or O] and their pharmaceutically acceptable salts or stereoisomers. Approx. 65 compds. I are prepared and claimed by name, and another 150 compds. are claimed. For instance, 2,5-difluoroacetophenone was lithiated and coupled with 3-(benzyloxy)benzaldehyde, followed by dehydration with trifluoroacetic anhydride, to give chalcone derivative II. This compound was debenzylated with BBr3, then cyclized with hydrazine and acetylated in situ with AcOH, to give title compound III. In a kinesin ATPase in vitro assay, using human KSP motor domain construct and microtubules from bovine brain tubulin, the example compds. had IC50 ≤ 50 μM.

IT **609813-18-5P**, 3-(2,5-Difluorophenyl)-N,N-dimethyl-5-[3-(acetylamino)phenyl]-4,5-dihydro-1H-pyrazole-1-carboxamide


609813-77-6P, 3-(2,5-Difluorophenyl)-N,N-dimethyl-5-(3-aminopropyl)-5-[3-(acetylamino)phenyl]-4,5-dihydro-1H-pyrazole-1-carboxamide

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of dihydropyrazole derivs. as mitotic kinesin inhibitors for use as anticancer agents)


RN 609813-18-5 CAPLUS

CN 1H-Pyrazole-1-carboxamide, 5-[3-(acetamino)phenyl]-3-(2,5-difluorophenyl)-4,5-dihydro-N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 609813-77-6 CAPLUS

CN 1H-Pyrazole-1-carboxamide, 5-[3-(acetamino)phenyl]-5-(3-aminopropyl)-3-(2,5-difluorophenyl)-4,5-dihydro-N,N-dimethyl- (9CI) (CA INDEX NAME)



L25 ANSWER 9 OF 88 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 2003:656795 CAPLUS
 DN 139:197770
 TI Preparation of lipopeptides having antimicrobial activity
 IN Mizuno, Hiroaki; Matsuda, Hiroshi; Toda, Ayako; Matsuya, Takahiro;
 Barrett, David; Matsuda, Keiji
 PA Fujisawa Pharmaceutical Co., Ltd., Japan
 SO PCT Int. Appl., 270 pp.
 CODEN: PIXXD2

DT Patent
 LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003068807	A2	20030821	WO 2003-JP1107	20030204
	WO 2003068807	A3	20040415		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRAI AU 2002-441 A 20020211

OS MARPAT 139:197770

AB The invention relates to new lipopeptides I [R1 = H, acyl; R2 = carbamoyl, (protected) aminoalkyl or guanidinoalkyl, hydroxy-substituted alkylaminoalkyl; R3 = H, OH; R4 = aminoalkyl, alkylcarbamoylalkyl, carboxyalkyl, etc.; R5 = OH or protected hydroxy] or their salts which have antimicrobial activities (especially antifungal activity) and inhibitory activity on β -1,3-glucan synthase and to a process for their synthesis. Pharmaceutical compns. containing I are used for prophylactic and/or therapeutic treatment of infectious diseases in a human being or an animal. Thus, cyclic peptide II.2HCl [R = p-[4-[(4-methoxybutoxy)methyl]-1-piperidinyl]phenyl] was prepared by N-acylation of I (R1 = H) and showed MIC < 0.2 μ g/mL against Candida albicans.

IT **583056-09-1P**



RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of lipopeptides having antimicrobial activity)

RN 583056-09-1 CAPLUS

CN Echinocandin C, 1-[(4R)-N2-[4-[5-[4-(hexyloxy)phenyl]-4H-pyrazol-3-yl]benzoyl]-4-hydroxy-L-ornithine]-4-[4-[3-(2-aminoethoxy)-4-hydroxyphenyl]-L-threonine]-5-[(3R)-3-hydroxy-L-ornithine]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● 2 HCl

L25 ANSWER 10 OF 88 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 2003:656748 CAPLUS
 DN 139:197385
 TI Preparation of N-quinolinyl and -isoquinolinyl amides for therapeutic use
 as vanilloid receptor modulators
 IN Rami, Harshad Kantilal; Thompson, Mervyn; MacDonald, Gregor James;
 Westaway, Susan Marie; Mitchell, Darren Jason
 PA Glaxo Group Limited, UK
 SO PCT Int. Appl., 125 pp.
 CODEN: PIXXD2

DT Patent
 LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003068749	A1	20030821	WO 2003-GB608	20030213
	W:		AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM		
	RW:		GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG		

PRAI GB 2002-3673 A 20020215
 GB 2002-3677 A 20020215
 GB 2002-3680 A 20020215
 GB 2002-9003 A 20020419
 GB 2002-9032 A 20020419
 GB 2002-9035 A 20020419
 GB 2002-21318 A 20020913

OS MARPAT 139:197385

AB N-quinolinyl and -isoquinolinyl amides, such as I [R = substituted or unsubstituted Ph, heteroaryl or heterocyclyl; R1, R2 = CN, NO2, OH, alkyl, halo, alkoxy, cycloalkyl, arylalkyl, alkylamino, alkylsulfonyl, sulfamoyl, etc.; q, r = 0-3; X = N, CO, NR8, CR1, CHR1, C(R1)2; Y = CR1, CHR1, C(R1)2, N, NR8, CO; R8 = H, alkyl, hydroxyalkyl, cycloalkyl, arylalkyl, acyl, alkylsulfonyl, etc.], were prepared for use in pharmaceutical compns. for treatment or prophylaxis of disorders in which antagonism of the vanilloid (VR1) receptor is beneficial. Thus, N-(1-methyl-1,2,3,4-tetrahydroquinolin-7-yl)-1,1'-biphenyl-4-carboxamide (II) was prepared by an amidation reaction of 7-amino-1-methyl-1,2,3,4-tetrahydroquinoline with 4-biphenylcarboxylic acid using 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride in CH2Cl2. The prepared amides were tested for VR1 antagonist activity using a FLIPR based calcium assay using astrocytoma 1321N1 cells expressing human VR1 and were tested for FCA-induced hyperalgesia in the guinea pig.

IT 582323-71-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation of N-quinolinyl and -isoquinolinyl amides for therapeutic use as vanilloid receptor antagonists)

RN 582323-71-5 CAPLUS

CN Benzamide, 4-(1-methyl-1H-pyrazol-4-yl)-N-(1,2,3,4-tetrahydro-1-methyl-7-

09/773,736

quinolinyl)- (9CI) (CA INDEX NAME)



RE.CNT 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L25 ANSWER 11 OF 88 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 2003:656742 CAPLUS
 DN 139:197375
 TI Preparation of piperidinyl alcohols as chemokine receptor modulators for
 treatment of diseases such as asthma
 IN Alcaraz, Lilian; Furber, Mark; Purdie, Mark; Springthorpe, Brian
 PA Astrazeneca A.B., Swed.
 SO PCT Int. Appl., 166 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003068743	A1	20030821	WO 2003-SE258	20030217
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			

PRAI SE 2002-465 A 20020218
 SE 2002-2673 A 20020909

OS CASREACT 139:197375; MARPAT 139:197375

AB The invention provides piperidinyl alcs. (shown as I; variables defined below; e.g. N-[(2R)-3-[4-(3,4-dichlorophenoxy)piperidin-1-yl]-2-hydroxypropyl]-2-(methylsulfonyl)benzamide) for use as modulators of chemokine receptor (especially CCR3) activity for use in, for example, treating asthma. For I: X is CH₂, O, S(O)₂ or NR₁₀; Y is a bond, CH₂, NR₃₅, CH₂NH, CH₂NHC(O), CH(OH), CH(NHCOR₃₃), CH(NHSO₂R₃₄), CH₂O or CH₂S; Z is C(O), or when Y is a bond Z can also be S(O)₂; R₁ is (un)substituted aryl, (un)substituted heterocyclyl or C₄-6 cycloalkyl fused to a benzene ring; addnl. details are given in the claims. Percent inhibition at 3 nM eotaxin of eotaxin-mediated human eosinophil chemotaxis is tabulated for 16 examples of I, e.g. 106 % for N-[(2R)-3-[4-(3,4-dichlorophenoxy)piperidin-1-yl]-2-hydroxypropyl]-1-oxo-1,2-dihydroisoquinoline-4-carboxamide. Histamine H₁ receptor binding activity was determined for the same compds., e.g. pK_i = 8.4 for N-[(2R)-3-[4-(3,4-dichlorophenoxy)piperidin-1-yl]-2-hydroxypropyl]-1-oxo-1,2-dihydroisoquinoline-4-carboxamide. 49 Example preps. of intermediates and 234 of I are included. For example, to prepare N-[(2R)-3-[4-(3,4-dichlorophenoxy)piperidin-1-yl]-2-hydroxypropyl]-2-(methylsulfonyl)benzamide (0.055 g), a mixture of 2-(methylsulfonyl)benzoic acid (0.063 g), (2R)-1-amino-3-[4-(3,4-dichlorophenoxy)piperidin-1-yl]propan-2-ol (0.1 g) and N,N-diisopropylethylamine (0.1 mL) in dry DMF (3 mL) was cooled to 0° with stirring; 2-(1H-9-azabenzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (0.13 g) was added and the mixture was stirred at 0° for 1-2 h. The invention also provides a process for making 4-(3,4-dichlorophenoxy)piperidine, which is useful as an intermediate for making certain compds. of the invention. The process comprises (a) reacting 4-hydroxypiperidine with a suitable base in a suitable solvent at room temperature; and (b) heating the mixture so produced

and

1,2-dichloro-4-fluorobenzene at 50-90°, or at reflux of the solvent used.

IT **583881-54-3P**, N-[(2R)-3-[4-(3,4-Dichlorophenoxy)piperidin-1-yl]-2-hydroxypropyl]-4-(1H-pyrazol-3-yl)benzamide


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of piperidinyl alcs. as chemokine receptor modulators for treatment of diseases such as asthma)

RN 583881-54-3 CAPLUS


CN Benzamide, N-[(2R)-3-[4-(3,4-dichlorophenoxy)-1-piperidinyl]-2-hydroxypropyl]-4-(1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RE.CNT 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L25 ANSWER 12 OF 88 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 2003:651482 CAPLUS
 DN 140:111332
 TI Syntheses, spectral characterization and antimicrobial evaluation of some new 2-pyrazolines
 AU Nagar, D. N.; Tushar, Mehta; Mehta; Shah, V. H.
 CS Chemical Research Laboratory, Department of Chemistry, Saurashtra University, Rajkot, 360 005, India
 SO Oriental Journal of Chemistry (2002), 18(3), 525-528
 CODEN: OJCHEG; ISSN: 0970-020X
 PB Oriental Scientific Publishing Co.
 DT Journal
 LA English
 AB New 5-aryl-3-(p-benzylaminophenyl)-1-H-pyrazolines, e.g. I, were prepared by the cyclocondensation of 3-aryl-1-(p-benzoylaminophenyl)-2-propene-1-ones, e.g. II, with hydrazine hydrate. The structure of compds. I were confirmed by elemental anal., IR, PMR and mass spectral data. Products I were screened for in vitro antibacterial and antifungal activities. Products I were evaluated for antibacterial activity against *Bacillus subtilis*, *Bacillus megaterium*, *Escherichia coli*, *Arobactor arozens*, and antifungal activity against *Aspergillus awamori* using DMF as a solvent at 40 µg/mL concentration by using cup-plate.
 IT **648430-57-3P 648430-58-4P 648430-59-5P**
648430-60-8P 648430-61-9P 648430-62-0P
648430-63-1P 648430-64-2P 648430-65-3P
648430-66-4P
 RL: BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (syntheses, mol structure, and antimicrobial evaluation of pyrazolines via cyclocondensation of aminophenylpropenone with hydrazine)
 RN 648430-57-3 CAPLUS
 CN Benzamide, N-[4-(4,5-dihydro-5-phenyl-1H-pyrazol-3-yl)phenyl]- (9CI) (CA INDEX NAME)




RN 648430-58-4 CAPLUS
 CN Benzamide, N-[4-[5-(2-chlorophenyl)-4,5-dihydro-1H-pyrazol-3-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 648430-59-5 CAPLUS

CN Benzamide, N-[4-[4,5-dihydro-5-(3-phenyl-2-propenyl)-1H-pyrazol-3-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 648430-60-8 CAPLUS

CN Benzamide, N-[4-[5-(2-furanylmethyl)-4,5-dihydro-1H-pyrazol-3-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 648430-61-9 CAPLUS

CN Benzamide, N-[4-[4,5-dihydro-5-(2-hydroxyphenyl)-1H-pyrazol-3-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 648430-62-0 CAPLUS

CN Benzamide, N-[4-[4,5-dihydro-5-(4-hydroxy-3-methoxyphenyl)-1H-pyrazol-3-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 648430-63-1 CAPLUS


CN Benzamide, N-[4-[4,5-dihydro-5-[4-(methythio)phenyl]-1H-pyrazol-3-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 648430-64-2 CAPLUS


CN Benzamide, N-[4-[4,5-dihydro-5-(4-methoxyphenyl)-1H-pyrazol-3-yl]phenyl]-
(9CI) (CA INDEX NAME)

RN 648430-65-3 CAPLUS

CN Benzamide, N-[4-[4,5-dihydro-5-(2-nitrophenyl)-1H-pyrazol-3-yl]phenyl]-
(9CI) (CA INDEX NAME)

RN 648430-66-4 CAPLUS

CN Benzamide, N-[4-[4,5-dihydro-5-(3-phenoxyphenyl)-1H-pyrazol-3-yl]phenyl]-
(9CI) (CA INDEX NAME)



RE.CNT 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L25 ANSWER 13 OF 88 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 2003:591153 CAPLUS
 DN 139:164789
 TI Preparation of phenylpyrazoles as 5-HT_{2A} serotonin receptor modulators
 IN Teegarden, Bradley; Drouet, Keith; Jayakumar, Honnappa; Thomsen, William;
 Maffuid, Paul; Elwell, Katie; Foster, Richard; Lawless, Michael; Liu,
 Qian; Smith, Julian; Feichtinger, Konrad
 PA Arena Pharmaceuticals, Inc., USA
 SO PCT Int. Appl., 266 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003062206	A2	20030731	WO 2003-US2059	20030123
	WO 2003062206	A3	20040108		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRAI US 2002-386198P P 20020123
 US 2002-386384P P 20020605
 US 2002-401467P P 20020805

OS MARPAT 139:164789

AB Title compds. I [wherein R₁ = H, halo, NR₅R₆, OH, or OR₇; R₂ = H, (cyclo)alkyl, or alkenyl; R₃ = halo, carboxy, CN, or (un)substituted alkoxy carbonyl, (cyclo)alkyl, alkenyl, alkynyl, or (hetero)aryl; R₄ = (cyclo)alkyl or alkenyl; R₅ and R₆ = independently H or (un)substituted (cyclo)alkyl, alkenyl, aryl(methyl); or NR₅R₆ = (un)substituted heterocyclyl; R₇ = H or alkyl; A = CO, CS, or SO₂; B = (NR₁₁)q(CHR₁₂)m(1,2-cyclopropylidene)nQ₁ or OQ₂; m, n, and q = independently 0-1; R₁₁ and R₁₂ = independently H, (cyclo)alkyl, or alkenyl; Q = (un)substituted Ph; Q₂ = (un)substituted (cyclo)alkyl, alkenyl, alkynyl, alkylaryl, or aryl(alkyl); and pharmaceutically acceptable salts thereof] were prepared as modulators of the 5-HT_{2A} serotonin receptor. For example, reaction of triphosgene with 3-(3-aminophenyl)-4-bromo-2-methylpyrazole in the presence of TEA in CH₂Cl₂, followed by addition of 4-(trifluoromethoxy)benzylamine provided the N-(pyrazolylphenyl)urea II (68%). The latter exhibited IC₅₀ values of 1.2 μM, 0.45 μM, and 0.0171 μM for AP-1, WT 5-HT_{2A}, and AP-3, resp., in a competitive binding assay. A number of the compds. of the invention evidenced inverse agonist activity against AP-1 (data given). Thus, I and pharmaceutical compns. thereof are directed to methods useful in the prophylaxis or treatment of reducing platelet aggregation, coronary artery disease, myocardial infarction, transient ischemic attack, angina, stroke, atrial fibrillation, reducing the risk of blood clot formation, asthma or symptoms thereof, agitation or a symptom, behavioral disorders, drug induced psychosis, excitative psychosis, Gilles de la Tourette's syndrome, manic disorder, organic or NOS psychosis, psychotic disorder, psychosis, acute schizophrenia, chronic schizophrenia and NOS schizophrenia, and


related disorders (no data). The present invention also relates to the method of prophylaxis or treatment of 5-HT_{2A} serotonin receptor mediated disorders in combination with a dopamine D₂ receptor antagonist such as haloperidol, administered sep. or together.

IT **573711-39-4P 573711-42-9P**, N-[3-(4-Bromo-2-methyl-2H-pyrazol-3-yl)phenyl]-4-trifluoromethoxyphenylcarboxamide
573711-43-0P 573711-44-1P, N-[3-(4-Bromo-2-methyl-2H-pyrazol-3-yl)phenyl]-2-[4-(trifluoromethoxy)phenyl]acetamide
573711-45-2P, N-[3-(4-Bromo-2-methyl-2H-pyrazol-3-yl)phenyl]-2-(3-fluorophenyl)acetamide **573711-46-3P**, N-[3-(4-Bromo-2-methyl-2H-pyrazol-3-yl)phenyl]-2-(3-methoxyphenyl)acetamide **573711-47-4P**, N-[3-(4-Bromo-2-methyl-2H-pyrazol-3-yl)phenyl]-2-(2-fluorophenyl)acetamide
573711-48-5P, N-[3-(4-Bromo-2-methyl-2H-pyrazol-3-yl)phenyl]-2-(4-nitrophenyl)acetamide **573711-49-6P**, N-[3-(4-Bromo-2-methyl-2H-pyrazol-3-yl)phenyl]-2-(2-methoxyphenyl)acetamide
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(5-HT_{2A} receptor modulator; preparation of phenylpyrazoles as 5-HT_{2A} serotonin receptor modulators for treatment of heart disease, stroke, psychosis, and other disorders)


RN 573711-39-4 CAPLUS

CN 2-Thiophenecarboxamide, N-[3-(4-bromo-1-methyl-1H-pyrazol-5-yl)phenyl]-(9CI) (CA INDEX NAME)




RN 573711-42-9 CAPLUS

CN Benzamide, N-[3-(4-bromo-1-methyl-1H-pyrazol-5-yl)phenyl]-4-(trifluoromethoxy)- (9CI) (CA INDEX NAME)




RN 573711-43-0 CAPLUS

CN Benzamide, N-[3-(4-bromo-1-methyl-1H-pyrazol-5-yl)phenyl]-4-chloro- (9CI) (CA INDEX NAME)




RN 573711-44-1 CAPLUS

CN Benzeneacetamide, N-[3-(4-bromo-1-methyl-1H-pyrazol-5-yl)phenyl]-4-(trifluoromethoxy)- (9CI) (CA INDEX NAME)




RN 573711-45-2 CAPLUS

CN Benzeneacetamide, N-[3-(4-bromo-1-methyl-1H-pyrazol-5-yl)phenyl]-3-fluoro- (9CI) (CA INDEX NAME)



RN 573711-46-3 CAPLUS


CN Benzeneacetamide, N-[3-(4-bromo-1-methyl-1H-pyrazol-5-yl)phenyl]-3-methoxy- (9CI) (CA INDEX NAME)




RN 573711-47-4 CAPLUS

CN Benzeneacetamide, N-[3-(4-bromo-1-methyl-1H-pyrazol-5-yl)phenyl]-2-fluoro-


(9CI) (CA INDEX NAME)



RN 573711-48-5 CAPLUS

CN Benzeneacetamide, N-[3-(4-bromo-1-methyl-1H-pyrazol-5-yl)phenyl]-4-nitro-
(9CI) (CA INDEX NAME)

RN 573711-49-6 CAPLUS

CN Benzeneacetamide, N-[3-(4-bromo-1-methyl-1H-pyrazol-5-yl)phenyl]-2-methoxy-
(9CI) (CA INDEX NAME)

L25 ANSWER 14 OF 88 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 2003:570962 CAPLUS
 DN 139:133578
 TI Preparation of N-acylbenzenesulfonamide derivatives as acetyl CoA
 carboxylase (ACC) inhibitors
 IN Suzuki, Nobuyasu; Nihei, Yukio; Ichinose, Hidehiro; Hatanaka, Toshihiro;
 Maezono, Katsumi; Ohsumi, Koji; Kondo, Nobuo; Yamamoto, Takashi;
 Nakanishi, Ei-ji
 PA Ajinomoto Co., Inc., Japan
 SO PCT Int. Appl., 53 pp.
 CODEN: PIXXD2
 DT Patent
 LA Japanese
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003059886	A1	20030724	WO 2003-JP99	20030109
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRAI JP 2002-2344	A	20020109		

OS MARPAT 139:133578

AB Acyl sulfonamide derivs. represented by the following general formula (I),
 its analog or pharmaceutically acceptable salts thereof [wherein R1 = each
 (un)substituted C1-20 alkyl, C2-20 alkenyl, C2-20 alkynyl, aromatic
 hydrocarbyl, aromatic heterocyclyl, NH2, C1-20 alkoxy, C2-20 alkenyloxy,
 C2-20 alkynyloxy, aromatic hydrocarbyloxy, or aromatic heterocyclyloxy; Y =
 (un)substituted CR3:CR4, N:CR3, CR3:N; R3-R6 = each (un)substituted aromatic
 hydrocarbyl, C1-12 alkyl, C2-12 alkynyl, C1-12 alkoxy, C1-12 amino, or
 C1-6 alkylthio, H, OH, SH, NO2, halo, cyano; R7, R8 = groups listed in
 R3-R6, carbonyl, thiocarbonyl, (un)substituted C1-12 alkoxy carbonyl; ring
 A = each (un)substituted aromatic hydrocarbyl, aromatic heterocyclyl, cyclic
 alkenyl, or cyclic alkyl; ring B = each (un)substituted aromatic hydrocarbyl,
 4- to 9-membered heterocyclyl, cyclic alkyl, or cyclic alkenyl; X = Q, Q1,
 Q2; wherein R11-R18 = groups listed in R3-R6; Z = CR9:N, N:CR9, CR9:N, S,
 O; Q = CR9:N; R9 = groups listed in R3-R4; ring C = each (un)substituted
 aromatic heterocyclyl, cyclic alkyl, or cyclic alkenyl excluding pyridine,
 furan, or thiophene ring] are prepared having an efficacious ACC activity
 inhibitory effect. Therefore, the above derivs. have an efficacious ACC
 activity inhibitory effect and are efficacious in treating obesity and
 hyperlipemia and fatty liver induced by obesity as well as impaired
 glucose tolerance, diabetes, diabetic complications, hypertension and
 arteriosclerosis. Thus, 777 mg 4-[4-[3,5-bis(trifluoromethyl)phenyl]isothiazol-2-yl]benzoic acid was treated with 2 mL SOCl2, stirred at 70°
 for 3 h, distilled to remove SOCl2 under reduced pressure, dissolved in 3 mL
 CH2Cl2, treated dropwise with a solution of 320 mg 2-aminobenzenesulfonamide
 in 5 mL pyridine at 0°, and stirred at room temperature for 3 h to give,
 after workup, 44% 2-[4-[4-[3,5-bis(trifluoromethyl)phenyl]isothiazol-2-yl]benzoylamino]benzenesulfonamide which (475 mg) was dissolved in 25 mL
 THF, treated with 195 mg 4-dimethylaminopyridine and 0.134 mL n-hexanoyl

chloride, and stirred at 60° for 1 h to give, 75%
N-hexanoyl-2-[4-[4-[3,5-bis(trifluoromethyl)phenyl]isothiazol-2-yl]benzoylamino]benzenesulfonamide (II). II showed IC50 of 0.29 μ M against ACC.


IT **566180-97-0P**

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of N-acylbenzenesulfonamide derivs. as acetyl CoA carboxylase inhibitors for treating obesity, hyperlipemia, fatty liver, impaired glucose tolerance, diabetes, diabetic complications, hypertension, and arteriosclerosis)

RN 566180-97-0 CAPLUS

CN Benzamide, N-[2-[[[(1-oxohexyl)amino]sulfonyl]phenyl]-4-[5-[3-(trifluoromethyl)phenyl]-1H-pyrazol-3-yl]]- (9CI) (CA INDEX NAME)



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L25 ANSWER 15 OF 88 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 2003:532647 CAPLUS
 DN 139:101122
 TI Preparation of 3,4-diarylpyrazoles as inhibitors of heat shock protein 90 (HSP90) and their use in the therapy of cancer
 IN Drysdale, Martin James; Dymock, Brian William; Barril-Alonso, Xavier; Workman, Paul; Pearl, Laurence Harris; Prodromou, Chrisostomos; MacDonald, Edward
 PA Ribotargets Limited, UK; Cancer Research Technology Limited; The Institute of Cancer Research
 SO PCT Int. Appl., 299 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003055860	A1	20030710	WO 2002-GB5778	20021219
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRAI GB 2001-30733 A 20011221
 GB 2002-25688 A 20021104

OS MARPAT 139:101122

AB A method of inhibiting HSP90 comprises administration of title compds. [I; Ar3, Ar4 = (substituted) C5-20 aryl; R5 = H, halo, OH, ether, formyl, acyl, CO2H, ester, acyloxy, oxycarbonyloxy, amido, acylamido, aminocarbonyloxy, tetrazolyl, amino, NO2, cyano, N3, sulfhydryl, thioether, sulfonamido, C1-7 alkyl, C3-20 heterocyclyl, C5-20 aryl; R = H, C1-7 alkyl, C3-20 heterocyclyl, C5-20 aryl] and pharmaceutically acceptable salts, solvates, amides, esters, ethers, chemical protected forms, and prodrugs thereof. Thus, 7-hydroxy-3-phenylchromen-4-one and hydrazine hydrate were refluxed 45 min. in EtOH to give 4-(4-phenyl-1H-pyrazol-3-yl)benzene-1,3-diol. This inhibited HSP90 activity with IC50 = 10-100 µM.


IT 558649-87-9P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of diarylpyrazoles as inhibitors of heat shock protein 90 and their use in the therapy of cancer)

RN 558649-87-9 CAPLUS

CN Benzamide, 4-[3-(5-chloro-2,4-dihydroxyphenyl)-1H-pyrazol-4-yl]-N-methyl- (9CI) (CA INDEX NAME)




IT 558645-02-6P 558645-06-0P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of diarylpyrazoles as inhibitors of heat shock protein 90 and their use in the therapy of cancer)


RN 558645-02-6 CAPLUS

CN Acetamide, N-[3-(4-iodo-5-methyl-1H-pyrazol-3-yl)phenyl]- (9CI) (CA INDEX NAME)



RN 558645-06-0 CAPLUS

CN Acetamide, N-[4-(4-iodo-5-methyl-1H-pyrazol-3-yl)phenyl]- (9CI) (CA INDEX NAME)



RE.CNT 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L25 ANSWER 16 OF 88 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 2003:376833 CAPLUS
 DN 138:368880
 TI Preparation of substituted diphenyl heterocycles for treating HCV infection
 IN Singh, Rajinder; Goff, Dane; Lu, Henry; Issankani, Sarkiz D.; Sun, Thomas
 PA Rigel Pharmaceuticals, Inc., USA
 SO PCT Int. Appl., 103 pp.
 CODEN: PIXXD2

DT Patent
 LA English
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003040112	A1	20030515	WO 2002-US35131	20021101
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

US 2003165561	A1	20030904	US 2002-286017	20021101
BR 2002006266	A	20031230	BR 2002-6266	20021101

PRAI US 2001-350107P P 20011102
 US 2002-405472P P 20020823
 WO 2002-US35131 W 20021101

OS MARPAT 138:368880

AB The title compds. [I; X, Y = N, O, provided that X and Y are not both O; Z = N, CH, provided that Z = CH when X and Y are both N; R2-R6, R8-R10, R13 = H, OH, SH, etc.; R11 = alkyl; R12 = monohalomethyl, dihalomethyl] that inhibit replication of HCV virus, were prepared and formulated. Thus, reacting 2,6-dichloro-N-hydroxybenzenecarboximidoyl chloride with 2,2-dichloro-N-(3-ethynylphenyl)acetamide (preps. given) in the presence of Et3N in THF afforded I [X = N; Y = O; Z = CH; R2 = Cl; R3-R5 = H; R6 = Cl; R8-R11 = H; R12 = CHCl2; R13 = H] which was evaluated for in rats by both s.c. and i.v. administration, and doses as high as 30 mg/kg/day were well tolerated.


IT **524685-47-0P**

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of substituted di-Ph heterocycles for treating HCV infection)

RN 524685-47-0 CAPLUS

CN Acetamide, 2,2-dichloro-N-[3-[5-(2,6-dichlorophenyl)-1H-pyrazol-3-yl]phenyl]- (9CI) (CA INDEX NAME)



RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L25 ANSWER 17 OF 88 CAPLUS COPYRIGHT 2004 ACS on STN

AN 2003:369188 CAPLUS

DN 138:376312

TI Silver halide emulsion for silver halide photographic materials

IN Yamada, Kosaburo; Maeda, Hideki; Asanuma, Naoki

PA Fuji Photo Film Co., Ltd., Japan

SO Jpn. Kokai Tokkyo Koho, 80 pp.

CODEN: JKXXAF

DT Patent

LA Japanese

FAN. CNT 5

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 2003140287	A2	20030514	JP 2002-188536	20020627
PRAI	JP 2001-250679	A	20010821		

AB The title silver halide emulsion contains a compound releasing ≥ 1 electrons after one electron oxidation and after a chemical bond formation.

The

photog. emulsion provides the silver halide photog. materials of high sensitivity, no fogging, and good storageability.


IT **521749-17-7P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(oxidizable compound in silver halide emulsion)

RN 521749-17-7 CAPLUS

CN Benzamide, N-[3-(3,5-dithio-4-pyrazolidinyl)phenyl]-3-[2-(4-hydroxyphenyl)-2-propenyl]-4-(methylamino)- (9CI) (CA INDEX NAME)



L25 ANSWER 18 OF 88 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 2003:319886 CAPLUS
 DN 138:338155
 TI Preparation of oxadiazolyl-biphenylcarboxamides as p38 kinase inhibitors
 IN Angell, Richard Martyn; Bamborough, Paul; Cockerill, George Stuart; Smith, Kathryn Jane; Walker, Ann Louise
 PA Glaxo Group Limited, UK
 SO PCT Int. Appl., 44 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003033482	A1	20030424	WO 2002-EP11574	20021016
	W:		AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM		
	RW:		GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG		

PRAI GB 2001-24932 A 20011017

OS MARPAT 138:338155


AB The title compds. [I; X = a bond, (un)substituted Ph; R1 = (un)substituted 5-7 membered heterocyclyl, 5-7 membered heteroaryl, fused bicycyl; R2 = H, alkyl, (CH2)pcycloalkyl; or when X = a bond and m and n are both zero, NR1R2 = 5-6 membered heterocyclyl optionally containing one addnl. heteroatom selected from O and N which can be optionally substituted by alkyl; R3 = II (wherein R4 = H, alkyl); U = Me, halo; V, Y = H, Me, halo; m, n = 0-2; m + n = 0-4; p = 0-1; r = 0-2; with the provisos], useful as pharmaceuticals, particularly as p38 kinase inhibitors, were prepared E.g., a 6-step synthesis of the carboxamide III, starting from 3-bromo-4-methylbenzoic acid, was given.

IT 515143-65-4P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of oxadiazolyl-biphenylcarboxamides as p38 kinase inhibitors)

RN 515143-65-4 CAPLUS

CN [1,1'-Biphenyl]-4-carboxamide, 2'-methyl-5'-(5-methyl-1,3,4-oxadiazol-2-yl)-N-[3-(1-methyl-1H-pyrazol-3-yl)phenyl]- (9CI) (CA INDEX NAME)



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD

L25 ANSWER 19 OF 88 CAPLUS COPYRIGHT 2004 ACS on STN

AN 2003:261813 CAPLUS

DN 138:287667

TI Preparation of 1-[2-(aryloxy)ethyl]-1H-pyrazoles useful in the treatment of hyper-proliferative disorders

IN Khire, Uday; Zhang, Chengzhi; Kluender, Harold C. E.; Mugge, Ingo; Hong, Zhenqiu; Shao, Jianxing; Bifulco, Neil; Trail, Pamela A.; Dumas, Jacques; Lavoie, Rico C.; Liu, Xiao-Gao; Agarwal, Veena; Verma, Sharad K.; Wang, Lei

PA Bayer Corporation, USA

SO PCT Int. Appl., 121 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003027074	AL	20030403	WO 2002-US29958	20020920
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRAI US 2001-324573P P 20010925

OS MARPAT 138:287667

AB Title compds. I and II [wherein R1 = H, halo, or CN; R2 = H, CN, COR6, halo, or alkyl; R3 = CF3 or (un)substituted alkyl, Ph, furyl, thienyl, isoxazolyl, pyridyl, or benzodioxolyl; R4 = H, alkyl, halo, or CN; X = O or NH; R5 = (un)substituted alkyl; R6 = H or alkyl; R7 = alkoxy, Br, Cl, F, CF3, CN, CO2H, NHCOR14, or (un)substituted alkyl, Ph, thienyl, pyridyl, pyrimidyl, pyrrolyl, furyl, oxazolyl, benzothienyl, benzofuryl, morpholinyl, pyrrolidinyl, piperidinyl, naphthyl, or benzodioxolyl; Y = H, alkyl, alkoxy, CN, or halo; R8 = (un)substituted Ph; R9 = H, alkyl, Br, Cl, or F; R10 = (un)substituted alkyl; R14 = alkyl; n = 0-2; or pharmaceutically acceptable salts thereof] were prepared as angiogenesis inhibitors. For example, etherification of 1,6-dibromo-2-naphthol with dibromoethane gave the bromoethoxy derivative (93%). Addition of NH2NH2•H2O in 2N HCl and CH2Cl2 provided 1-[2-[(1,6-dibromo-2-naphthyl)oxy]ethyl]hydrazine•HCl (78%). Cyclization of the hydrazine with Et benzoylacetate afforded the pyrazolone (39%), which was treated with 1,1'-(azodicarbonyl)dipiperidine, PBU3, and EtOH to give III (78%). In an in vivo tumor model assay using human colon tumor HCT-116 cells implanted in mice, I and II significantly inhibited tumor growth compared to controls. All treatments were well tolerated with no lethality or weight loss in any group. Thus, I and II are useful for the treatment of hyper-proliferative disorders and angiogenesis dependent disorders, especially colon, breast, and lung cancer.

IT **503815-37-0P**, 3-[1-[2-[2-Chloro-4-(4-methyl-2-thienyl)phenoxy]ethyl]-5-ethoxy-1H-pyrazol-3-yl]-N-(4-morpholinylmethyl)benzamide **503815-38-1P**, 3-[1-[2-[2-Chloro-4-(4-methyl-2-thienyl)phenoxy]ethyl]-5-ethoxy-1H-pyrazol-3-yl]-N-[(diethylamino)methyl]benzamide **503815-39-2P**,


3-[1-[2-[2-Chloro-4-(4-methyl-2-thienyl)phenoxy]ethyl]-5-ethoxy-1H-pyrazol-3-yl]-N-[(dimethylamino)methyl]benzamide **503815-40-5P**,
 3-[1-[2-[2-Chloro-4-(4-methyl-2-thienyl)phenoxy]ethyl]-5-ethoxy-1H-pyrazol-3-yl]-N-(2-methoxyethyl)benzamide **503815-41-6P**,
 3-[1-[2-[2-Chloro-4-(4-methyl-2-thienyl)phenoxy]ethyl]-5-ethoxy-1H-pyrazol-3-yl]-N-propylbenzamide

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(anticancer agent; preparation of [(aryloxy)ethyl]pyrazoles for treatment of hyper-proliferative disorders)


RN 503815-37-0 CAPLUS

CN Benzamide, 3-[1-[2-[2-chloro-4-(4-methyl-2-thienyl)phenoxy]ethyl]-5-ethoxy-1H-pyrazol-3-yl]-N-(4-morpholinylmethyl)- (9CI) (CA INDEX NAME)




RN 503815-38-1 CAPLUS

CN Benzamide, 3-[1-[2-[2-chloro-4-(4-methyl-2-thienyl)phenoxy]ethyl]-5-ethoxy-1H-pyrazol-3-yl]-N-[(diethylamino)methyl]- (9CI) (CA INDEX NAME)



RN 503815-39-2 CAPLUS


CN Benzamide, 3-[1-[2-[2-chloro-4-(4-methyl-2-thienyl)phenoxy]ethyl]-5-ethoxy-1H-pyrazol-3-yl]-N-[(dimethylamino)methyl]- (9CI) (CA INDEX NAME)



RN 503815-40-5 CAPLUS


CN Benzamide, 3-[1-[2-[2-chloro-4-(4-methyl-2-thienyl)phenoxy]ethyl]-5-ethoxy-

1H-pyrazol-3-yl]-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)



RN 503815-41-6 CAPLUS

CN Benzamide, 3-[1-[2-[2-chloro-4-(4-methyl-2-thienyl)phenoxy]ethyl]-5-ethoxy-1H-pyrazol-3-yl]-N-propyl- (9CI) (CA INDEX NAME)



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L25 ANSWER 20 OF 88 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 2003:261667 CAPLUS
 DN 138:287976
 TI Preparation of pyrazole amino acid derivatives for increasing endogenous
 testosterone levels
 IN Brondyk, William H.; McKenna, Sean; Arkinstall, Stephen J.
 PA Applied Research Systems ARS Holding N.V., Neth. Antilles
 SO PCT Int. Appl., 76 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003026649	A1	20030403	WO 2002-US30801	20020927
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRAI US 2001-325470P P 20010927

OS MARPAT 138:287976

AB Pyrazole compds., e.g., I [R1 = (un)substituted alk(en)(yn)yl, carbocyclic
 aryl, aralkyl, heteroaryl, heteroalicyclicyl, heteroaralkyl, or
 heteroalicycliclalkyl; R2, R3 = H, (un)substituted alk(en)(yn)yl, alkoxy,
 alkylthio, alkylsulfinyl, alkylsulfonyl, or ring groups defined for R1; X
 = (hetero)alk(en)(yn)ylene or ring groups defined for R1; Y =
 (un)substituted amino or methylene, CO, SO2; Z = optionally-substituted
 alkylamino, an amino acid, or a glycine; m, n = 0 or 1] or their
 pharmaceutically-acceptable salts were prepared for treatment of conditions,
 disorders or diseases which would benefit patients by increasing
 endogenous testosterone levels. Thus, in vivo testosterone induction
 activities for regioisomeric 5-[2-(4-tert-butylphenyl)-5-pyridin-3(or
 4)-yl-2H-pyrazol-3-yl]pentanoic acid [1-carbamoyl-2-(4-
 hydroxyphenyl)ethyl]amide are shown in bar graphs.

IT **373607-52-4P 373607-56-8P 373607-67-1P**
373607-69-3P 503862-37-1P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(preparation of pyrazole amino acid derivs. for increasing endogenous
 testosterone levels)

RN 373607-52-4 CAPLUS

CN Benzenepropanamide, α -[[3-[1-[[4-(1,1-dimethylethyl)phenyl]methyl]-3-
 (4-pyridinyl)-1H-pyrazol-5-yl]benzoyl]amino]-4-hydroxy-, (α S)- (9CI)
 (CA INDEX NAME)


Absolute stereochemistry.



RN 373607-56-8 CAPLUS

CN Benzenepropanamide, α -[[4-[1-butyl-3-(2-furanyl)-1H-pyrazol-5-yl]benzoyl]amino]-4-hydroxy-, (α S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 373607-67-1 CAPLUS

CN Benzenebutanamide, α -[[4-[3-(2-furanyl)-1-(2-pyridinyl)-1H-pyrazol-5-yl]benzoyl]amino]-4-hydroxy- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 373607-69-3 CAPLUS

CN Benzenepropanamide, α -[[4-[3-[3-(dimethylamino)phenyl]-1-(2-pyridinyl)-1H-pyrazol-5-yl]benzoyl]amino]-4-hydroxy-, (α S)- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 503862-37-1 CAPLUS

CN Benzenepropanamide, α-[[3-[1-[[4-(1,1-dimethylethyl)phenyl]methyl]-3-(3-pyridinyl)-1H-pyrazol-5-yl]benzoyl]amino]-4-hydroxy-, (αS)- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L25 ANSWER 21 OF 88 CAPLUS COPYRIGHT 2004 ACS on STN

AN 2003:254172 CAPLUS

DN 138:281081

TI Drug screening with non-endogenous, constitutively activated human serotonin receptors and small molecule modulators thereof

IN Behan, Dominic P.; Chalmers, Derek T.; Liaw, Chen W.; Russo, Joseph F.; Thomsen, William J.

PA Arena Pharmaceuticals, Inc., USA

SO U.S., 62 pp., Cont.-in-part of U.S. Ser. No. 60,188.

CODEN: USXXAM

DT Patent

LA English

FAN.CNT 16

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6541209	B1	20030401	US 1999-292072	19990414
	US 6140509	A	20001031	US 1999-292069	19990414
	US 6420541	B1	20020716	US 2000-767013	20001222
	US 2003224442	A1	20031204	US 2002-55555	20020123
	US 2003153004	A1	20030814	US 2002-176255	20020619
PRAI	US 1997-839449	B2	19970414		
	US 1998-60188	A2	19980414		
	US 1998-90783P	P	19980626		
	US 1998-112909P	P	19981218		
	US 1999-123000P	P	19990305		
	US 1998-90793P	P	19980625		
	US 1999-292072	A3	19990414		
	US 2000-767013	A3	20001222		

X

←

Does not disclose
Compds.

AB Disclosed herein are non-endogenous, constitutively activated forms of the human 5-HT_{2A} and human 5-HT_{2C} receptors and uses of such receptors to screen candidate compds. Further disclosed herein are candidate compds. identified by the screening method which act at the 5HT_{2A} receptors. Yet further disclosed is a new class of compds. which act at the 5HT_{2A} receptors.

IT 247037-94-1P 247037-95-2P 247037-97-4P

247037-98-5P 247037-99-6P 247038-00-2P


247038-01-3P 247038-02-4P 247038-03-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug screening with non-endogenous, constitutively activated human serotonin receptors and small mol. modulators thereof)


RN 247037-94-1 CAPLUS

CN Benzamide, N-[3-(4-bromo-1-methyl-1H-pyrazol-3-yl)phenyl]-4-(trifluoromethoxy)- (9CI) (CA INDEX NAME)




RN 247037-95-2 CAPLUS

CN 2-Thiophenecarboxamide, N-[3-(4-bromo-1-methyl-1H-pyrazol-3-yl)phenyl]- (9CI) (CA INDEX NAME)




RN 247037-97-4 CAPLUS

CN Benzamide, N-[3-(4-bromo-1-methyl-1H-pyrazol-3-yl)phenyl]-4-chloro- (9CI)
(CA INDEX NAME)




RN 247037-98-5 CAPLUS

CN Benzeneacetamide, N-[3-(4-bromo-1-methyl-1H-pyrazol-3-yl)phenyl]-4-(trifluoromethoxy)- (9CI) (CA INDEX NAME)




RN 247037-99-6 CAPLUS

CN Benzeneacetamide, N-[3-(4-bromo-1-methyl-1H-pyrazol-3-yl)phenyl]-3-fluoro- (9CI) (CA INDEX NAME)




RN 247038-00-2 CAPLUS

CN Benzeneacetamide, N-[3-(4-bromo-1-methyl-1H-pyrazol-3-yl)phenyl]-3-methoxy- (9CI) (CA INDEX NAME)




RN 247038-01-3 CAPLUS

CN Benzeneacetamide, N-[3-(4-bromo-1-methyl-1H-pyrazol-3-yl)phenyl]-2-fluoro-
(9CI) (CA INDEX NAME)




RN 247038-02-4 CAPLUS

CN Benzeneacetamide, N-[3-(4-bromo-1-methyl-1H-pyrazol-3-yl)phenyl]-4-nitro-
(9CI) (CA INDEX NAME)



RN 247038-03-5 CAPLUS

CN Benzeneacetamide, N-[3-(4-bromo-1-methyl-1H-pyrazol-3-yl)phenyl]-2-methoxy-
(9CI) (CA INDEX NAME)



RE.CNT 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L25 ANSWER 22 OF 88 CAPLUS COPYRIGHT 2004 ACS on STN

AN 2002:754333 CAPLUS

DN 137:279214

TI Preparation of benzoic acid derivatives as nuclear factor κ B inhibitors

IN Suzuki, Kenji; Nunokawa, Youichi; Ogou, Naohisa

PA Suntory Limited, Japan; Suntory Biomedical Research Limited

SO PCT Int. Appl., 243 pp.

CODEN: PIXXD2

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002076918	A1	20021003	WO 2002-JP3017	20020327
	WO 2002076918	C1	20021031		
	W: BR, CA, CN, HU, JP, KR, US				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR				
	BR 2002004678	A	20030429	BR 2002-4678	20020327
	EP 1314712	A1	20030528	EP 2002-708696	20020327
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY, TR				
PRAI	JP 2001-91003	A	20010327		
	WO 2002-JP3017	W	20020327		

OS MARPAT 137:279214


AB The title compds. I [R₁ = (1,4-benzoquinon-2-yl)methyl (with substituents selected from H, alkyl, etc.) (generic structure given), etc.; R₂ = H, (un)substituted alkyl, etc.; X = carboxyl (which may esterified or amidated)] are prepared. In an in vitro test for nuclear factor κ B inhibiting activity, N-[5-(5,6-dimethoxy-3-methyl-1,4-benzoquinon-2-yl)methyl-2-hydroxybenzoyl]-4-aminobenzoic acid Et ester showed IC₅₀ value of 3 μ g/mL.

IT **464215-68-7P**

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of benzoic acid derivs. as nuclear factor κ B inhibitors)

RN 464215-68-7 CAPLUS

CN Benzamide, 2-(acetyloxy)-5-[(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)methyl]-N-[4-(1H-pyrazol-3-yl)phenyl]- (9CI) (CA INDEX NAME)


IT **464215-69-8P**

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of benzoic acid derivs. as nuclear factor κB inhibitors)

RN 464215-69-8 CAPLUS

CN Benzamide, 5-[(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)methyl]-2-hydroxy-N-[4-(1H-pyrazol-3-yl)phenyl]- (9CI) (CA INDEX NAME)




RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L25 ANSWER 23 OF 88 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 2002:275753 CAPLUS
 DN 136:309843
 TI Preparation of thiophenes as phosphate transport inhibitors
 IN Weinstock, Joseph; Franz, Robert G.
 PA Smithkline Beecham Corporation, USA
 SO PCT Int. Appl., 66 pp.
 CODEN: PIXXD2

DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002028353	A2	20020411	WO 2001-US31318	20011005
	WO 2002028353	A3	20020711		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2002013048	A5	20020415	AU 2002-13048	20011005
PRAI	US 2000-238068P	P	20001005		
	WO 2001-US31318	W	20011005		
OS	MARPAT 136:309843				
AB	The title compds. [I-III; X = S, O; R1 = H, alkyl, aryl, etc.; R2, R3 = alkyl, haloalkyl, alky; interrupted by one or more O or S atoms, etc.; n = 0-3], useful for treatment of chronic renal failure and uremic bone disease, were prepared E.g., a 4-step synthesis of I [X = S; R1 = H; R2 = 4-FC6H4; R3 = Ph], starting with Me 3-aminothiophene-2-carboxylate, was presented. Biol. data were given.				
IT	409363-05-9P RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of thiophenes as phosphate transport inhibitors)				
RN	409363-05-9 CAPLUS				
CN	2-Thiophenecarboxamide, N-[3-(1-methyl-1H-pyrazol-3-yl)phenyl]-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)				



L25 ANSWER 24 OF 88 CAPLUS COPYRIGHT 2004 ACS on STN

AN 2002:107327 CAPLUS

DN 136:167394

TI Preparation of carboxamide compounds and their use as antagonists of a human 11CBY receptor

IN Johnson, Christopher Norbert; Jones, Martin; O'Toole, Catherine Anne; Stemp, Geoffrey; Thewlis, Kevin Michael; Witty, David

PA Smithkline Beecham P.L.C., UK

SO PCT Int. Appl., 77 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002010146	A1	20020207	WO 2001-EP8637	20010726
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	EP 1305304	A1	20030502	EP 2001-956562	20010726
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
	BR 2001012856	A	20030701	BR 2001-12856	20010726
	JP 2004505070	T2	20040219	JP 2002-515877	20010726
	NO 2003000471	A	20030328	NO 2003-471	20030130
	BG 107510	A	20030930	BG 2003-107510	20030130
	US 2004063686	A1	20040401	US 2003-343424	20030930
PRAI	GB 2000-18758	A	20000731		
	GB 2001-12544	A	20010523		
	WO 2001-EP8637	W	20010726		

OS MARPAT 136:167394

AB Title compds. [I; A = H, C1-6alkyl optionally substituted by hydroxyl, C1-6alkoxy, C1-6alkenyl, C1-6 acyl, halogeno, OH, CN, CF3; R3 = H, CH3, CH3CH2; R4 = aromatic carbocycle, heterocycle; Z = O, S, NH, CH2, single bond, at the 3 or 4 position of R4 relative to the carbonyl group; R5 = aromatic carbocycle, heterocycle; Q = XYNR1R2; X = O, S; Y = C2-4 alkylene, C5-6 cycloalkylene; R1, R2 independently = C1-6 alkyl, phenyl-C1-6 alkyl; R1R2 = 5-, 6-, 7-membered ring optionally containing one or more heteroatom selected from O, S, N; etc.], pharmaceutically acceptable salts, and solvate are prepared and as antagonists of a human 11CBY receptor. Title compds. and pharmaceutical composition are useful in the treatment and/or prophylaxis of one or more of the disorder, such as, major depression, manic depression, anxiety, etc. Thus, the title compound II was prepared from 2'-methyl-biphenyl-4-carboxylic acid and 4-(2-diisopropylamino-ethoxy)-3-methoxy-phenylamine in DMF in the presence of 1-(3-dimethylaminopropyl)-3-Et carbodiimide hydrochloride and 1-hydroxy-7-azabenzotriazole.


IT **395677-26-6P 395679-10-4P**

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of carboxamide compds. as antagonists of human 11CBY receptor)


RN 395677-26-6 CAPLUS

CN Benzamide, N-[4-[2-[bis(1-methylethyl)amino]ethoxy]-3-methoxyphenyl]-4-(1-methyl-1H-pyrazol-4-yl)- (9CI) (CA INDEX NAME)




RN 395679-10-4 CAPLUS

CN 2-Thiophenecarboxamide, N-[4-[2-[bis(1-methylethyl)amino]ethoxy]-3-methoxyphenyl]-5-[1-methyl-3-(trifluoromethyl)-1H-pyrazol-5-yl]- (9CI) (CA INDEX NAME)




RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L25 ANSWER 25 OF 88 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 2002:71213 CAPLUS
 DN 136:401679
 TI Regioselective synthesis of pyrazoles via the ring cleavage of
 3-substituted N-alkylated 3-hydroxyisoindolin-1-ones
 AU Chang, Kyu-Tae; Choi, Yong Hyun; Kim, Seung-Ho; Yoon, Yong-Jin; Lee, Woo
 Song
 CS Proteome Research Laboratory, Korea Research Institute of Bioscience and
 Biotechnology, Taejon, 305-333, S. Korea
 SO Journal of the Chemical Society, Perkin Transactions 1 (2002), (2),
 207-210
 CODEN: JCSPCE; ISSN: 1472-7781
 PB Royal Society of Chemistry
 DT Journal
 LA English
 OS CASREACT 136:401679
 AB N-Alkyl (Me, Et, iPr, tBu)-substituted phthalimides I (R = Me, Et, i-Pr,
 t-Bu) were easily transformed to mono-, di-, or tri-substituted pyrazoles,
 e.g., II via a one-pot addition-decyclization-cyclocondensation process. The
 regiochem. of the pyrazole ring was determined by X-ray crystallog. anal. and
 1H NOE expts.
 IT **431877-75-7P**
 RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)
 (preparation and crystal structure of pyrazoles from N-alkylphthalimides via
 addition of lithium alkylacetylides, ring cleavage of intermediate
 N-alkylhydroxyisoindolinones and subsequent regioselective
 cyclocondensation with hydrazines)
 RN 431877-75-7 CAPLUS
 CN Benzamide, N-(1,1-dimethylethyl)-2-(1H-pyrazol-3-yl)- (9CI) (CA INDEX
 NAME)




IT **431877-69-9P 431877-70-2P 431877-71-3P**
431877-72-4P 431877-73-5P 431877-74-6P
431877-76-8P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of pyrazoles from N-alkylphthalimides via addition of lithium
 alkylacetylides, ring cleavage of intermediate N-
 alkylhydroxyisoindolinones and subsequent regioselective
 cyclocondensation with hydrazines)
 RN 431877-69-9 CAPLUS
 CN Benzamide, N-methyl-2-(5-phenyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)




RN 431877-70-2 CAPLUS

CN Benzamide, N-methyl-2-[5-(4-methylphenyl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 431877-71-3 CAPLUS

CN Benzamide, N-ethyl-2-(5-phenyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)




RN 431877-72-4 CAPLUS


CN Benzamide, N-(1-methylethyl)-2-(5-phenyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)




RN 431877-73-5 CAPLUS
 CN Benzamide, N-(1,1-dimethylethyl)-2-(5-phenyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



RN 431877-74-6 CAPLUS
 CN Benzamide, N-(1,1-dimethylethyl)-2-(1-methyl-3-phenyl-1H-pyrazol-5-yl)- (9CI) (CA INDEX NAME)



RN 431877-76-8 CAPLUS
 CN Benzamide, N-(1,1-dimethylethyl)-2-[5-(4-methylphenyl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RE.CNT 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L25 ANSWER 26 OF 88 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 2001:850926 CAPLUS
 DN 135:371991
 TI Preparation of pyrazole compounds for treatment of infertility
 IN Shroff, Hitesh; Reddy, Adulla P.; El Tayar, Nabil; Brugger, Nadia;
 Jorand-Lebrun, Catherine
 PA Serono Reproductive Biology Institute, Inc., USA
 SO PCT Int. Appl., 90 pp.
 CODEN: PIXXD2

DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001087287	A2	20011122	WO 2001-US16189	20010519
	WO 2001087287	A3	20020516		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	US 2002132844	A1	20020919	US 2001-860658	20010519
	EP 1282418	A2	20030212	EP 2001-939143	20010519
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
	JP 2004501100	T2	20040115	JP 2001-583755	20010519
PRAI	US 2000-205814P	P	20000519		
	WO 2001-US16189	W	20010519		
OS	MARPAT 135:371991				
AB	Substituted pyrazole compds. I [R1 is H, optionally substituted alkyl, alkenyl, alkynyl, carbocyclic aryl, aralkyl, heteroaryl, heteroalicycloalkyl, heteroaralkyl or heteroalicycloalkyl; R2, R3 are H, halo, optionally substituted alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, carbocyclic aryl, aralkyl, heteroaryl, heteroalicycloalkyl, heteroaralkyl or heteroalicycloalkyl; X is optionally substituted alkylene, alkenylene, alkynylene, heteroalkylene, heteroalkenylene, heteroalkynylene, alicyclyl, carbocyclic aryl, heteroalicycloalkyl, heteroaryl, heteroaralkyl, or heteroalicycloalkyl; Y is optionally substituted amino or methylene, carbonyl, sulfonyl; Z is an optionally substituted alkylamine, an amino acid or a glycine; m, n are 0 or 1] or their pharmaceutically acceptable salts were prepared for treatment of mammalian infertility. Thus, tyrosinamide II was prepared by the solid-phase method and shown to be human FSH receptor specific in tests on untransfected CHO parental cells.				
IT	373607-43-3P 373607-52-4P 373607-56-8P 373607-67-1P 373607-69-3P RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of pyrazole compds. for treatment of infertility)				
RN	373607-43-3 CAPLUS				
CN	Benzenepropanamide, α -[[4-[1-[[4-(1,1-dimethylethyl)phenyl]methyl]-3-(3-pyridinyl)-1H-pyrazol-5-yl]benzoyl]amino]-4-hydroxy-, (α S)- (9CI) (CA INDEX NAME)				


Absolute stereochemistry.



RN 373607-52-4 CAPLUS

CN Benzenepropanamide, α -[[3-[1-[[4-(1,1-dimethylethyl)phenyl]methyl]-3-(4-pyridinyl)-1H-pyrazol-5-yl]benzoyl]amino]-4-hydroxy-, (α S)- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 373607-56-8 CAPLUS


CN Benzenepropanamide, α -[[4-[1-butyl-3-(2-furanyl)-1H-pyrazol-5-yl]benzoyl]amino]-4-hydroxy-, (α S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 373607-67-1 CAPLUS
 CN Benzenebutanamide, α-[[4-[3-(2-furanyl)-1-(2-pyridinyl)-1H-pyrazol-5-yl]benzoyl]amino]-4-hydroxy- (9CI) (CA INDEX NAME)

PAGE 1-A






RN 373607-69-3 CAPLUS

CN Benzenepropanamide, α -[[4-[3-[3-(dimethylamino)phenyl]-1-(2-pyridinyl)-1H-pyrazol-5-yl]benzoyl]amino]-4-hydroxy-, (α S)- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.



L25 ANSWER 27 OF 88 CAPLUS COPYRIGHT 2004 ACS on STN

AN 2001:816458 CAPLUS

DN 135:344479

TI Preparation of pyrazoles and pyrazolones as RNA polymerase inhibitors and antibacterial agent

IN Li, Leping; Chen, Xiaoqi; Cutler, Serena T.

PA Tularik Inc., USA

SO PCT Int. Appl., 61 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001082930	A1	20011108	WO 2001-US14439	20010502
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 2002049205	A1	20020425	US 2001-847962	20010502
US 6673923	B2	20040106		
PRAI US 2000-201988P	P	20000503		

OS MARPAT 135:344479


AB Pyrazoles I and pyrazolones II [R1 = H, OH, alkoxy, (un)substituted NH2; R2, R3 = (un)substituted aryl, heteroaryl, alkyl, heteroalkyl, heteroaralkyl, heteroarylheteroalkyl, arylheteroalkyl] were prepared for use as RNA polymerase inhibitors and antimicrobial agents. Thus, 3-F3CC6H4CH2CN was treated with PhCHO and cyclized with Me3SiCN2 to give I [R1 = H, R2 = Ph, R3 = 3-F3CC6H4], which had min. inhibitory concns. against Staphylococcus aureus and Escherichia coli of <500 µM.

IT **371254-04-5P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of pyrazoles and pyrazolones as RNA polymerase inhibitors and antibacterial agents)

RN 371254-04-5 CAPLUS

CN Acetamide, N-[3-[3-[4-fluoro-3-(trifluoromethyl)phenyl]-1H-pyrazol-4-yl]phenyl]-2-phenoxy- (9CI) (CA INDEX NAME)



RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L25 ANSWER 28 OF 88 CAPLUS COPYRIGHT 2004 ACS on STN

AN 2001:581873 CAPLUS

DN 135:152802

TI Preparation of 4-(1H-pyrazol-3-yl)-1H-pyrrole-2-carboxylic acid derivatives as inhibitors of ERK

IN Green, Jeremy; Cao, Jingrong; Hale, Michael; Baker, Christopher; Maltais, Francois; Janetka, James; Mullican, Michael; Bemis, Guy; Xie, Xiaoling; Straub, Judith; Tang, Qing; Mashall, Robert

PA Vertex Pharmaceuticals Incorporated, USA

SO PCT Int. Appl., 72 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001057022	A2	20010809	WO 2001-US3911	20010205
	WO 2001057022	A3	20020307		
	W:		AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM		
	RW:		GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG		
AU	2001036723	A5	20010814	AU 2001-36723	20010205
BR	2001004424	A	20020108	BR 2001-4424	20010205
EP	1200422	A2	20020502	EP 2001-908911	20010205
	R:		AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR		
TR	200103787	T1	20021021	TR 2001-200103787	20010205
JP	2003522163	T2	20030722	JP 2001-557854	20010205
NO	2001004837	A	20011204	NO 2001-4837	20011004
US	2003040536	A1	20030227	US 2001-972437	20011005
US	6528509	B2	20030304		
LT	4981	B	20030127	LT 2001-103	20011017
BG	106054	A	20020628	BG 2001-106054	20011026
US	6593357	B1	20030715	US 2002-225719	20020822
US	2003225151	A1	20031204	US 2003-335793	20030102
US	6699865	B2	20040302		
US	2004048861	A1	20040311	US 2003-437419	20030513
US	2004102506	A1	20040527	US 2003-688613	20031017
PRAI	US 2000-180506P	P	20000205		
	US 2000-191956P	P	20000324		
	US 2000-242935P	P	20001024		
	WO 2001-US3911	W	20010205		
	US 2001-971533	A3	20011005		
	US 2001-972437	A3	20011005		
	US 2002-225719	A3	20020822		
	US 2003-335793	A3	20030102		

OS MARPAT 135:152802

AB The title compds. [I; R1 = R, halo, OR, etc.; T = a bond, linker group; R = H, alkyl; R2 = H, CN, halo, etc.; R3 = R, OH, OR, etc.; Q = a bond, CO, CO2, etc.; R4 = NH2, NHR5, R5, etc.; R5 = alkyl, aryl, aralkyl, etc.], useful as protein kinase inhibitors (such as ERK2, JAK, JNK, Aurora-2, GSK-3, KDR or ATK), were prepared E.g., a 4-step synthesis of I [R1 = H; T


= a bond; R2 = Ph; R3 = H; Q = CO; R4 = NHCH2Ph] which showed Ki of < 1 μ M in ERK2 inhibition assay, was given. The compds. I are useful for treating disease states in mammals that are alleviated by a protein kinase inhibitor, particularly diseases such as cancer, inflammatory disorders, restenosis, and cardiovascular disease.

IT **353252-11-6P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 4-(1H-pyrazol-3-yl)-1H-pyrrole-2-carboxylic acid derivs. as inhibitors of ERK)

RN 353252-11-6 CAPLUS

CN 1H-Pyrrole-2-carboxamide, 4-[4-[3-[(ethylamino)carbonyl]phenyl]-1H-pyrazol-3-yl]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



L25 ANSWER 29 OF 88 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 2001:545674 CAPLUS
 DN 135:137516
 TI Synthesis of heteroarylbenzamides and analogs used for inhibiting protein kinases
 IN Bender, Steven Lee; Bhumralkar, Dilip; Collins, Michael Raymond; Cripps, Stephan James; Deal, Judith Gail; Nambu, Mitchell David; Palmer, Cynthia Louise; Peng, Zhengwei; Varney, Michael David; Jia, Lei
 PA Agouron Pharmaceuticals, Inc., USA
 SO PCT Int. Appl., 237 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001053274	A1	20010726	WO 2001-US1723	20010119
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	US 2002103203	A1	20020801	US 2001-764306	20010119
	US 6635641	B2	20031021		
	EP 1252146	A1	20021030	EP 2001-906592	20010119
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
	BR 2001008025	A	20021105	BR 2001-8025	20010119
	JP 2003529558	T2	20031007	JP 2001-553276	20010119
	US 2004092747	A1	20040513	US 2003-621979	20030717
PRAI	US 2000-177059P	P	20000121		
	US 2001-764306	A3	20010119		
	WO 2001-US1723	W	20010119		

OS MARPAT 135:137516

AB Title compds. I [Z = CH, NH; Q = moiety such that ring A is (un)substituted mono- or bicyclic heteroaryl which has at least 2 carbon atoms in the heteroaryl ring system; X = CH₂, O, S, NH; Y = CH₂, O, S, provided at least one of X and Y = CH₂ or X and Y form a cyclopropyl ring; R₂₋₃ = H, Me, halo, CF₃, CN; R₄ = CONHR₅, NHCOR₆; where R₅ = (un)substituted aryl, heteroaryl, cycloalkyl, etc.; R₆ = (un)substituted aryl, heteroaryl, cycloalkyl, etc.] are prepared Examples include synthetic procedures for over 150 compds., 11 biol. assays and 3 sample formulations. For instance, 3-mercaptopbenzoic acid was treated with α -chloro-N-methoxy-N-methylacetamide followed by carbodiimide coupling to 2-methyl-6-aminoquinoline to give II. II was converted to a β -thiono-ketone with thioacetanilide/n-BuLi followed by treatment with hydrazine to give pyrazole III. III gave 85% inhibition of an lck protein tyrosine kinase at 5 μ M and had K_i = 2.21 nM for VEGF-R2A50. Treatment of cancer as well as other disease states associated with unwanted angiogenesis and/or cellular proliferation, such as diabetic retinopathy, neovascular glaucoma, rheumatoid arthritis, and psoriasis are claimed uses of the invention.


IT 351319-33-0P 351319-45-4P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological

study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);
 BIOL (Biological study); PREP (Preparation); USES (Uses)
 (synthesis of heteroarylbenzamides used for inhibiting protein kinases)


RN 351319-33-0 CAPLUS

CN Benzamide, N-[4-(5-bromo-1-methyl-1H-pyrazol-3-yl)phenyl]-3-
 [(pyrazinylthio)methyl]- (9CI) (CA INDEX NAME)



RN 351319-45-4 CAPLUS

CN Benzamide, N-[4-(4-bromo-1-methyl-1H-pyrazol-3-yl)phenyl]-3-[(1H-pyrazolo[3,4-d]pyrimidin-4-ylthio)methyl]- (9CI) (CA INDEX NAME)



RE.CNT 7


THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L25 ANSWER 30 OF 88 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 2001:416929 CAPLUS
 DN 135:33475
 TI Preparation of heterocyclo-alkylsulfonyl pyrazole derivatives as
 anti-inflammatory/analgesic agents
 IN Cheng, Hengmiao; Li, Jin; Lundy, Kristin Marie; Minich, Martha Lou; Sakya,
 Subas Man; Uchida, Chikara
 PA Pfizer Products Inc., USA
 SO PCT Int. Appl., 130 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2001040216	A1	20010607	WO 2000-IB1748	20001124
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SI, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
BR 2000016031	A	20020723	BR 2000-16031	20001124
EP 1233959	A1	20020828	EP 2000-974741	20001124
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2003517475	T2	20030527	JP 2001-541900	20001124
US 6531492	B1	20030311	US 2000-724446	20001128
BG 106694	A	20030331	BG 2002-106694	20020513
ZA 2002004285	A	20030529	ZA 2002-4285	20020529
NO 2002002624	A	20020730	NO 2002-2624	20020603
US 2003236258	A1	20031225	US 2003-342666	20030114
PRAI US 1999-168701P	P	19991203		
WO 2000-IB1748	W	20001124		
US 2000-724446	A3	20001128		
OS MARPAT 135:33475				
AB The title compds. [I; A = II-IV (wherein m = 0-2; X = CR8, N; R4 = alkyl optionally substituted by halo; R5 = H, halo, SH, etc.; R8 = H, halo, OH, etc.), etc.; R2 = H, halo, alkyl, etc.; R3 = H, halo, alkyl, etc.; R6 = (un)substituted Ph, Ph fused to (un)saturated 5-7 membered aromatic ring, etc.], useful in the treatment or alleviation of inflammation and other inflammation associated disorders, such as osteoarthritis, rheumatoid arthritis, colon cancer and Alzheimer's disease, in mammals (preferably humans, dogs, cats and livestock), were prepared and formulated. Thus, reacting 5-hydrazino-2-(methylsulfonyl)pyridine.HCl with 3-phenyl-2-propynal in trifluoroethanol afforded the pyrazole V. Biol. data for compds. I were given.				

IT **343628-60-4P**
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological
 study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);
 BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of heterocyclo-alkylsulfonyl pyrazole derivs. as
 anti-inflammatory/analgesic agents)
 RN 343628-60-4 CAPLUS

CN Benzamide, N-methyl-4-[1-[5-(methylsulfonyl)-2-pyridinyl]-3-(trifluoromethyl)-1H-pyrazol-5-yl]- (9CI) (CA INDEX NAME)



RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L25 ANSWER 31 OF 88 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 2001:338350 CAPLUS
 DN 134:326537
 TI Preparation of acylazole derivatives as kainic acid neurocytotoxicity inhibitors
 IN Shishikura, Jun-ichi; Inami, Hiroshi; Kaku, Hidetaka; Tsutsumi, Rie; Yamashita, Hiroshi; Ohno, Kazushige
 PA Yamanouchi Pharmaceutical Co., Ltd., Japan
 SO PCT Int. Appl., 50 pp.
 CODEN: PIXXD2
 DT Patent
 LA Japanese
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001032173	A1	20010510	WO 2000-JP7572	20001027
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			

PRAI JP 1999-310035 A 19991029

OS MARPAT 134:326537

AB Kainic acid neurocytotoxicity inhibitors containing as the active ingredient acyl-nitrogen-containing 5-membered heterocycle derivs. or pharmaceutically acceptable salts thereof [I; A = O, S; X, Y = C, CH, N; Z = C, CH, N, O; n = 0,1; the solid line accompanied with a dotted line represents a single or double bond; R1, R3, R4 = each (un)substituted lower alkyl, alkenyl, hydrocarbyl, heterocyclyl, aryl-lower alkyl, heteroaryl-lower alkyl, aryl-lower alkenyl, or heteroaryl-lower alkenyl; R2 = H, (un)substituted lower alkyl; R5, R6 = absent, H, (un)substituted lower alkyl; or R3 and R5 or R6, or R4 and R6 are united to form an (un)substituted cycloalkane, cycloalkene, heterocycloalkane, or heterocycloalkene] are prepared Also prepared are 1-acyl-2-pyrazoline derivs. [II; A, n, R1, R2 = same as above; one of R3 and R4 = (un)substituted pyridyl or pyrazyl and the other = each (un)substituted lower alkyl, alkenyl, hydrocarbyl, heterocyclyl, aryl-lower alkyl, heteroaryl-lower alkyl, aryl-lower alkenyl, or heteroaryl-lower alkenyl; or R3 and R5 or R6 are united to form an (un)substituted cycloalkane, cycloalkene, heterocycloalkane, or heterocycloalkene and R4 = each (un)substituted lower alkyl, alkenyl, hydrocarbyl, heterocyclyl, aryl-lower alkyl, heteroaryl-lower alkyl, aryl-lower alkenyl, or heteroaryl-lower alkenyl] or pharmaceutically acceptable salts thereof. These compds. also possess noncompetitive antagonism against AMPA (2-amino-3-(3-hydroxy-5-methyl-4-isoxazolyl)propionic acid) receptor and are useful as nerve cell protectants or therapeutics for epilepsy. Thus, a mixture of chalcone, hydrazine monohydrate, and ethanol was refluxed for 1 h to give 1-benzoyl-4,5-dihydro-3,5-diphenyl-1H-pyrazole (III). III and (+)-3-(1-benzoyl-5-phenyl-4,5-dihydro-1H-pyrazol-3-yl)pyridine showed IC50 of 2.6 and 1.3 μ M, resp., for inhibiting the.


IT **336795-99-4P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of acylazole derivs. as kainic acid neurocytotoxicity inhibitors, nerve cell protectants, and antiepileptics)

RN 336795-99-4 CAPLUS

CN Acetamide, N-[4-[1-benzoyl-4,5-dihydro-3-(3-pyridinyl)-1H-pyrazol-5-yl]phenyl]- (9CI) (CA INDEX NAME)



RE.CNT 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L25 ANSWER 32 OF 88 CAPLUS COPYRIGHT 2004 ACS on STN

AN 2001:31473 CAPLUS

DN 134:100864

TI Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use

IN Kania, Robert Steven; Bender, Steven Lee; Borchardt, Allen J.; Braganza, John F.; Cripps, Stephan James; Hua, Ye; Johnson, Michael David; Johnson, Theodore Otto, Jr.; Luu, Hiep The; Palmer, Cynthia Louise; Reich, Siegfried Heinz; Tempczyk-russell, Anna Maria; Teng, Min; Thomas, Christine; Varney, Michael David; Wallace, Michael Brennan

PA Agouron Pharmaceuticals, Inc., USA

SO PCT Int. Appl., 439 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001002369	A2	20010111	WO 2000-US18263	20000630
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	BR 2000012352	A	20020514	BR 2000-12352	20000630
	EP 1218348	A2	20020703	EP 2000-943375	20000630
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL			
	JP 2003503481	T2	20030128	JP 2001-507809	20000630
	NZ 516676	A	20030926	NZ 2000-516676	20000630
	US 6531491	B1	20030311	US 2001-983786	20011025
	US 6534524	B1	20030318	US 2001-983783	20011025
	NO 2001005797	A	20020301	NO 2001-5797	20011128
	ZA 2001010061	A	20030206	ZA 2001-10061	20011206
	BG 106380	A	20020930	BG 2002-106380	20020201
PRAI	US 1999-142130P	P	19990702		
	US 2000-609335	B3	20000630		
	WO 2000-US18263	W	20000630		

OS MARPAT 134:100864

AB Indazole compds. I [R1 = substituted or unsubstituted aryl or heteroaryl, R3CH:CH, R3N:CH; R2 = substituted or unsubstituted aryl, heteroaryl, Y-X; R3 = substituted or unsubstituted alkyl alkenyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl; Y = O, S, C(:CH2), CO, SO, SO2, alkylidene, NH, N(C1-C8 alkyl); X = substituted or unsubstituted aryl, heteroaryl, NH(alkyl), NH(cycloalkyl), NH(heterocycloalkyl), NH(aryl), NH(heteroaryl), NH(alkoxy), NH(dialkylamide)] and their pharmaceutically acceptable prodrugs, active metabolites, and salts are disclosed. The compds. modulate and/or inhibit the activity of certain protein kinases. In particular, I and pharmaceutical compns. containing them are capable of mediating tyrosine kinase signal transduction, and thereby modulate and/or inhibit unwanted cell proliferation. The invention is also directed to the therapeutic or prophylactic use of pharmaceutical compns. containing such compds., and to methods of treating cancer and other disease states associated with unwanted angiogenesis and/or cellular proliferation, such as

diabetic retinopathy, neovascular glaucoma, rheumatoid arthritis, and psoriasis, by administering effective amts. of such compds. E.g., I [R1 = (E)-3,4-(MeO)2C6H3CH:CH; R2 = 4-HO-3-MeOC6H3] (II) was prepared from 6-aminoindazole by diazotization and substitution with iodide, protection of the indazole nitrogen with 2,4,6-Me3C6H2SO2Cl, coupling of the regioisomeric mixture with 4-(methoxymethoxy)-3-methoxybenzeneboronic acid in the presence of dichlorobis(triphenylphosphine)palladium, and deprotection of the indazole moiety and iodination at the 3-position of the indazole. Treatment of the 3-indazolyl iodide with sec-butyllithium, phenyllithium, and DMF, regioselective protection of the indazole with 2,4,6-Me3C6H2SO2Cl, olefination with 3,4-dimethoxybenzyltriphenylphosphonium bromide, deprotection of the indazole, deprotection of the methoxymethyl group, and equilibration of the double bond with iodine gave II. Biol. data on protein kinase inhibition, cell proliferation inhibition, neovascularization inhibition, and i.p. and oral bioavailability, are given.

IT **319469-02-8P**


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of combinatorial libraries of aryl-substituted indazole derivs. as modulators and inhibitors of protein kinases in the treatment of tumor growth, cellular proliferation, and angiogenesis)

RN 319469-02-8 CAPLUS

CN Benzamide, N-[3-(1H-pyrazol-3-yl)phenyl]-2-[[3-[(1E)-2-(2-pyridinyl)ethenyl]-1H-indazol-6-yl]thio]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



L25 ANSWER 33 OF 88 CAPLUS COPYRIGHT 2004 ACS on STN

AN 2000:847300 CAPLUS

DN 134:147535

TI Synthesis of 1-hydroxy-substituted pyrazolo[3,4-c]- and pyrazolo[4,3-c]quinolines and -isoquinolines from 4- and 5-aryl-Substituted 1-benzyloxypyrazoles

AU Pawlas, Jan; Vedso, Per; Jakobsen, Palle; Huusfeldt, Per Olaf; Begtrup, Mikael

CS Department of Medicinal Chemistry, The Royal Danish School of Pharmacy, Copenhagen, DK-2100, Den.

SO Journal of Organic Chemistry (2000), 65(26), 9001-9006

CODEN: JOCEAH; ISSN: 0022-3263

PB American Chemical Society

DT Journal

LA English

OS CASREACT 134:147535


AB 1-Hydroxypyrazolo[3,4-c]quinoline (I), 1-hydroxypyrazolo[4,3-c]quinoline (II), 1-hydroxypyrazolo[3,4-c]isoquinoline (III), and 1-hydroxypyrazolo[4,3-c]isoquinoline (IV) were prepared from 1-benzyloxypyrazole, establishing the pyridine B-ring in the terminal step. The pyridine ring of the 1-benzyloxy derivative of pyrazoloquinolines II and I was formed via cyclization of a formyl group at C-4 or C-5 and an amino group of a 2-aminophenyl substituent at C-5 or C-4 in 1-benzyloxypyrazole. The pyridine ring of 1-benzyloxy derivs. of pyrazoloisoquinolines III and IV was created via cyclization of a formyl group in a 2-formylphenyl substituent at C-4 or C-5 with an iminophosphorane group installed at C-5 or C-4 of 1-benzyloxypyrazole by lithiation followed by reaction with tosyl azide and then with tributylphosphine utilizing the Staudinger/aza-Wittig protocol. The 2-aminophenyl and the 2-formylphenyl substituent were introduced at C-5 or C-4 by regioselective metalation followed by transmetalation to the pyrazolylzinc halide and subsequent palladium-catalyzed cross-coupling with 2-iodoaniline or 2-bromobenzaldehyde. The order of reactions and use of protecting groups in the individual sequences have been optimized. The 1-benzyloxy-substituted pyrazoloquinolines and isoquinolines thus obtained were debenzylated by strong acid to the corresponding 1-hydroxy-substituted pyrazoloquinolines and isoquinolines I-IV.

IT 323582-82-7P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of hydroxy pyrazoloquinolines and -isoquinolines via cyclization of arylbenzyloxypyrazoles)

RN 323582-82-7 CAPLUS

CN Propanamide, N-[2-[4-iodo-1-(phenylmethoxy)-1H-pyrazol-5-yl]phenyl]-2,2-dimethyl- (9CI) (CA INDEX NAME)



RE.CNT 39 THERE ARE 39 CITED REFERENCES AVAILABLE FOR THIS RECORD

L25 ANSWER 34 OF 88 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 2000:553562 CAPLUS
 DN 133:164049
 TI Preparation of pyrazolylbenzamides as antianemic agents
 IN Stoltefuss, Jurgen; Braunlich, Gabriele; Hinzen, Berthold; Kramer, Thomas;
 Pernerstorfer, Josef; Studemann, Thomas; Nielsch, Ulrich; Bechem, Martin;
 Lohrmann, Emanuel; Gerdes, Christoph; Sperzel, Michael; Lustig, Klemens;
 Mayr, Lorenz
 PA Bayer Aktiengesellschaft, Germany
 SO PCT Int. Appl., 36 pp.
 CODEN: PIXXD2
 DT Patent
 LA German
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000046207	A1	20000810	WO 2000-EP504	20000124
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG DE 19904391 A1 20000810 DE 1999-19904391 19990204				

PRAI DE 1999-19904391 A 19990204
 OS MARPAT 133:164049


AB Title compds. (I; R = R₃NHCOZ)(II; R₁ = H or alkyl, R₂ = (hetero)aryl; R₃ = (cyclo)alkyl; Z = (un)substituted 1,4-phenylene] were prepared. Thus, aminoresin-bound 4-(HO₂C)C₆H₄COMe was condensed with 4-(F₃C)C₆H₄CO₂Me and the product cyclocondensed with MeNHNH₂ to give, after N-methylation and cleavage, II [R₁ = R₃ = Me, R₂ = C₆H₄(CF₃)-4, Z = 1,4-phenylene]. Data for biol. activity of 1 prepared I were given.

IT **287936-37-2P 287936-41-8P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of pyrazolylbenzamides as antianemic agents)


RN 287936-37-2 CAPLUS

CN Benzamide, N-methyl-4-[1-methyl-5-[4-(trifluoromethyl)phenyl]-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)



RN 287936-41-8 CAPLUS

CN Benzamide, N-methyl-4-(1-methyl-5-phenyl-1H-pyrazol-3-yl)- (9CI) (CA
INDEX NAME)



RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L25 ANSWER 35 OF 88 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 2000:260283 CAPLUS
 DN 132:293757
 TI Preparation of novel 4,5-dihydroisoxazole derivatives and their use as
 pharmaceuticals for T cell-mediated diseases
 IN Freyne, Eddy Jean Edgard; Andres-Gil, Jose Ignacio; Deroose, Frederik
 Dirk; Petit, Davy Petrus Franciscus Maria; Matesanz-Ballesteros, Maria
 Encarnacion; Alvarez Escobar, Rosa Maria
 PA Janssen Pharmaceutica N.V., Belg.
 SO PCT Int. Appl., 108 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2000021959	A1	20000420	WO 1999-EP7803	19991007
W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
CA 2346396	AA	20000420	CA 1999-2346396	19991007
EP 1119568	A1	20010801	EP 1999-953847	19991007
EP 1119568	B1	20040218		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO			
JP 2002527438	T2	20020827	JP 2000-575865	19991007
AU 763460	B2	20030724	AU 2000-10393	19991007
AT 259803	E	20040315	AT 1999-953847	19991007
US 6583141	B1	20030624	US 2001-807149	20010406
US 2004019059	A1	20040129	US 2003-403543	20030331
PRAI EP 1998-203394	A	19981009		
WO 1999-EP7803	W	19991007		
US 2001-807149	A3	20010406		

OS MARPAT 132:293757

AB The invention concerns title compds. I and their N-oxides, pharmaceutically acceptable addition salts, quaternary ammonium salts, and stereochem. isomeric forms [wherein m, n, p = 0 or 1; R1 = (un)substituted pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl or phenyl; B = amide, ketone, or oxadiazole; D = (un)substituted aryl or heterocyclyl; Q = bond, CO, (un)substituted NH, CONH, CH2, CH(:CH2), C(:NH), SO, SO, 3-oxobutenyl, pyrazole, isoxazole, or thiazole nucleus; L = (un)substituted aryl or heteroaryl; R2, R3 = H, halo, C1-6 alkyloxy, or (un)substituted C1-6 alkyl]. Also disclosed is a process for their preparation, compns. comprising them, and their medical use. The compds. show growth inhibitory activity against T cell blasts and keratinocytes in vitro. The compds. are claimed for use in the treatment of prevention of rheumatic, arthritic, and inflammatory diseases, psoriasis, T cell leukemia, transplant rejection, and graft-vs.-host disease. For instance, base-catalyzed cycloaddn. of N-hydroxy-3-pyridinecarboximidoyl chloride with Me 2-propenoate gave 98% Me 4,5-dihydro-3-(3-pyridinyl)-5-isoxazolecarboxylate, which was amidated with (4-aminophenyl)phenylmethanone to give 58% title compound II. At a concentration of 10⁻⁶ M, II gave 81% inhibition of T cell blast formation in

human whole blood.


IT **264605-72-3P 264605-73-4P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(target compound; preparation of dihydroisoxazole derivs. as antiproliferatives and immunomodulators)


RN 264605-72-3 CAPLUS

CN 5-Isioxazolecarboxamide, N-[4-(4,5-dihydro-1-methyl-3-phenyl-1H-pyrazol-5-yl)phenyl]-4,5-dihydro-3-(3-pyridinyl)- (9CI) (CA INDEX NAME)



RN 264605-73-4 CAPLUS

CN 5-Isioxazolecarboxamide, N-[4-(4,5-dihydro-1-methyl-5-phenyl-1H-pyrazol-3-yl)phenyl]-4,5-dihydro-3-(3-pyridinyl)- (9CI) (CA INDEX NAME)



RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L25 ANSWER 36 OF 88 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 2000:247417 CAPLUS
 DN 132:265193
 TI Preparation of phenylpyrazoles and hypolipidemic agents
 IN Yamada, Hiroichi; Mochizuki, Nobuo; Uchida, Seiichi; Umeda, Nobihito
 PA Nippon Soda Co., Ltd., Japan
 SO Jpn. Kokai Tokkyo Koho, 19 pp.
 CODEN: JKXXAF

DT Patent
 LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 2000109465	A2	20000418	JP 1999-221791	19990804
PRAI	JP 1998-222159		19980805		

OS CASREACT 132:265193; MARPAT 132:265193

AB Title compds. I [R1 = H, C1-6 alkyl; X = CO, SO2; A = (CR3R2)p(CR4:CR5)q; B = (CR6R7)r; R2, R3, R6, R7 = H, cyano, OH, halo, C1-6 alkyl, C1-6 alkoxy etc.; R4, R5 = H, C1-6 alkyl, C1-6 haloalkyl, (un)substituted benzyl; p, r = 0-6; q = 0-1; Y = O, S, SO, SO2, CO, etc.; n = 0-1; D = (un)substituted Ph; naphthyl, tetrahydronaphthyl, indanyl; R11 = halo, C1-6 alkyl, C1-6 alkoxy; m = 0-2; R12 = H, C1-6 alkyl] or their pharmaceutically acceptable salts are prepared by dehydration of pyrazoles II (R1, R11, R12, m = same as I) with HO2CAY1BD (A, B, Y, D, n = same as I). 5-(4-Aminophenyl)pyrazole (1.59 g) was reacted with 3.09 g benzoyl chloride in the presence of NEt3 in DMF at room temperature for 20 h to give 1.31 g phenyl-N-[4-(pyrazol-5-yl)phenyl]carboxamide showing in vivo good hypolipidemic activity.

IT **263257-72-3P 263257-75-6P 263257-76-7P**

263257-77-8P 263257-78-9P 263257-79-0P


263257-80-3P 263257-81-4P 263257-82-5P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); IMF (Industrial manufacture); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of phenylpyrazoles by dehydration of aminophenylpyrazoles and carboxylic acids)


RN 263257-72-3 CAPLUS

CN Benzamide, N-[4-(1H-pyrazol-3-yl)phenyl]- (9CI) (CA INDEX NAME)




RN 263257-75-6 CAPLUS

CN Benzamide, 4-chloro-N-[4-(1H-pyrazol-3-yl)phenyl]- (9CI) (CA INDEX NAME)




RN 263257-76-7 CAPLUS

CN Benzamide, 4-fluoro-N-[4-(1H-pyrazol-3-yl)phenyl]- (9CI) (CA INDEX NAME)




RN 263257-77-8 CAPLUS

CN Benzamide, 2,4-dichloro-N-[4-(1H-pyrazol-3-yl)phenyl]- (9CI) (CA INDEX NAME)




RN 263257-78-9 CAPLUS

CN Acetamide, 2-phenoxy-N-[4-(1H-pyrazol-3-yl)phenyl]- (9CI) (CA INDEX NAME)




RN 263257-79-0 CAPLUS

CN Propanamide, 2-(4-chlorophenoxy)-2-methyl-N-[4-(1H-pyrazol-3-yl)phenyl]- (9CI) (CA INDEX NAME)




RN 263257-80-3 CAPLUS

CN Benzamide, N-[4-(1H-pyrazol-4-yl)phenyl]- (9CI) (CA INDEX NAME)




RN 263257-81-4 CAPLUS

CN Benzamide, N-[4-(1-methyl-1H-pyrazol-5-yl)phenyl]- (9CI) (CA INDEX NAME)



RN 263257-82-5 CAPLUS

CN Benzamide, N-[4-(1-methyl-1H-pyrazol-3-yl)phenyl]- (9CI) (CA INDEX NAME)



L25 ANSWER 37 OF 88 CAPLUS COPYRIGHT 2004 ACS on STN

AN 2000:98525 CAPLUS

DN 132:137396

TI Phenylazole compounds, process for producing the same and drugs for hyperlipemia

IN Umeda, Nobuhiro; Mochizuki, Nobuo; Uchida, Seiichi; Nishibe, Tadayuki; Yamada, Hirokazu; Ito, Kunihiro; Horikoshi, Hiromi

PA Nippon Soda Co., Ltd., Japan

SO PCT Int. Appl., 92 pp.

CODEN: PIXXD2

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000006550	A1	20000210	WO 1999-JP4070	19990729
	W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	CA 2339123	AA	20000210	CA 1999-2339123	19990729
	AU 9949297	A1	20000221	AU 1999-49297	19990729
	AU 753360	B2	20021017		
	EP 1101759	A1	20010523	EP 1999-933152	19990729
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO			
	CN 1131217	B	20031217	CN 1999-809019	19990729
	JP 2000290280	A2	20001017	JP 1999-216581	19990730
	JP 2000281656	A2	20001010	JP 1999-221789	19990804
	JP 2000281658	A2	20001010	JP 1999-221790	19990804
	US 6342516	B1	20020129	US 2001-744786	20010126
PRAI	JP 1998-218316	A	19980731		
	JP 1998-222157	A	19980805		
	JP 1999-16846	A	19990126		
	JP 1999-19670	A	19990128		
	JP 1999-24318	A	19990201		
	WO 1999-JP4070	W	19990729		

OS MARPAT 132:137396

AB Phenylpyrazole and phenylimidazole compds. represented by general formula (I; wherein A represents (un)substituted imidazolyl or pyrazolyl; B represents (un)substituted (CH₂)_k or (CH:CH)_k; Y = bond, O, S, SO₂, CO, OCH₂, C1-5 alkyl-(un)substituted NHCO or NH; Z = (un)substituted and saturated or unsatd. heterocycle containing 1 to 4 N, O or S atoms, (un)substituted benzoquinonyl or naphthoquinonyl) or pharmaceutically acceptable salts thereof are prepared Claimed are drugs for hyperlipemia which contain these compds. I as the active ingredient. Among all, compds. wherein Z is substituted chroman-2-yl, 2,3-dihydrobenzofuran-2-yl, etc. have an effect of inhibiting the formation of lipid peroxides too. Thus, 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid, 1-(4-aminophenyl)imidazole 4.0, 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride 2.82, 1-hydroxybenzotriazole 2.72 g, and 2.5 mL Et₃N were added to 30 mL DMF and stirred at room temperature for 20 h to give title compound (II). II and N-[4-(imidazol-1-yl)phenyl]-1-methyl-3-


pyrrolecarboxamide (III) at 25 mg/kg p.o. lowered total serum level of cholesterol 40 and 75%, resp., and serum triglyceride level by 62 and 91%, resp. A tablet formulation containing I was prepared

IT 256660-56-7P 256660-90-9P 256660-94-3P
256660-96-5P 256660-98-7P 256661-19-5P
256661-45-7P 256661-55-9P 256661-65-1P
256661-66-2P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of phenylazole compds. as hypolipidemics and inhibitors of lipid peroxide formation)


RN 256660-56-7 CAPLUS

CN 2H-1-Benzopyran-2-carboxamide, 3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyl-N-[4-(1H-pyrazol-3-yl)phenyl]- (9CI) (CA INDEX NAME)




RN 256660-90-9 CAPLUS

CN Naphtho[1,2-b]furan-2-carboxamide, 5-(acetyloxy)-2,3-dihydro-2,4-dimethyl-N-[5-oxo-5-[[4-(1H-pyrazol-3-yl)phenyl]amino]pentyl]- (9CI) (CA INDEX NAME)




RN 256660-94-3 CAPLUS

CN 2H-1-Benzopyran-2-carboxamide, 3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyl-N-[4-(1H-pyrazol-4-yl)phenyl]- (9CI) (CA INDEX NAME)




RN 256660-96-5 CAPLUS

CN 2H-1-Benzopyran-2-carboxamide, 3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyl-N-[4-(1-methyl-1H-pyrazol-3-yl)phenyl]- (9CI) (CA INDEX NAME)




RN 256660-98-7 CAPLUS

CN 1,3-Benzoxathiole-2-propanamide, 6-hydroxy-4,5,7-trimethyl-N-[4-(1H-pyrazol-3-yl)phenyl]- (9CI) (CA INDEX NAME)




RN 256661-19-5 CAPLUS

CN 1H-Indole-2-carboxamide, N-[4-(1H-pyrazol-3-yl)phenyl]- (9CI) (CA INDEX NAME)



RN 256661-45-7 CAPLUS


CN 3-Pyridinecarboxamide, N-[4-(1H-pyrazol-3-yl)phenyl]- (9CI) (CA INDEX NAME)



RN 256661-55-9 CAPLUS


CN 1H-Pyrrole-2-carboxamide, 1-methyl-N-[4-(1H-pyrazol-3-yl)phenyl]- (9CI)

(CA INDEX NAME)




RN 256661-65-1 CAPLUS

CN 2-Furancarboxamide, N-[4-(1H-pyrazol-3-yl)phenyl]- (9CI) (CA INDEX NAME)



RN 256661-66-2 CAPLUS

CN 2-Furancarboxamide, N-[4-(1H-pyrazol-4-yl)phenyl]- (9CI) (CA INDEX NAME)



L25 ANSWER 38 OF 88 CAPLUS COPYRIGHT 2004 ACS on STN

AN 1999:672842 CAPLUS

DN 131:317743

TI Drug screening with non-endogenous, constitutively activated human serotonin receptors and small molecule modulators thereof

IN Behan, Dominic P.; Chalmers, Derek T.; Foster, Richard J.; Glen, Robert C.; Lawless, Michael S.; Liaw, Chen W.; Liu, Qian; Russo, Joseph F.; Smith, Julian R.; Thomsen, William J.

PA Arena Pharmaceuticals, Inc., USA; Tripos, Inc.

SO PCT Int. Appl., 142 pp.


CODEN: PIXXD2

DT Patent

LA English


FAN.CNT 16

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9952927	A1	19991021	WO 1999-US8168	19990414
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	CA 2325559	AA	19991021	CA 1999-2325559	19990414
	AU 9937466	A1	19991101	AU 1999-37466	19990414
	AU 764766	B2	20030828		
	US 6107324 X	A	20000822	US 1999-292071	19990414
	US 6140509	A	20001031	US 1999-292069	19990414
	EP 1071701	A1	20010131	EP 1999-919835	19990414
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	JP 2003514763	T2	20030422	JP 2000-543483	19990414
PRAI	US 1998-60188	A	19980414		
	US 1998-90783P	P	19980626		
	US 1998-112909P	P	19981218		
	US 1999-123000P	P	19990305		
	WO 1999-US8168	W	19990414		
OS	MARPAT 131:317743				
AB	Disclosed herein are non-endogenous, constitutively activated forms of the human 5-HT2A and human 5-HT2C receptors and uses of such receptors to screen candidate compds. Further disclosed herein are candidate compds. identified by the screening method which act at the 5HT2A receptors. Yet further disclosed is a new class of compds. which act at the 5HT2A receptors.				
IT	247037-94-1P 247037-95-2P 247037-97-4P 247037-98-5P 247037-99-6P 247038-00-2P 247038-01-3P 247038-02-4P 247038-03-5P RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (drug screening with non-endogenous, constitutively activated human serotonin receptors and small mol. modulators thereof)				
RN	247037-94-1 CAPLUS				
CN	Benzamide, N-[3-(4-bromo-1-methyl-1H-pyrazol-3-yl)phenyl]-4-(trifluoromethoxy)- (9CI) (CA INDEX NAME)				




RN 247037-95-2 CAPLUS

CN 2-Thiophenecarboxamide, N-[3-(4-bromo-1-methyl-1H-pyrazol-3-yl)phenyl]-
(9CI) (CA INDEX NAME)




RN 247037-97-4 CAPLUS

CN Benzamide, N-[3-(4-bromo-1-methyl-1H-pyrazol-3-yl)phenyl]-4-chloro- (9CI)
(CA INDEX NAME)




RN 247037-98-5 CAPLUS

CN Benzeneacetamide, N-[3-(4-bromo-1-methyl-1H-pyrazol-3-yl)phenyl]-4-
(trifluoromethoxy)- (9CI) (CA INDEX NAME)




RN 247037-99-6 CAPLUS

CN Benzeneacetamide, N-[3-(4-bromo-1-methyl-1H-pyrazol-3-yl)phenyl]-3-fluoro-
(9CI) (CA INDEX NAME)




RN 247038-00-2 CAPLUS

CN Benzeneacetamide, N-[3-(4-bromo-1-methyl-1H-pyrazol-3-yl)phenyl]-3-methoxy-
(9CI) (CA INDEX NAME)




RN 247038-01-3 CAPLUS

CN Benzeneacetamide, N-[3-(4-bromo-1-methyl-1H-pyrazol-3-yl)phenyl]-2-fluoro-
(9CI) (CA INDEX NAME)




RN 247038-02-4 CAPLUS

CN Benzeneacetamide, N-[3-(4-bromo-1-methyl-1H-pyrazol-3-yl)phenyl]-4-nitro-
(9CI) (CA INDEX NAME)



RN 247038-03-5 CAPLUS

CN Benzeneacetamide, N-[3-(4-bromo-1-methyl-1H-pyrazol-3-yl)phenyl]-2-methoxy-
(9CI) (CA INDEX NAME)



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L25 ANSWER 39 OF 88 CAPLUS COPYRIGHT 2004 ACS on STN

AN 1999:271338 CAPLUS

DN 130:311815

TI Preparation of pyrazole derivatives as calcium release-dependent calcium channel inhibitors and inhibitors of interleukin-2 (IL-2) production

IN Kubota, Hirokazu; Yonetoku, Yasuhiro; Sugasawa, Keizou; Funatsu, Masashi; Kawazoe, Souichirou; Toyoshima, Akira; Okamoto, Yoshinori; Ishikawa, Jun; Takeuchi, Makoto

PA Yamanouchi Pharmaceutical Co., Ltd., Japan

SO PCT Int. Appl., 54 pp.

CODEN: PIXXD2

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9919303	A1	19990422	WO 1998-JP4583	19981012
	W: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, RO, RU, SD, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	AU 9887139	A1	19990429	AU 1998-87139	19980929
	AU 751139	B2	20020808		
	BR 9803883	A	20000516	BR 1998-3883	19981006
	RU 2185381	C2	20020720	RU 1998-118557	19981009
	CA 2304979	AA	19990422	CA 1998-2304979	19981012
	AU 9894593	A1	19990503	AU 1998-94593	19981012
	EP 1024138	A1	20000802	EP 1998-947818	19981012
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
	MX 9808433	A	20000930	MX 1998-8433	19981012
	TW 495498	B	20020721	TW 1998-87116918	19981012
	CN 1218046	A	19990602	CN 1998-121354	19981013
	CN 1107671	B	20030507		
	JP 11240832	A2	19990907	JP 1998-290734	19981013
	US 6348480	B1	20020219	US 2000-529131	20000407
	NO 2000001907	A	20000609	NO 2000-1907	20000412
	US 2001011090	A1	20010802	US 2001-773736	20010202
PRAI	JP 1997-279093	A	19971013		
	WO 1998-JP4583	W	19981012		
	US 2000-529131	A3	20000407		

OS MARPAT 130:311815

AB Pyrazole derivs. represented by general formula [I; ring D = pyrazolyl optionally substituted by 1-3 substituents selected from alkyl, lower alkenyl, lower alkynyl, lower haloalkyl, cycloalkylalkyl, alkoxyalkyl, cycloalkyl, alkoxy, CO₂H, alkoxy carbonyl, and halo; ring B = phenylene, a nitrogen-containing, divalent, saturated ring group, or an optionally alkylated, monocyclic, divalent heteroarom. ring group; X = -NR₁-CR₂R₃-, -CR₂R₃-NR₁-, -NR₁-SO₂-, -SO₂-NR₁- or -CR₄:CR₅-; wherein R₁ = H, OH, alkyl, alkoxy, alkylcarbonyl; R₂, R₃ = H or alkyl or R₂R₃ = O or S; R₄, R₅ = H, halo, lower haloalkyl; A = (1) Ph optionally having one or more substituents, (2) mono-, di- or tricyclic fused heteroaryl optionally having one or more substituents, (3) cycloalkyl optionally having one or more substituents, (4) a nitrogen-containing, saturated ring group optionally having one or more

substituents, (5) lower alkenyl optionally having one or more substituents, (6) lower alkynyl optionally having one or more substituents, or (7) alkyl optionally having one or more substituents; or A and X are combined together to represent 1-pyrrolidinylcarbonyl, pyrazolidinylcarbonyl, piperidinocarbonyl, piperazinylcarbonyl, morpholinocarbonyl, 3,4-dihydro-1,4-benzoxazin-4-ylcarbonyl, or indolylcarbonyl] are prepared. Also claimed are medicinal compns., in particular, calcium release-dependent calcium channel inhibitors, IL-2 production inhibitors, and therapeutics or preventives for allergies, inflammations, or autoimmune diseases, bronchial asthma, or rheumatoid arthritis for containing the above compds. I as the active ingredients. Thus, 4-methylthiazole-5-carboxylic acid was condensed with 4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]aniline using 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride in 1,2-dichloroethane at room temperature overnight to give the title compound, 4'-pyrazolylthiazole-5-carboxanilide derivative (II). II in vitro showed IC₅₀ of $\leq 1 \mu\text{M}$ $\mu\text{g/mL}$ for inhibiting the production of IL-2 in Jurkat cells.

IT 223499-51-2P 223499-52-3P 223499-53-4P

223499-54-5P 223499-55-6P 223499-56-7P

223499-57-8P 223499-58-9P 223499-62-5P

223499-64-7P 223499-65-8P 223499-68-1P

223499-69-2P 223499-70-5P 223499-71-6P

223499-72-7P 223499-73-8P 223499-74-9P

223499-75-0P 223499-76-1P 223499-77-2P

223499-78-3P 223499-79-4P 223499-81-8P

223499-82-9P 223499-83-0P 223499-84-1P

223499-85-2P 223499-86-3P 223499-87-4P

223499-88-5P 223499-90-9P 223499-91-0P

223499-92-1P 223499-93-2P 223499-95-4P

223499-96-5P 223499-98-7P 223499-99-8P


223500-00-3P 223500-01-4P 223500-02-5P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyrazole derivs. as calcium release-dependent calcium channel inhibitors and inhibitors of interleukin-2 production for treatment and prevention of diseases)


RN 223499-51-2 CAPLUS

CN 2-Thiophenecarboxamide, N-(4-chlorophenyl)-5-[1,4-dimethyl-5-(trifluoromethyl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 223499-52-3 CAPLUS

CN 2-Thiophenecarboxamide, N-(4-chlorophenyl)-5-[1,4-dimethyl-3-(trifluoromethyl)-1H-pyrazol-5-yl]- (9CI) (CA INDEX NAME)




RN 223499-53-4 CAPLUS

CN 2-Thiophenecarboxamide, N-(2-chlorophenyl)-5-[1-methyl-3-(trifluoromethyl)-1H-pyrazol-5-yl]- (9CI) (CA INDEX NAME)




RN 223499-54-5 CAPLUS

CN 2-Thiophenecarboxamide, N-(1-methyl-1H-pyrrol-2-yl)-5-[1-methyl-3-(trifluoromethyl)-1H-pyrazol-5-yl]- (9CI) (CA INDEX NAME)



RN 223499-55-6 CAPLUS


CN 2-Thiophenecarboxamide, N-ethyl-5-[1-methyl-3-(trifluoromethyl)-1H-pyrazol-5-yl]- (9CI) (CA INDEX NAME)



RN 223499-56-7 CAPLUS


CN 2-Thiophenecarboxamide, 5-[1-methyl-5-(trifluoromethyl)-1H-pyrazol-3-yl]-N-

2-thiazolyl- (9CI) (CA INDEX NAME)




RN 223499-57-8 CAPLUS

CN Benzamide, N-(4-chlorophenyl)-3-[1-methyl-5-(trifluoromethyl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 223499-58-9 CAPLUS

CN Benzamide, N-(4-chlorophenyl)-3-[1-methyl-3-(trifluoromethyl)-1H-pyrazol-5-yl]- (9CI) (CA INDEX NAME)




RN 223499-62-5 CAPLUS

CN 2-Thiophenecarboxamide, N-(4-chlorophenyl)-5-[5-(trifluoromethyl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 223499-64-7 CAPLUS

CN 2-Thiophenecarboxamide, N-(4-chlorophenyl)-5-[1-(1-methylethyl)-5-(trifluoromethyl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 223499-65-8 CAPLUS

CN 2-Thiophenecarboxamide, N-(4-chlorophenyl)-5-[1-methyl-3-(trifluoromethyl)-1H-pyrazol-5-yl]- (9CI) (CA INDEX NAME)



RN 223499-68-1 CAPLUS


CN 2-Thiophenecarboxamide, 5-[1-methyl-3-(trifluoromethyl)-1H-pyrazol-5-yl]-N-4-pyridinyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 223499-69-2 CAPLUS

CN 2-Thiophenecarboxamide, N-(4-hydroxyphenyl)-5-[1-methyl-3-(trifluoromethyl)-1H-pyrazol-5-yl]- (9CI) (CA INDEX NAME)




RN 223499-70-5 CAPLUS

CN 2-Thiophenecarboxamide, N-(2-methylphenyl)-5-[1-methyl-3-(trifluoromethyl)-1H-pyrazol-5-yl]- (9CI) (CA INDEX NAME)




RN 223499-71-6 CAPLUS

CN 2-Thiophenecarboxamide, N-(2,4-dichlorophenyl)-5-[1-methyl-3-(trifluoromethyl)-1H-pyrazol-5-yl]- (9CI) (CA INDEX NAME)



RN 223499-72-7 CAPLUS


CN 2-Thiophenecarboxamide, N-(2-fluorophenyl)-5-[1-methyl-3-(trifluoromethyl)-1H-pyrazol-5-yl]- (9CI) (CA INDEX NAME)



RN 223499-73-8 CAPLUS


CN 2-Thiophenecarboxamide, 5-[1-methyl-3-(trifluoromethyl)-1H-pyrazol-5-yl]-N-

phenyl- (9CI) (CA INDEX NAME)




RN 223499-74-9 CAPLUS

CN 2-Thiophenecarboxamide, N-(4-fluorophenyl)-5-[1-methyl-3-(trifluoromethyl)-1H-pyrazol-5-yl]- (9CI) (CA INDEX NAME)




RN 223499-75-0 CAPLUS

CN 2-Thiophenecarboxamide, N-(4-bromophenyl)-5-[1-methyl-3-(trifluoromethyl)-1H-pyrazol-5-yl]- (9CI) (CA INDEX NAME)




RN 223499-76-1 CAPLUS

CN 2-Thiophenecarboxamide, 5-[1-methyl-3-(trifluoromethyl)-1H-pyrazol-5-yl]-N-1H-tetrazol-5-yl- (9CI) (CA INDEX NAME)




RN 223499-77-2 CAPLUS

CN 2-Thiophenecarboxamide, 5-[1-methyl-3-(trifluoromethyl)-1H-pyrazol-5-yl]-N-2-thienyl- (9CI) (CA INDEX NAME)




RN 223499-78-3 CAPLUS

CN 2-Thiophenecarboxamide, 5-[1-methyl-3-(trifluoromethyl)-1H-pyrazol-5-yl]-N-3-thienyl- (9CI) (CA INDEX NAME)




RN 223499-79-4 CAPLUS

CN 2-Thiophenecarboxamide, 5-[1-methyl-3-(trifluoromethyl)-1H-pyrazol-5-yl]-N-4H-1,2,4-triazol-4-yl- (9CI) (CA INDEX NAME)




RN 223499-81-8 CAPLUS

CN 2-Thiophenecarboxamide, N-(3-chlorophenyl)-5-[1-methyl-5-(trifluoromethyl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 223499-82-9 CAPLUS

CN 2-Thiophenecarboxamide, N-[(4-chlorophenyl)methyl]-5-[1-methyl-5-(trifluoromethyl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 223499-83-0 CAPLUS

CN 2-Thiophenecarboxamide, N-(4-chlorophenyl)-5-[1-methyl-5-(trifluoromethyl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 223499-84-1 CAPLUS

CN 2-Thiophenecarboxamide, 5-[1-methyl-5-(trifluoromethyl)-1H-pyrazol-3-yl]-N-(4-nitrophenyl)- (9CI) (CA INDEX NAME)



RN 223499-85-2 CAPLUS


CN 2-Thiophenecarboxamide, N-[4-(dimethylamino)phenyl]-5-[1-methyl-5-(trifluoromethyl)-1H-pyrazol-3-yl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 223499-86-3 CAPLUS

CN 2-Thiophenecarboxamide, 5-[1-methyl-5-(trifluoromethyl)-1H-pyrazol-3-yl]-N-3-pyridinyl- (9CI) (CA INDEX NAME)




RN 223499-87-4 CAPLUS

CN 2-Thiophenecarboxamide, 5-[1-methyl-5-(trifluoromethyl)-1H-pyrazol-3-yl]-N-1H-pyrrol-1-yl- (9CI) (CA INDEX NAME)




RN 223499-88-5 CAPLUS

CN 1,2,3-Thiadiazole-5-carboxamide, 4-methyl-N-[5-[1-methyl-3-(trifluoromethyl)-1H-pyrazol-5-yl]-2-thienyl]- (9CI) (CA INDEX NAME)




RN 223499-90-9 CAPLUS

CN Benzamide, 4-chloro-N-[5-[1-methyl-5-(trifluoromethyl)-1H-pyrazol-3-yl]-2-thienyl]- (9CI) (CA INDEX NAME)




RN 223499-91-0 CAPLUS

CN Benzamide, 4-chloro-N-[5-[1-methyl-3-(trifluoromethyl)-1H-pyrazol-5-yl]-2-thienyl]- (9CI) (CA INDEX NAME)




RN 223499-92-1 CAPLUS

CN Benzamide, 4-chloro-N-[4-[1-methyl-3-(trifluoromethyl)-1H-pyrazol-5-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 223499-93-2 CAPLUS

CN 1,2,3-Thiadiazole-5-carboxamide, 4-methyl-N-[4-[1-methyl-3-(trifluoromethyl)-1H-pyrazol-5-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 223499-95-4 CAPLUS

CN 2-Thiophenecarboxamide, N-(4-chlorophenyl)-5-(1,3-dimethyl-1H-pyrazol-5-yl)- (9CI) (CA INDEX NAME)




RN 223499-96-5 CAPLUS

CN 2-Thiophenecarboxamide, N-(4-chlorophenyl)-5-(1-methyl-1H-pyrazol-5-yl)- (9CI) (CA INDEX NAME)




RN 223499-98-7 CAPLUS

CN 2-Thiophenecarboxamide, N-[4-(1-methylethyl)phenyl]-5-[1-methyl-3-(trifluoromethyl)-1H-pyrazol-5-yl]- (9CI) (CA INDEX NAME)




RN 223499-99-8 CAPLUS

CN 2-Thiophenecarboxamide, N-(4-cyanophenyl)-5-[1-methyl-3-(trifluoromethyl)-1H-pyrazol-5-yl]- (9CI) (CA INDEX NAME)




RN 223500-00-3 CAPLUS

CN 2-Thiophenecarboxamide, N-(4-aminophenyl)-5-[1-methyl-3-(trifluoromethyl)-1H-pyrazol-5-yl]- (9CI) (CA INDEX NAME)




RN 223500-01-4 CAPLUS

CN 2-Thiophenecarboxamide, N-(4-methoxyphenyl)-5-[1-methyl-3-(trifluoromethyl)-1H-pyrazol-5-yl]- (9CI) (CA INDEX NAME)



RN 223500-02-5 CAPLUS

CN Benzoic acid, 4-[[[5-[1-methyl-3-(trifluoromethyl)-1H-pyrazol-5-yl]-2-thienyl]carbonyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




IT 223500-11-6

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of pyrazole derivs. as calcium release-dependent calcium channel inhibitors and inhibitors of interleukin-2 production for treatment and prevention of diseases)

RN 223500-11-6 CAPLUS

CN 2-Thiophenecarboxamide, N-(4-chlorophenyl)-5-[4-methyl-5-(trifluoromethyl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)



RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L25 ANSWER 40 OF 88 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 1998:745030 CAPLUS
 DN 130:13915
 TI Indole derivatives having combined 5HT1A, 5HT1B, and 5HT1D receptor antagonist activity
 IN Gaster, Laramie Mary; Rami, Harshad Kantilal; Wyman, Paul Adrian
 PA Smithkline Beecham PLC, UK
 SO PCT Int. Appl., 119 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9850358	A1	19981112	WO 1998-EP2262	19980414
	W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, VZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, RW:	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG		
	AU 9874310	A1	19981127	AU 1998-74310	19980414
	AU 732863	B2	20010503		
	EP 975593	A1	20000202	EP 1998-921462	19980414
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI			
	TR 9902590	T2	20000621	TR 1999-9902590	19980414
	JP 2001524116	T2	20011127	JP 1998-547660	19980414
	BR 9809092	A	20020122	BR 1998-9092	19980414
	ZA 9803242	A	19991018	ZA 1998-3242	19980417
	TW 509687	B	20021111	TW 1998-87105843	19980417
	NO 9905065	A	19991015	NO 1999-5065	19991015
	MX 9909583	A	20000331	MX 1999-9583	19991018
PRAI	GB 1997-7829	A	19970418		
	GB 1998-1882	A	19980129		
	WO 1998-EP2262	W	19980414		
OS	MARPAT 130:13915				
AB	The title compds. I [Ra is a group of formula Q, in which Pl is Ph, bicyclic aryl, a 5- to 7-membered heterocyclic ring containing 1 to 3 heteroatoms selected from oxygen, nitrogen and sulfur, or a bicyclic heterocyclic ring containing 1 to 3 heteroatoms selected from oxygen, nitrogen and sulfur; R1 = H, halo, C1-6alkyl, C3-6cycloalkyl, COC1-6alkyl, C1-6alkoxy, hydroxy, hydroxyC1-6alkyl, hydroxyC1-6alkoxy, C1-6alkoxyC1-6alkoxy, C1-6alkanoyl, nitro, trifluoromethyl, cyano, SR9, SOR9, SO2R9, SO2NR10R11, CO2R10, CONR10R11, CO2NR10R11, CONR10(CH2)cCO2R11, (CH2)cNR10R11, (CH2)cCONR10R11, (CH2)cNR10COR11, (CH2)cCO2C1-6alkyl, CO2(CH2)cOR10, NR10R11, NR10CO2R11, NR10CONR10R11, CR10:NOR11, NR10COOR11, CNR10:NOR11, where R10 and R11 are independently hydrogen or C1-6alkyl and c is 1 to 4; R2 = H, halo, C1-6alkyl, C3-6cycloalkyl, C3-6cycloalkenyl, C1-6alkoxy, acyl, aryl, acyloxy, hydroxy, nitro, trifluoromethyl, cyano, CO2R10, CONR10R11, NR10R11 where R10 and R11 are as defined for R1; a is 1, 2 or 3; or Ra is a group containing bridged rings; Y = NH, alkylamino, CH2, O; V = O, S; D = N, C, CH; W = (CR16R17)t where t = 2-4 and R16 and R17 = H, alkyl, etc.; Rb = H, halo, OH, etc.; Rc = H, alkyl] were prepared and their 5HT1A,, 5HT1B, and 5HT1D receptor binding determined E.g., 5-methoxy-6-(4-methylpiperazin-1-yl)indole				

was treated with KOCMe₃, then with 4-bromo-3-methylphenyl isocyanate to give 1-[(4-bromo-3-methylphenyl)aminocarbonyl]-5-methoxy-6-(4-methylpiperazin-1-yl)indole.


IT **216059-23-3P 216059-24-4P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of indole derivs. having combined 5HT_{1A}, 5HT_{1B}, and 5HT_{1D} receptor antagonist activity)


RN 216059-23-3 CAPLUS

CN 1H-Indole-1-carboxamide, 5-chloro-2,3-dihydro-6-(4-methyl-1-piperazinyl)-N-[4-(1-methyl-1H-pyrazol-4-yl)phenyl]- (9CI) (CA INDEX NAME)



RN 216059-24-4 CAPLUS


CN 1H-Indole-1-carboxamide, 5-bromo-2,3-dihydro-6-(4-methyl-1-piperazinyl)-N-[4-(1-methyl-1H-pyrazol-4-yl)phenyl]- (9CI) (CA INDEX NAME)



RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L25 ANSWER 41 OF 88 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 1998:604906 CAPLUS
 DN 129:216422
 TI Preparation of N-(ar)alkyl-4-(hetero)arylbenzamides and analogs as class
 III antiarrhythmic agents
 IN Lloyd, John; Rovnyak, George C.; Stein, Philip D.; Ahmad, Saleem; Atwal,
 Karnail S.; Caulfield, Thomas J.; Poss, Michael A.
 PA Bristol-Myers Squibb Co., USA
 SO PCT Int. Appl., 143 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9837068	A1	19980827	WO 1998-US2364	19980206
	W:	AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
	AU 9863209	A1	19980909	AU 1998-63209	19980206
	US 2002137968	A1	20020926	US 2001-973826	20011010
	US 6624309	B1	20030923	US 2002-254398	20020925
PRAI	US 1997-38811P	P	19970221		
	US 1998-8825	B1	19980120		
	WO 1998-US2364	W	19980206		
	US 1999-468648	A1	19991221		
	US 2001-973826	B1	20011010		
OS	MARPAT 129:216422				
AB	R2ZC(:X)NHR1 [R1 = (cyclo)alkyl, heterocyclyl, aryl, etc.; R2 = heterocyclyl, aryl; X = O, S, (alkyl)imino, NCN, etc.; Z = bond, C:C (sic), NH] were prepared as class III antiarrhythmic agents (no data). Thus, 2,2-dimethylcyclopentanone was treated with 4-MeC6H4SO2CH2NC and the reduced product amidated by 4-(BuCH2CH2O)C6H4COCl to give 4-(BuCH2CH2O)C6H4CONHR1 (R1 = 2,2-dimethylcyclopentylmethyl).				
IT	212379-92-5P 212380-07-9P 212381-41-4P RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of N-(ar)alkyl-4-(hetero)arylbenzamides and analogs as class III antiarrhythmic agents)				
RN	212379-92-5 CAPLUS				
CN	2-Thiophenecarboxamide, N-(3,3-dimethylbutyl)-5-[1-methyl-3-(trifluoromethyl)-1H-pyrazol-5-yl]- (9CI) (CA INDEX NAME)				



Provin.


RN 212380-07-9 CAPLUS

CN 2-Thiophenecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-5-[1-methyl-3-(trifluoromethyl)-1H-pyrazol-5-yl]- (9CI) (CA INDEX NAME)



RN 212381-41-4 CAPLUS

CN Benzamide, 4-(5-butyl-1H-pyrazol-3-yl)-N-[(2,2-dimethylcyclopentyl)methyl]- (9CI) (CA INDEX NAME)



RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L25 ANSWER 42 OF 88 CAPLUS COPYRIGHT 2004 ACS on STN

AN 1998:603272 CAPLUS

DN 129:230732

TI Preparation of N-(2-heterocyclylphenyl)amides as herbicides

IN Andree, Roland; Drewes, Mark Wilhelm; Findeisen, Kurt; Kluth, Joachim;
Linker, Karl-Heinz; Mueller, Klaus-Helmut; Schallner, Otto; Dollinger,
Markus

PA Bayer A.-G., Germany

SO Ger. Offen., 70 pp.


CODEN: GWXXBX

DT Patent

LA German


FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 19708928	A1	19980910	DE 1997-19708928	19970305
	WO 9839304	A1	19980911	WO 1998-EP972	19980220
	W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
	AU 9866226	A1	19980922	AU 1998-66226	19980220
	AU 731129	B2	20010322		
	EP 973752	A1	20000126	EP 1998-908103	19980220
	R:	BE, CH, DE, DK, ES, FR, GB, IT, LI, NL			
	BR 9808200	A	20000516	BR 1998-8200	19980220
	JP 2001513785	T2	20010904	JP 1998-538103	19980220
	MX 9908144	A	20000131	MX 1999-8144	19990903
	US 6602826	B1	20030805	US 1999-367476	19990920
	US 6686318	B1	20040203	US 2003-420203	20030422
PRAI	DE 1997-19708928	A	19970305		
	WO 1998-EP972	W	19980220		
	US 1999-367476	A3	19990920		
OS	MARPAT 129:230732				
AB	RZNR1R2 [I; R = heterocyclyl; R1 = H, OH, alkyl, (di)(alkyl)amino, acyl, etc.; R2 = alkanoyl, aroyl, alkoxycarbonyl, alkylsulfonyl, etc.; Z = (un)substituted 1,2-phenylene] were prepared Thus, 5,2-Cl(O2N)C6H3NH2 was treated successively with ClCO2CCl3 and EtOH and the product cyclocondensed with F3CC(NH2):CHCO2Et to give phenylpyrimidinedione II (R3 = NO2) which was converted in 2 steps to II (R3 = NHCOCMe3). Data for biol. activity of I were given.				
IT	212903-85-0P 212903-87-2P				
	RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)				
	(preparation of N-(2-heterocyclylphenyl)amides as herbicides)				
RN	212903-85-0 CAPLUS				
CN	Benzamide, N-[2-[1-methyl-5-(trifluoromethyl)-1H-pyrazol-3-yl]phenyl]-(9CI) (CA INDEX NAME)				



RN 212903-87-2 CAPLUS

CN Benzamide, N-[2-[4-chloro-1-methyl-5-(trifluoromethyl)-1H-pyrazol-3-yl]phenyl]- (9CI) (CA INDEX NAME)



L25 ANSWER 43 OF 88 CAPLUS COPYRIGHT 2004 ACS on STN

AN 1998:269994 CAPLUS

DN 128:278647

TI New Azole Antifungals. 2. Synthesis and Antifungal Activity of Heterocyclecarboxamide Derivatives of 3-Amino-2-aryl-1-azolyl-2-butanol

AU Bartroli, Javier; Turmo, Enric; Alguero, Monica; Boncompte, Eulalia; Vericat, Maria L.; Conte, Lourdes; Ramis, Joaquim; Merlos, Manuel; Garcia-Rafanell, Julian; Forn, Javier

CS Research Center, J. Uriach Cia. S.A., Barcelona, 08026, Spain

SO Journal of Medicinal Chemistry (1998), 41(11), 1855-1868

CODEN: JMCMAR; ISSN: 0022-2623

PB American Chemical Society

DT Journal

LA English

AB A series of 92 azole antifungals containing an amido alc. unit was synthesized. The nature and substitution of the amide portion was systematically modified in search of improved antifungal activity, especially against filamentous fungi. The compds. were tested in vitro against a variety of clin. important pathogens and in vivo (po) in a murine candidosis model. Thiazole and thiophene carboxamides carrying both a substituted Ph ring and a small alkyl group were best suited for activity against filamentous fungi. In a subset of these compds., the amide portion was conformationally locked by means of a pyrimidone ring and it was proven that only an orthogonal orientation of the Ph ring yields bioactive products. A tendency to display long plasma elimination half-lives was observed in both series. Two compds., I and 107, representative of the open and cyclic amides, resp., were chosen for further studies. Both candidates showed excellent activity in in vivo murine models of candidosis and aspergillosis, but their long elimination rates and high toxicities were still unsatisfactory. This work describes the SARs found within this series. The next paper displays the results obtained in a related series of compds., the quinazolinones.

IT 187997-93-9P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(synthesis and antifungal activity of heterocyclecarboxamide derivs. of 3-amino-2-aryl-1-azolyl-2-butanol)

RN 187997-93-9 CAPLUS

CN 2-Thiophenecarboxamide, N-[2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl]-5-[1-methyl-3-(trifluoromethyl)-1H-pyrazol-5-yl]-, [R-(R*,R*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



L25 ANSWER 44 OF 88 CAPLUS COPYRIGHT 2004 ACS on STN

AN 1997:752936 CAPLUS

DN 128:34690

TI Preparation of N-(acylaminobutyl)tetrahydroisoquinoline derivatives as modulators of dopamine D3 receptors.

IN Stemp, Geoffrey; Johns, Amanda

PA Smithkline Beecham P.L.C., UK; Stemp, Geoffrey; Johns, Amanda

SO PCT Int. Appl., 53 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9743262	A1	19971120	WO 1997-EP2434	19970506
	W:	AL, AM, AT, AU, AZ, BA, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, AM, AZ, BY, BG, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
	AU 9728974	A1	19971205	AU 1997-28974	19970506
	EP 917530	A1	19990526	EP 1997-923065	19970506
	EP 917530	B1	20030219		
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI			
	CN 1224418	A	19990728	CN 1997-196136	19970506
	BR 9709220	A	19990810	BR 1997-9220	19970506
	TR 9802284	T2	20000522	TR 1998-9802284	19970506
	NZ 332477	A	20000728	NZ 1997-332477	19970506
	JP 2000510137	T2	20000808	JP 1997-540515	19970506
	AT 232850	E	20030315	AT 1997-923065	19970506
	ES 2191838	T3	20030916	ES 1997-923065	19970506
	ZA 9704026	A	19981125	ZA 1997-4026	19970509
	US 6046210	A	20000404	US 1998-180156	19981103
	NO 9805242	A	19981209	NO 1998-5242	19981110
	KR 2000010905	A	20000225	KR 1998-709052	19981110
PRAI	GB 1996-9888	A	19960511		
	GB 1996-17189	A	19960816		
	GB 1997-4490	A	19970305		
	WO 1997-EP2434	W	19970506		

OS MARPAT 128:34690


AB Title compds. [I; R1 = H, halo, OH, cyano, NO2, CF3, OCF3, F3CSO2O, alkyl, alkoxy, aralkoxy, alkylthio, alkoxyalkyl, cycloalkylalkoxy, alkanoyl, alkoxy carbonyl, alkylsulfonyl, alkylsulfonyloxy, alkylsulfonylalkyl, arylsulfonyl, arylsulfonyloxy, arylsulfonylalkyl, alkylsulfonamido, alkylamido, alkylsulfonamidoalkyl, alkylamidoalkyl, arylsulfonamido, arylcarboxamido, arylsulfonamidoalkyl, arylcarboxamidoalkyl, aroyl, aroylalkyl, arylalkanoyl, etc.; R2 = H, alkyl; q = 1, 2; Ar, Ar1 = (substituted) Ph, 5-6 membered aromatic heterocyclyl; Y = bond, NHCO, CONH, CH2, (CH2)mY1(CH2)n; Y1 = O, S, SO2, CO; m, n = 0, 1; m+n = 0, 1], were prepared as, e.g., antipsychotics (no data). Thus, sodium triacetoxymethylborohydride, 4-(4-phenylbenzoylamino)butyraldehyde, and 7-methoxy-1,2,3,4-tetrahydroisoquinoline were stirred 16 h in 1,2-dichloroethane to give 83% 7-methoxy-N-[4-(4-phenylbenzoylamino)butyl]-1,2,3,4-tetrahydroisoquinoline.

IT 199677-02-6P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of N-(acylaminobutyl)tetrahydroisoquinoline derivs. as modulators of dopamine D3 receptors)

RN 199677-02-6 CAPLUS


CN Methanesulfonic acid, trifluoro-, 1,2,3,4-tetrahydro-2-[4-[[4-(1-methyl-1H-pyrazol-4-yl)benzoyl]amino]butyl]-7-isoquinoliny] ester (9CI) (CA INDEX NAME)



L25 ANSWER 45 OF 88 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 1997:698412 CAPLUS
 DN 127:332777
 TI Synthesis of some new pyrazolines from 4-amino-4-methoxybenzalacetophenone as dyestuffs intermediates
 AU Sayed, A. Z.; Eman, H. A.; Selim, M. R.
 CS Chemistry Department, Faculty of Science, Al-Azhar University, Nasr City, Egypt
 SO Pakistan Journal of Scientific and Industrial Research (1996), 39(1-4), 14-17
 CODEN: PSIRAA; ISSN: 0030-9885
 PB Pakistan Council of Scientific and Industrial Research
 DT Journal
 LA English
 AB New aminopyrazoline derivs. (I), where R = H, COCH₃; R' = H, Ph, SO₂R'', R'' = Ph, 4-tolyl, 2,5-(NHCOCH₃)(CH₃)C₆H₃ has been obtained by the reaction of new benzalacetophenone derivs. with hydrazine hydrate and their derivs. Further reactions were carried out to prepare other pyrazolines. The structural determination of the prepared compds. has been confirmed using elemental anal., chemical reactions and spectral data.
 IT **85791-58-8P**
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (synthesis of some new pyrazolines from 4-amino-4-methoxybenzalacetophenone as dyestuffs intermediates)
 RN 85791-58-8 CAPLUS
 CN Acetamide, N-[4-[4,5-dihydro-5-(4-methoxyphenyl)-1H-pyrazol-3-yl]phenyl]-(9CI) (CA INDEX NAME)




IT **85791-61-3P 188291-90-9P 188291-91-0P**
188291-92-1P 188291-93-2P 188291-94-3P
188291-95-4P 188291-96-5P 188291-97-6P
197960-91-1P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (synthesis of some new pyrazolines from 4-amino-4-methoxybenzalacetophenone as dyestuffs intermediates)
 RN 85791-61-3 CAPLUS
 CN Acetamide, N-[4-[1-acetyl-4,5-dihydro-5-(4-methoxyphenyl)-1H-pyrazol-3-yl]phenyl]-(9CI) (CA INDEX NAME)




RN 188291-90-9 CAPLUS

CN Acetamide, N-[4-[1-formyl-4,5-dihydro-5-(4-methoxyphenyl)-1H-pyrazol-3-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 188291-91-0 CAPLUS

CN Acetamide, N-[4-[4,5-dihydro-5-(4-methoxyphenyl)-1-(1-oxopropyl)-1H-pyrazol-3-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 188291-92-1 CAPLUS

CN Acetamide, N-[4-[4,5-dihydro-5-(4-methoxyphenyl)-1-(1-oxobutyl)-1H-pyrazol-3-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 188291-93-2 CAPLUS

CN Acetamide, N-[4-[4,5-dihydro-5-(4-methoxyphenyl)-1-(2-methyl-1-oxopropyl)-1H-pyrazol-3-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 188291-94-3 CAPLUS

CN Acetamide, N-[4-[4,5-dihydro-5-(4-methoxyphenyl)-1-(1-oxopentyl)-1H-pyrazol-3-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 188291-95-4 CAPLUS

CN Acetamide, N-[4-[4,5-dihydro-5-(4-methoxyphenyl)-1-(1-oxohexyl)-1H-pyrazol-3-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 188291-96-5 CAPLUS

CN Acetamide, N-[4-[1-benzoyl-4,5-dihydro-5-(4-methoxyphenyl)-1H-pyrazol-3-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 188291-97-6 CAPLUS

CN Acetamide, N-[4-[4,5-dihydro-5-(4-methoxyphenyl)-1-(4-nitrobenzoyl)-1H-pyrazol-3-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 197960-91-1 CAPLUS


CN Acetamide, N-[4-[1-(4-ethenylbenzoyl)-4,5-dihydro-5-(4-methoxyphenyl)-1H-pyrazol-3-yl]phenyl]- (9CI) (CA INDEX NAME)



L25 ANSWER 46 OF 88 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 1997:576862 CAPLUS
 DN 127:293164
 TI Functionalized pyrazoles through a facile one-pot procedure from
 N-tolyl-N-propargylhydrazine and aryl iodides or vinyl triflates
 AU Cacchi, Sandro; Fabrizi, Giancarlo; Carangio, Antonella
 CS Dipartimento Studi Chimica Tecnologia Sostanze Biologicamente Attive,
 Universita "La Sapienza", Rome, I-00185, Italy
 SO Synlett (1997), (8), 959-961
 CODEN: SYNLES; ISSN: 0936-5214
 PB Thieme
 DT Journal
 LA English
 OS CASREACT 127:293164
 AB 3-Substituted pyrazoles were prepared in good overall yield through a facile
 one-pot procedure. The synthesis includes the Pd-catalyzed coupling of
 readily available N-tosyl-N-propargylhydrazine with aryl iodides or vinyl
 triflates, the Pd-catalyzed annulation of the resulting
 N-tosyl-N-(1-aryl/vinyl-1-propyn-3-yl)hydrazines, and subsequent treatment
 with KOCMe₃.
 IT **197093-24-6P 197093-26-8P**
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of pyrazoles from tolylpropargylhydrazine and aryl iodides or
 vinyl triflates)
 RN 197093-24-6 CAPLUS
 CN Acetamide, N-[3-(1H-pyrazol-3-yl)phenyl]- (9CI) (CA INDEX NAME)




RN 197093-26-8 CAPLUS
 CN Acetamide, N-[4-(1H-pyrazol-3-yl)phenyl]- (9CI) (CA INDEX NAME)




L25 ANSWER 47 OF 88 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 1997:226815 CAPLUS
 DN 126:212156
 TI Preparation of heteroarylcarboxamides as agrochemical and medical fungicides
 IN Bartroli, Javier; Turmo, Enric; Anguita, Manuel
 PA J. Uriach & Cia. S.A., Spain; Bartroli, Javier; Turmo, Enric; Anguita, Manuel
 SO PCT Int. Appl., 84 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9705131	A1	19970213	WO 1996-EP3419	19960802
	W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE				
	RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM				
	ES 2107376	A1	19971116	ES 1995-1564	19950802
	ES 2107376	B1	19980701		
	BR 9606546	A	19980714	BR 1996-6546	19950802
	ES 2112774	A1	19980401	ES 1995-2042	19951020
	ES 2112774	B1	19990516		
	CA 2201478	AA	19970213	CA 1996-2201478	19960802
	AU 9667889	A1	19970226	AU 1996-67889	19960802
	EP 783502	A1	19970716	EP 1996-928404	19960802
	R: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
	JP 10507205	T2	19980714	JP 1996-507253	19960802
	US 5888941	A	19990330	US 1997-809815	19970331
	NO 9701471	A	19970530	NO 1997-1471	19970401
PRAI	ES 1995-1564	A	19950802		
	ES 1995-2042	A	19951020		
	WO 1996-EP3419	W	19960802		
OS	MARPAT 126:212156				
AB	RCH2CR5(OR4)CR1R2NR3COZ1(CH2)mZ2(CH2)qR6 [I; R = imidazolo or 1,2,4-triazo-1-yl; R1 = alkyl; R2 = H or alkyl; R1R2 = alkylene; R3 = H (halo)alkyl, Ph, etc.; R4 = H; R3R4 = CH2, CH2CH2, CH(OH)CH2, COCH2; R5 = (halo- or CF3-substituted) Ph; R6 = (un)substituted Ph, -heterocyclyl; Z1 = (un)substituted phenylene or -heterocyclylene; Z2 = bond, O, SOO-2, NR6; m,q = 0-2] were prepared Thus, (2R,3R)-3-amino-2-(2,4-difluorophenyl)-1-(1H-1,2,4-triazol-1-yl)-2-butanol was amidated by 1-(4-chlorophenyl)-1H-pyrazole-4-carboxylic acid (preparation given) to give title compound (R,R)-II. Data for biol. activity of I were given.				
IT	187997-93-9P RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of heteroarylcarboxamides as agrochem. and medical fungicides)				
RN	187997-93-9 CAPLUS				
CN	2-Thiophenecarboxamide, N-[2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl]-5-[1-methyl-3-(trifluoromethyl)-1H-pyrazol-5-yl]-, [R-(R*,R*)]- (9CI) (CA INDEX NAME)				


Absolute stereochemistry. Rotation (-).



L25 ANSWER 48 OF 88 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 1997:194068 CAPLUS
 DN 126:225248
 TI Synthesis of new pyrazolines from aminomethoxychalcones
 AU Sayed, A. Z.; Emam, H. A.; Selim, M. R.
 CS Chemistry Department, Faculty of Science, Al-Azhar University, Nasr, Egypt
 SO Al-Azhar Journal of Pharmaceutical Sciences (1996), 17, 107-115
 CODEN: AAJPFT; ISSN: 1110-1644
 PB Al-Azhar University, Faculty of Pharmacy
 DT Journal
 LA English
 AB Pyrazolines I (R = 4-aminophenyl, 4-acetamidophenyl; R1 = H, Ph, arylsulfonyl, acyl, etc.) were prepared from 4-RCOCH:CHC6H4OMe.
 IT **85791-61-3P 188291-90-9P 188291-91-0P**
188291-92-1P 188291-93-2P 188291-94-3P
188291-95-4P 188292-02-6P 188292-03-7P
188292-04-8P 188292-05-9P 188292-06-0P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 85791-61-3 CAPLUS
 CN Acetamide, N-[4-[1-acetyl-4,5-dihydro-5-(4-methoxyphenyl)-1H-pyrazol-3-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 188291-90-9 CAPLUS
 CN Acetamide, N-[4-[1-formyl-4,5-dihydro-5-(4-methoxyphenyl)-1H-pyrazol-3-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 188291-91-0 CAPLUS

CN Acetamide, N-[4-[4,5-dihydro-5-(4-methoxyphenyl)-1-(1-oxopropyl)-1H-pyrazol-3-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 188291-92-1 CAPLUS

CN Acetamide, N-[4-[4,5-dihydro-5-(4-methoxyphenyl)-1-(1-oxobutyl)-1H-pyrazol-3-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 188291-93-2 CAPLUS

CN Acetamide, N-[4-[4,5-dihydro-5-(4-methoxyphenyl)-1-(2-methyl-1-oxopropyl)-1H-pyrazol-3-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 188291-94-3 CAPLUS

CN Acetamide, N-[4-[4,5-dihydro-5-(4-methoxyphenyl)-1-(1-oxopentyl)-1H-pyrazol-3-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 188291-95-4 CAPLUS

CN Acetamide, N-[4-[4,5-dihydro-5-(4-methoxyphenyl)-1-(1-oxohexyl)-1H-pyrazol-3-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 188292-02-6 CAPLUS

CN 1H-Pyrazole-1-carboxamide, 3-[4-(acetylamino)phenyl]-4,5-dihydro-5-(4-methoxyphenyl)-N-methyl- (9CI) (CA INDEX NAME)




RN 188292-03-7 CAPLUS

CN 1H-Pyrazole-1-carboxamide, 3-[4-(acetylamino)phenyl]-4,5-dihydro-5-(4-methoxyphenyl)-N-phenyl- (9CI) (CA INDEX NAME)




RN 188292-04-8 CAPLUS

CN Acetamide, N-[4-[4,5-dihydro-5-(4-methoxyphenyl)-1-[(methylamino)thioxomethyl]-1H-pyrazol-3-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 188292-05-9 CAPLUS

CN Acetamide, N-[4-[4,5-dihydro-5-(4-methoxyphenyl)-1-[(phenylamino)thioxomethyl]-1H-pyrazol-3-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 188292-06-0 CAPLUS

CN Benzamide, N-[[3-[4-(acetylamino)phenyl]-4,5-dihydro-5-(4-methoxyphenyl)-1H-pyrazol-1-yl]thioxomethyl]- (9CI) (CA INDEX NAME)




IT 85791-58-8P 188291-66-9P 188291-68-1P
 188291-71-6P 188291-96-5P 188291-97-6P
 188291-98-7P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation of pyrazolines)


RN 85791-58-8 CAPLUS

CN Acetamide, N-[4-[4,5-dihydro-5-(4-methoxyphenyl)-1H-pyrazol-3-yl]phenyl]-
 (9CI) (CA INDEX NAME)




RN 188291-66-9 CAPLUS

CN Acetamide, N-[4-[4,5-dihydro-5-(4-methoxyphenyl)-1-(phenylsulfonyl)-1H-
 pyrazol-3-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 188291-68-1 CAPLUS

CN Acetamide, N-[4-[4,5-dihydro-5-(4-methoxyphenyl)-1-[(4-methylphenyl)sulfonyl]-1H-pyrazol-3-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 188291-71-6 CAPLUS


CN Acetamide, N-[4-[1-[[2-(acetamido)-5-methylphenyl]sulfonyl]-4,5-dihydro-5-(4-methoxyphenyl)-1H-pyrazol-3-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 188291-96-5 CAPLUS


CN Acetamide, N-[4-[1-benzoyl-4,5-dihydro-5-(4-methoxyphenyl)-1H-pyrazol-3-

yl]phenyl]- (9CI) (CA INDEX NAME)




RN 188291-97-6 CAPLUS

CN Acetamide, N-[4-[4,5-dihydro-5-(4-methoxyphenyl)-1-(4-nitrobenzoyl)-1H-pyrazol-3-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 188291-98-7 CAPLUS

CN Acetamide, N-[4-[4,5-dihydro-5-(4-methoxyphenyl)-1-(1-oxo-3-phenyl-2-propenyl)-1H-pyrazol-3-yl]phenyl]- (9CI) (CA INDEX NAME)



L25 ANSWER 49 OF 88 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 1996:462227 CAPLUS
 DN 125:115150
 TI Cyclic hexapeptides having antibiotic activity
 IN Ohki, Hidenori; Tomishima, Masaki; Yamada, Akira; Takasugi, Hisashi
 PA Fujisawa Pharmaceutical Co., Ltd., Japan
 SO PCT Int. Appl., 273 pp.

CODEN: PIXXD2

DT Patent
 LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9611210	A1	19960418	WO 1995-JP1983	19950929
	W: AU, CA, CN, FI, HU, JP, KR, MX, NO, RU, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	CA 2202058	AA	19960418	CA 1995-2202058	19950929
	AU 9535780	A1	19960502	AU 1995-35780	19950929
	AU 696949	B2	19980924		
	EP 788511	A1	19970813	EP 1995-932935	19950929
	EP 788511	B1	20021211		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
	CN 1168675	A	19971224	CN 1995-196643	19950929
	JP 10507174	T2	19980714	JP 1995-512472	19950929
	JP 2897427	B2	19990531		
	HU 77736	A2	19980728	HU 1998-338	19950929
	JP 10324695	A2	19981208	JP 1998-136756	19950929
	JP 3518665	B2	20040412		
	RU 2165423	C2	20010420	RU 1997-107338	19950929
	AT 229541	E	20021215	AT 1995-932935	19950929
	PT 788511	T	20030430	PT 1995-932935	19950929
	ES 2187575	T3	20030616	ES 1995-932935	19950929
	IL 115484	A1	20000716	IL 1995-115484	19951002
	ZA 9508458	A	19960507	ZA 1995-8458	19951006
	BR 9504791	A	19961022	BR 1995-4791	19951006
	FI 9701397	A	19970527	FI 1997-1397	19970404
	NO 9701544	A	19970604	NO 1997-1544	19970404
	US 6107458	A	20000822	US 1997-809723	19970521
	US 6265536	B1	20010724	US 1999-248267	19990211
PRAI	GB 1994-20425	A	19941007		
	GB 1995-8745	A	19950428		
	JP 1996-512472	A3	19950929		
	WO 1995-JP1983	W	19950929		
	US 1997-809723	A3	19970521		

OS MARPAT 125:115150

AB The invention relates to new cyclic polypeptide derivs. I [R1 = variety of substituted acyl groups] and their pharmaceutically acceptable salts. The compds. have antimicrobial activities (especially, antifungal activities) and inhibitory activity on β -1,3-glucan synthase (no data), and are useful for prophylactic and/or therapeutic treatment of infectious diseases including Pneumocystis carinii infection (e.g., P. carinii pneumonia). Examples include 124 compds. I, plus 346 precursor prepsns. For instance, reaction of the precursor I.Na [R1 = H] with 1-[6-[(octyloxy)methyl]picolinoyl]benzotriazole 3-oxide in DMF in the presence of DMAP gave title compound I [R1 = Q1]. In a test against Candida albicans FP-633 in vitro, I [R1 = Q2] had MIC of 0.2 μ g/mL.


IT 179166-01-9P 179166-34-8P 179166-54-2P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of cyclic hexapeptides active against fungi and *Pneumocystis carinii*)

RN 179166-01-9 CAPLUS

CN Proline, 4,5-dihydroxy-N2-[4-[5-[4-(pentyloxy)phenyl]-1H-pyrazol-3-yl]benzoyl]ornithylthreonyl-4-hydroxyprolyl-4-hydroxy-4-[4-hydroxy-3-(sulfooxy)phenyl]threonyl-3-hydroxyglutaminyl-3-hydroxy-4-methyl-, cyclic (6→1)-peptide, monosodium salt (9CI) (CA INDEX NAME)


PAGE 1-A






● Na

RN 179166-34-8 CAPLUS
 CN Proline, N2-[4-[5-[4-(hexyloxy)phenyl]-1H-pyrazol-3-yl]benzoyl]-4,5-dihydroxyornithylthreonyl-4-hydroxyprolyl-4-hydroxy-4-[4-hydroxy-3-(sulfooxy)phenyl]threonyl-3-hydroxyglutaminyl-3-hydroxy-4-methyl-, cyclic (6→1)-peptide, monosodium salt (9CI) (CA INDEX NAME)




PAGE 2-A




● Na

RN 179166-54-2 CAPLUS
 CN Proline, N2-[4-(1-heptyl-1H-pyrazol-4-yl)benzoyl]-4,5-dihydroxyornithylthreonyl-4-hydroxyprolyl-4-hydroxy-4-[4-hydroxy-3-(sulfooxy)phenyl]threonyl-3-hydroxyglutaminyl-3-hydroxy-4-methyl-, cyclic (6→1)-peptide, monosodium salt (9CI) (CA INDEX NAME)

PAGE 1-A





● Na

L25 ANSWER 50 OF 88 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 1996:451675 CAPLUS
 DN 125:100003
 TI Image formation method of silver halide photographic photoreceptor
 IN Suzuki, Keiichi; Hirano, Shigeo
 PA Fuji Photo Film Co Ltd, Japan
 SO Jpn. Kokai Tokkyo Koho, 52 pp.
 CODEN: JKXXAF

DT Patent
 LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 08095208	A2	19960412	JP 1994-256062	19940927
PRAI	JP 1994-256062		19940927		

AB A photog. photoreceptor composed of a ≥ 1 photosensitive Ag halide emulsion layer formed on a support is exposed to light and developed, wherein (A) the Ag halide photoreceptor containing ≥ 1 compound shown as I (Z1 = nonmetallic atom. group which is necessary for formation of 6-membered N-containing aromatic hetero ring with N and X1; X1 = N, CR12, R12 = same as R11; R1 = alkyl, alkenyl, alkynyl, aryl, hetero ring; R11 = H, halo, substitution group which bond to ring via C, O, N, and S; m1 = 0, integral number equal or less than the maximum possible substitution no; when


m1 are ≥ 2 , R11 may be same or different, maybe bonded to each other to form ring; 2 radicals, which are formed by loosing 1 H from I, may be bonded to form bis-type structure; Y1 = ion pair for charge balance; n1 = required number for charge balance) are contained in the emulsion layer and/or other hydrophilic colloidal layer, (B) a solid disperse dye are contained in the photoreceptor, and (C) the developer liquid containing a main agent are shown as II [P, Q = OH, hydroxyalkyl, carboxyl, carboxyalkyl, sulfo, sulfoalkyl, amino, aminoalkyl, alkyl, alkoxy, mercapto; P and Q may be an atom. group which may be bonded to each other to form 5-7-membered ring with 2 vinyl C whose R1 and R2 are substituted and C whose Y is substituted; examples of the ring structures may be formed with O, CR4R5, CR6, C(:O), NR7, N::; R4-7 = H, OH, carboxyl, C1-10 alkyl which may be substituted with OH, carboxyl, sulfo].

IT **165126-08-9P**

RL: PNU (Preparation, unclassified); TEM (Technical or engineered material use); PREP (Preparation); USES (Uses)
 (image formation method of silver halide photog. photoreceptor)

RN 165126-08-9 CAPLUS

CN Acetamide, N-[4-[4-[5-[3-[4-(acetyl-amino)phenyl]-1,5-dihydro-5-oxo-4H-pyrazol-4-ylidene]-1,3-pentadienyl]-5-hydroxy-1H-pyrazol-3-yl]phenyl]-(9CI) (CA INDEX NAME)



L25 ANSWER 51 OF 88 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 1996:121332 CAPLUS
 DN 124:289529
 TI 3-[4-(Methylsulfonyl)phenyl]-1H-pyrazoles and 4-(1H-pyrazol-3-yl)benzenesulfonamides as selective inhibitors of cyclooxygenase II useful as inflammation inhibitors
 IN Lee, Len F.; Penning, Thomas D.; Kramer, Steven W.
 PA G. D. Searle and Co., USA
 SO U.S., 40 pp.
 CODEN: USXXAM
 DT Patent
 LA English
 FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5486534	A	19960123	US 1994-278297	19940721
	CA 2195123	AA	19960208	CA 1995-2195123	19950720
	WO 9603385	A1	19960208	WO 1995-US8788	19950720
	W:	AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TT			
	RW:	KE, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
	AU 9531267	A1	19960222	AU 1995-31267	19950720
	EP 772597	A1	19970514	EP 1995-927154	19950720
	EP 772597	B1	20011212		
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE			
	JP 10503201	T2	19980324	JP 1995-505781	19950720
	EP 1127878	A1	20010829	EP 2001-112883	19950720
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE			
	AT 210648	E	20011215	AT 1995-927154	19950720
	PT 772597	T	20020531	PT 1995-927154	19950720
	ES 2169760	T3	20020716	ES 1995-927154	19950720
	JP 3490716	B2	20040126	JP 1996-505781	19950720
	US 5580985	A	19961203	US 1995-535688	19950928
	US 5756530	A	19980526	US 1996-721787	19960925
	US 6028072	A	20000222	US 1997-776090	19970609
PRAI	US 1994-278297	A	19940721		
	EP 1995-927154	A3	19950720		
	WO 1995-US8788	W	19950720		

OS MARPAT 124:289529

AB A class of pyrazolyl compds. is described for use in treating inflammation and inflammation-related disorders and is defined by formula I wherein R1 is a radical selected from hydrido, alkyl, alkenyl, alkynyl, haloalkyl, aralkyl, hydroxyalkyl, alkoxyalkyl, cyanoalkyl, aminoalkyl, alkylaminoalkyl, carboxyalkyl, alkoxycarbonylalkyl, alkylaminocarbonylalkyl, N-hydroxyaminocarbonylalkyl, N-hydroxy-N-alkylaminocarbonylalkyl, arylaminocarbonylalkyl and aminocarbonylalkyl; wherein R2 is aryl substituted at a substitutable position with a radical selected from alkylsulfonyl and sulfamyl; wherein R3 is selected from aryl, cycloalkyl, and cycloalkenyl; wherein R3 is optionally substituted at a substitutable position with one or more radicals selected from halo, alkylthio, alkylsulfinyl, alkyl, cyano, carboxyl, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl, arylaminocarbonyl, N-alkyl-N-arylaminocarbonyl, haloalkyl, hydroxyl, alkoxy, hydroxyalkyl, haloalkoxy, amino, alkylamino, arylamino, heterocyclo and nitro; and wherein R4 is

selected from hydrido, alkyl, haloalkyl, carboxyalkyl, alkoxyalkyl, aralkoxyalkyl, aminocarbonylalkyl, hydroxyalkyl and aralkoxyalkyl; or a pharmaceutically-acceptable salt thereof. Thus, e.g., acylation of thioanisole with 4-fluorophenylacetic acid afforded 2-(4-fluorophenyl)-1-[4-(methylthio)phenyl]ethanone; acylation of the latter with 1-trifluoroacetylpyrazole followed by heterocyclization with hydrazine afforded 4-(4-fluorophenyl)-3-[4-(methylthio)phenyl]-5-(trifluoromethyl)-1H-pyrazole; oxidation of latter to the 4-methylsulfonyl derivative followed by 1-ethylation afforded 1-ethyl-4-(4-fluorophenyl)-3-[4-(methylsulfonyl)phenyl]-5-(trifluoromethyl)-1H-pyrazole (II) which exhibited selective inhibition of cyclooxygenase II: ID₅₀ = >10 μ M for COX I, and <0.1 μ M for COX II.



IT 175677-39-1P 175677-40-4P 175677-74-4P
175677-75-5P 175678-89-4P 175678-90-7P
175679-25-1P 175679-26-2P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(3-[4-(methylsulfonyl)phenyl]-1H-pyrazoles and 4-(1H-pyrazol-3-yl)benzenesulfonamides as selective inhibitors of cyclooxygenase II useful as inflammation inhibitors)


RN 175677-39-1 CAPLUS

CN Acetamide, N-[4-[3-[4-(methylsulfonyl)phenyl]-5-(trifluoromethyl)-1H-pyrazol-4-yl]phenyl]- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A




RN 175677-40-4 CAPLUS
 CN Acetamide, 2,2,2-trifluoro-N-[4-[3-[4-(methylsulfonyl)phenyl]-5-(trifluoromethyl)-1H-pyrazol-4-yl]phenyl]- (9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 2-A




RN 175677-74-4 CAPLUS
 CN Acetamide, N-[4-[3-[4-(methylsulfonyl)phenyl]-1H-pyrazol-4-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 175677-75-5 CAPLUS



CN Acetamide, 2,2,2-trifluoro-N-[4-[3-[4-(methylsulfonyl)phenyl]-1H-pyrazol-4-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 175678-89-4 CAPLUS

CN Acetamide, N-[4-[3-[4-(aminosulfonyl)phenyl]-5-(trifluoromethyl)-1H-pyrazol-4-yl]phenyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 175678-90-7 CAPLUS
 CN Acetamide, N-[4-[3-[4-(aminosulfonyl)phenyl]-5-(trifluoromethyl)-1H-pyrazol-4-yl]phenyl]-2,2,2-trifluoro- (9CI) (CA INDEX NAME)


PAGE 1-A




PAGE 2-A



RN 175679-25-1 CAPLUS


CN Acetamide, N-[4-[3-[4-(aminosulfonyl)phenyl]-1H-pyrazol-4-yl]phenyl]-
(9CI) (CA INDEX NAME)

RN 175679-26-2 CAPLUS

CN Acetamide, N-[4-[3-[4-(aminosulfonyl)phenyl]-1H-pyrazol-4-yl]phenyl]-2,2,2-
trifluoro- (9CI) (CA INDEX NAME)

L25 ANSWER 52 OF 88 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 1996:119090 CAPLUS
 DN 124:170374
 TI Potentially active antimicrobial agents from 2-benzenesulfonyloxyphenyl-3,1-benzoxazine-4-one derivative
 AU Habib, O.M.; Moawad, E.B.; Girges, M.M.; El-Shafei, A.M.
 CS Chemistry Department, Mansoura Faculty of Science, Mansoura, Egypt
 SO Bollettino Chimico Farmaceutico (1995), 134(9), 503-8
 CODEN: BCFAAI; ISSN: 0006-6648
 PB Societa Editoriale Farmaceutica
 DT Journal
 LA English
 AB Fourteen of nitrogeneous heterocyclic compds. that accommodate the sulfonate-ester moiety were synthesized through interaction of 2-benzenesulfonyloxyphenyl-3,1-benzoxazine-4-one with some nucleophilic reagents. The assigned structures for the prepared new compds. were confirmed on the basis of elemental and spectral data. Evaluation of the antimicrobial activity of these products, relative to standard antibiotics was tested and discussed.
 IT **173984-93-5P**
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PNU (Preparation, unclassified); PRP (Properties); BIOL (Biological study); PREP (Preparation)
 (potentially active antimicrobial agents from 2-benzenesulfonyloxyphenyl-3,1-benzoxazine-4-one derivative)
 RN 173984-93-5 CAPLUS
 CN Benzenesulfonic acid, 4-[[[2-[[[4-[5-(4-chlorophenyl)-4,5-dihydro-1H-pyrazol-3-yl]phenyl]amino]carbonyl]phenyl]amino]carbonyl]-, phenyl ester (9CI) (CA INDEX NAME)

PAGE 1-A



09/773,736

PAGE 2-A

|
Cl

L25 ANSWER 53 OF 88 CAPLUS COPYRIGHT 2004 ACS on STN

AN 1996:61279 CAPLUS

DN 124:131438

TI High contrast silver halide photographic material with excellent storage stability

IN Suzuki, Keiichi; Sakurai, Seiya

PA Fuji Photo Film Co Ltd, Japan

SO Jpn. Kokai Tokkyo Koho, 81 pp.

CODEN: JKXXAF

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 07295131	A2	19951110	JP 1994-110200	19940427
PRAI	JP 1994-110200		19940427		

AB The title material contains a hydrazine derivative(s), R1NA1NA2G1R2 [R1 = aliphatic, aromatic; R2 = H, alkyl, aryl, unsatd. heterocyclyl, alkoxy, aryloxy, amino, hydrazino; G1 = CO, SO2, SO, POR3, COCO, thiocarbonyl, iminomethylene; A1, A2 = H, alkylsulfonyl, arylsulfonyl, acyl; R3 = H, alkyl, aryl, unsatd. heterocyclyl, alkoxy, aryloxy, amino, hydrazino], and a surfactant(s), OP(Q1R1)(Q2R2)(Q3LZ) [R1 = aliphatic, alicyclic, aromatic, heterocyclyl; R2 = aliphatic, alicyclic, aromatic, heterocyclyl, LZ; Q1-3 = single bond, O, S, NR3, NR3CO; R3 = H, aliphatic, alicyclic, aromatic, heterocyclyl, LZ; L = divalent connecting group; Z = ionic group] in a photog. emulsion layer(s) and/or hydrophilic colloidal layer(s), and dye solid dispersions.


IT **173063-40-6**

RL: DEV (Device component use); USES (Uses)

(high contrast silver halide photog. material with excellent storage stability containing)

RN 173063-40-6 CAPLUS

CN Acetamide, N-[4-[4-[5-[3-[4-(acetlamino)phenyl]-1,5-dihydro-5-oxo-4H-pyrazol-4-ylidene]-1,3-pentadienyl]-4,5-dihydro-5-oxo-1H-pyrazol-3-yl]phenyl]- (9CI) (CA INDEX NAME)



L25 ANSWER 54 OF 88 CAPLUS COPYRIGHT 2004 ACS on STN

AN 1995:835463 CAPLUS

DN 123:256771

TI Guanidine derivatives as inhibitors of Na⁺/H⁺ exchange in cellsIN Kuno, Atsushi; Inoue, Yoshikazu; Takasugi, Hisashi; Mizuno, Hiroaki;
Yamasaki, Kumi

PA Fujisawa Pharmaceutical Co., Ltd., Japan

SO PCT Int. Appl., 212 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9426709	A1	19941124	WO 1994-JP786	19940512
	W: AU, CA, CN, HU, JP, KR, RU, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	TW 393487	B	20000611	TW 1994-83104223	19940510
	CA 2163004	AA	19941124	CA 1994-2163004	19940512
	AU 9466912	A1	19941212	AU 1994-66912	19940512
	AU 685457	B2	19980122		
	HU 70206	A2	19950928	HU 1994-3233	19940512
	EP 699185	A1	19960306	EP 1994-914623	19940512
	EP 699185	B1	20010905		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
	CN 1123545	A	19960529	CN 1994-192121	19940512
	CN 1080257	B	20020306		
	JP 08511243	T2	19961126	JP 1994-525245	19940512
	RU 2141946	C1	19991127	RU 1995-122558	19940512
	AT 205191	E	20010915	AT 1994-914623	19940512
	ES 2159558	T3	20011016	ES 1994-914623	19940512
	PT 699185	T	20020130	PT 1994-914623	19940512
	ZA 9403388	A	19950123	ZA 1994-3388	19940517
	US 5824691	A	19981020	US 1995-532804	19951109
	GR 3036549	T3	20011231	GR 2001-401402	20010906
PRAI	GB 1993-10074	A	19930517		
	GB 1993-25268	A	19931210		
	WO 1994-JP786	W	19940512		

OS MAREPAT 123:256771

AB The N-benzoylguanidine derivs. or N-(heteroaroyl)guanidine derivs. I (X, Y, Z = nitrogen, methine; R₂ = H, aryl, etc.; R₃ = H, alkoxy, hydroxy, etc.) and pharmaceutically acceptable salts thereof were disclosed as pharmaceuticals. I inhibit the sodium/hydrogen exchange in cells and are hence useful for the treatment of cardiovascular diseases, cerebrovascular diseases, renal diseases, arteriosclerosis or shock. A claimed example compound is N-[3-(1H-pyrrol-1-yl)benzoyl]guanidine [i.e., N-(aminoiminomethyl)-3-(1H-pyrrol-1-yl)benzamide] (II).


IT 168620-95-9P 168621-61-2P

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of N-(aroyl)guanidine derivs. as sodium exchange inhibitors)


RN 168620-95-9 CAPLUS

CN Benzamide, N-(aminoiminomethyl)-3-(1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



RN 168621-61-2 CAPLUS

CN Benzamide, N-(aminoiminomethyl)-3-(1H-pyrazol-3-yl)-, monohydrochloride
(9CI) (CA INDEX NAME)



● HCl


L25 ANSWER 55 OF 88 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 1995:686962 CAPLUS
 DN 123:70241
 TI Formation of high-contrast images with safe photographic developer
 IN Yamamoto, Seiichi; Inoe, Nobuaki; Yasuda, Shoji
 PA Fuji Photo Film Co Ltd, Japan
 SO Jpn. Kokai Tokkyo Koho, 68 pp.
 CODEN: JKXXAF
 DT Patent
 LA Japanese
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 07114152	A2	19950502	JP 1993-282117	19931018
PRAI	JP 1993-282117		19931018		

AB The title image formation includes exposing a photog. material that has an emulsion layer containing ≥ 90 mol% AgCl and $\geq 1 \times 10^{-6}$ mol Rh, Ru, Re, Os complex per mol Ag, and a hydrazine compound in the emulsion layer or other hydrophilic colloid layer, and then developing with a developer solution containing no dihydroxy benzene or its derivs. but ascorbic acid or its isomers or derivs.

IT **165126-08-9**
 RL: DEV (Device component use); USES (Uses)
 (solid dispersing dye contained in photog. material for image formation)

RN 165126-08-9 CAPLUS
 CN Acetamide, N-[4-[4-[5-[3-[4-(acetylamino)phenyl]-1,5-dihydro-5-oxo-4H-pyrazol-4-ylidene]-1,3-pentadienyl]-5-hydroxy-1H-pyrazol-3-yl]phenyl]-(9CI) (CA INDEX NAME)



L25 ANSWER 56 OF 88 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 1995:677719 CAPLUS
 DN 123:183350
 TI Silver halide photographic material containing solid dispersion of oxonol dye
 IN Yabuki, Yoshiharu; Suzuki, Keiichi
 PA Fuji Photo Film Co Ltd, Japan
 SO Jpn. Kokai Tokkyo Koho, 14 pp.
 CODEN: JKXXAF
 DT Patent
 LA Japanese
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 07084339	A2	19950331	JP 1993-228397	19930914
	JP 3074550	B2	20000807		
	US 5441859	A	19950815	US 1994-305451	19940913
PRAI	JP 1993-228397	A	19930914		

AB The material has a supported hydrophilic colloid layer containing a dispersion of solid particles of the dye I (R = alkyl, aryl, amino, alkoxy, etc.; L1, L2, L3 = methyne; Y = H, alkyl, alkoxy, halo; R and Y may form a ring). Advantages include non-diffusibility throughout manufacturing stages and before processing, and easy wash-off property.


IT **167409-33-8 167409-34-9**

RL: DEV (Device component use); USES (Uses)

(Ag halide photog. material containing solid dispersion of oxonol dye)


RN 167409-33-8 CAPLUS

CN Acetamide, N-[4-[4-[[3-[4-(acetylamino)phenyl]-1,5-dihydro-5-oxo-4H-pyrazol-4-ylidene]methyl]-5-hydroxy-1H-pyrazol-3-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 167409-34-9 CAPLUS

CN Acetamide, N-[4-[4-[3-[3-[4-(acetylamino)phenyl]-1,5-dihydro-5-oxo-4H-pyrazol-4-ylidene]-1-propenyl]-5-hydroxy-1H-pyrazol-3-yl]phenyl]- (9CI) (CA INDEX NAME)




IT **165126-08-9P**

RL: DEV (Device component use); PNU (Preparation, unclassified); PREP (Preparation); USES (Uses)

(Ag halide photog. material containing solid dispersion of oxonol dye)

RN 165126-08-9 CAPLUS

CN Acetamide, N-[4-[4-[5-[3-[4-(acetamino)phenyl]-1,5-dihydro-5-oxo-4H-pyrazol-4-ylidene]-1,3-pentadienyl]-5-hydroxy-1H-pyrazol-3-yl]phenyl]- (9CI) (CA INDEX NAME)




IT **99844-13-0**

RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of oxonol photog. dye)

RN 99844-13-0 CAPLUS

CN Acetamide, N-[4-(4,5-dihydro-5-oxo-1H-pyrazol-3-yl)phenyl]- (9CI) (CA INDEX NAME)



L25 ANSWER 57 OF 88 CAPLUS COPYRIGHT 2004 ACS on STN

AN 1995:432039 CAPLUS

DN 122:314473

TI Convenient synthesis of some heterocyclic compounds bearing a succinimido moiety

AU Essawy, S. A.; Wasfy, A. A. F.

CS Faculty Science, Benha University, Benha, Egypt

SO Egyptian Journal of Chemistry (1994), 37(3), 283-93

CODEN: EGJCA3; ISSN: 0367-0422

PB National Information and Documentation Centre

DT Journal

LA English

OS CASREACT 122:314473


AB The incorporation of the succinimido moiety into isoxazoline, pyrazoline, pyran, etc., derivs., is described. E.g., reaction of I with semicarbazide/NaOAc, followed by thionyl chloride, gave thiadiazole II.

IT **163487-76-1P 163487-83-0P**

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)


RN 163487-76-1 CAPLUS

CN 1-Pyrrolidineacetamide, N-[4-[5-(4-chlorophenyl)-4,5-dihydro-1H-pyrazol-3-yl]phenyl]-2,5-dioxo- (9CI) (CA INDEX NAME)



RN 163487-83-0 CAPLUS

CN 1-Pyrrolidineacetamide, N-[4-[5-(4-chlorophenyl)-4,5-dihydro-4-hydroxy-1H-pyrazol-3-yl]phenyl]-2,5-dioxo- (9CI) (CA INDEX NAME)



L25 ANSWER 58 OF 88 CAPLUS COPYRIGHT 2004 ACS on STN

AN 1992:417141 CAPLUS

DN 117:17141

TI Silver halide photographic material containing pyrazolone dye

IN Usagawa, Yasushi; Kawashima, Yasuhiko; Kagawa, Nobuaki

PA Konica Co., Japan

SO Jpn. Kokai Tokkyo Koho, 16 pp.

CODEN: JKXXAF

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 03208043	A2	19910911	JP 1990-2212	19900109
PRAI	JP 1990-2212		19900109		

OS MARPAT 117:17141

AB A silver halide photog. material has on a support at least one photog. layer containing a solid microparticle dispersion of a pyrazolone dye (I; R1, R2 = CO₂H or group having CO₂H; R3, R4 = H, a substituent without CO₂H; L1-L3 = methine; n = 0-2; when n = 2, L2 and L3 are same or different). The photog. material shows improved image quality, storage stability, and sharpness with little reduction in sensitivity.


IT **141795-79-1 141795-80-4**

RL: USES (Uses)

(photog. films containing, for improved image quality and storage stability)

RN 141795-79-1 CAPLUS

CN Butanoic acid, 4-[[[3-[4-[3-[3-[3-[(3-carboxy-1-oxopropyl)amino]phenyl]-1,5-dihydro-1-(2-hydroxyethyl)-5-oxo-4H-pyrazol-4-ylidene]-1-propenyl]-5-hydroxy-1-(2-hydroxyethyl)-1H-pyrazol-3-yl]phenyl]amino]-4-oxo- (9CI) (CA INDEX NAME)




RN 141795-80-4 CAPLUS


CN Butanoic acid, 4-[[[3-[4-[5-[3-[3-[(3-carboxy-1-oxopropyl)amino]phenyl]-1,5-

dihydro-1-(2-hydroxyethyl)-5-oxo-4H-pyrazol-4-ylidene]-1,3-pentadienyl]-5-hydroxy-1-(2-hydroxyethyl)-1H-pyrazol-3-yl]phenyl]amino]-4-oxo- (9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 2-A



L25 ANSWER 59 OF 88 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 1992:106219 CAPLUS
 DN 116:106219
 TI Synthesis of some heterocyclic compounds containing the phthalimido moiety
 AU Essawy, S. A.
 CS Fac. Sci., Benha Univ., Benha, Egypt
 SO Bulletin of the Faculty of Pharmacy (Cairo University) (1991), 29(2),
 49-52
 CODEN: BFPHA8; ISSN: 0575-1373
 DT Journal
 LA English
 AB Cyclocondensation of $\text{RCOCH:CHC}_6\text{H}_4\text{Cl-4}$ ($\text{R} = \text{Q}$) with R_1NHNH_2 ($\text{R}_1 = \text{H, Ph}$)
 and H_2NCXNH_2 ($\text{X} = \text{S, O, NH}$) gave pyrazoles I and pyrimidines II, resp.
 Condensing RCOMe with $\text{H}_2\text{NCONHNH}_2$ gave RCMe:NNHCONH_2 which cyclized with
 SeO_2 and SOCl_2 to give seleno- and thiadiazole III ($\text{Z} = \text{Se, S}$).
 IT **139054-00-5P**
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 139054-00-5 CAPLUS
 CN 2H-Isoindole-2-acetamide, N-[4-[5-(4-chlorophenyl)-4,5-dihydro-1H-pyrazol-
 3-yl]phenyl]-1,3-dihydro-1,3-dioxo- (9CI) (CA INDEX NAME)




L25 ANSWER 60 OF 88 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 1991:546539 CAPLUS
 DN 115:146539
 TI Silver halide photographic material containing tricyanoethylene dye
 IN Kagawa, Nobuaki; Tanaka, Mari; Kawashima, Yasuhiko; Usagawa, Yasushi
 PA Konica Co., Japan
 SO Jpn. Kokai Tokkyo Koho, 16 pp.
 CODEN: JKXXAF

DT Patent
 LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 03031840	A2	19910212	JP 1989-167228	19890628
PRAI	JP 1989-167228		19890628		
OS	MARPAT 115:146539				
AB	The photog. material has, on a support, ≥ 1 layer containing dye AC(CN):C(CN) ₂ (I; A = pyrazole or imidazole ring). The dye has good decoloring properties and the material gives clear images without fog. Thus, a Ag(Br,Cl) emulsion containing I (A = II) was coated on a film base to make a photog. film.				
IT	135716-51-7 RL: USES (Uses) (dye, photog. film containing)				
RN	135716-51-7 CAPLUS				
CN	Octanamide, N-[4-[4,5-dihydro-5-oxo-4-(tricyanoethenyl)-1H-pyrazol-3-yl]phenyl]- (9CI) (CA INDEX NAME)				



L25 ANSWER 61 OF 88 CAPLUS COPYRIGHT 2004 ACS on STN

AN 1991:228909 CAPLUS

DN 114:228909

TI Preparation of pesticidal N-aryl-3-aryl-4,5-dihydro-1H-pyrazole-1-carboxamides

IN Jacobson, Richard M.

PA Rohm and Haas Co., USA

SO U.S., 72 pp. Cont.-in-part of U.S. 4,663,341.

CODEN: USXXAM

DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 4863947	A	19890905	US 1986-894981	19860811
	US 4663341	A	19870505	US 1985-689671	19850111
	CA 1275289	A1	19901016	CA 1985-473376	19850201
	IL 74305	A1	19890731	IL 1985-74305	19850211
	ZA 8501044	A	19860326	ZA 1985-1044	19850212
	NO 8500545	A	19850819	NO 1985-545	19850213
	NO 171364	B	19921123		
	NO 171364	C	19930303		
	AU 8538674	A1	19850822	AU 1985-38674	19850213
	AU 588796	B2	19890928		
	BR 8500673	A	19851001	BR 1985-673	19850213
	ES 540366	A1	19860516	ES 1985-540366	19850213
	FI 8500620	A	19850817	FI 1985-620	19850214
	FI 90975	B	19940114		
	FI 90975	C	19940425		
	DK 8500682	A	19850817	DK 1985-682	19850214
	JP 60190765	A2	19850928	JP 1985-25369	19850214
	JP 07059556	B4	19950628		
	HU 36346	A2	19850930	HU 1985-553	19850214
	HU 206248	B	19921028		
	CN 85101497	A	19860716	CN 1985-101497	19850401
	CN 1030682	B	19960117		
	DD 241845	A5	19870107	DD 1985-279716	19850815
	DD 253029	A5	19880106	DD 1985-299114	19850815
	DD 253028	A5	19880106	DD 1987-299113	19870106
PRAI	US 1984-580963		19840216		
	US 1985-689671		19850111		

OS MARPAT 114:228909

AB The title compds. I [A, B = (substituted) aryl; U = O, S, etc.; V = C3-6 cycloalkyl, RQ; Y = (substituted) alkyl, aryl, etc.; Q = H, halo, cyano, NO2, etc.; R = (CR1R2)n; R1,R2 = H, halo, cyano, NO2, OH, etc.; n = 0-10] were prepared A solution of N,3-bis(4-chlorophenyl)-4-phenyl-4,5-dihydro-1H-pyrazole-1-carboxamide in THF was added to a mixture of (Me2CH2NH and BuLi in hexane. The resulting mixture was stirred for 15 min. To this solution was added MeI and, after 15 min, AcOH was added. The reaction mixture was worked up to give pyrazole II. At 600 ppm, II gave 100% kill of Mexican bean beetle.


IT 131824-88-9P 131824-89-0P 131825-13-3P

RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of, as pesticide)

RN 131824-88-9 CAPLUS


CN 1H-Pyrazole-4-carboxylic acid, 3-[4-(acetylamino)phenyl]-4,5-dihydro-4-

methyl-1-[[[4-(trifluoromethyl)phenyl]amino]carbonyl]-, methyl ester (9CI)
(CA INDEX NAME)




RN 131824-89-0 CAPLUS

CN 1H-Pyrazole-4-carboxylic acid, 3-[4-[(4-chlorobenzoyl)amino]phenyl]-4,5-dihydro-4-methyl-1-[[[4-(trifluoromethyl)phenyl]amino]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 131825-13-3 CAPLUS


CN 1H-Pyrazole-4-carboxylic acid, 4,5-dihydro-4-methyl-3-[4-[(trifluoroacetyl)amino]phenyl]-1-[[[4-(trifluoromethyl)phenyl]amino]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)




L25 ANSWER 62 OF 88 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 1991:23918 CAPLUS
 DN 114:23918
 TI Synthesis and some reactions of pyrimidine-2-thione derivatives
 AU Mahmoud, M. R.; Soliman, A. Y.; Bakeer, H. M.
 CS Fac. Sci., Ain Shams Univ., Cairo, Egypt
 SO Indian Journal of Chemistry, Section B: Organic Chemistry Including
 Medicinal Chemistry (1990), 29B(9), 830-5
 CODEN: IJSBDB; ISSN: 0376-4699
 DT Journal
 LA English
 OS CASREACT 114:23918
 AB Cyclization of p-H₂NC₆H₄COCO:CHR₁ (R₁ = Ph, p-ClC₆H₄) with H₂NC(S)NH₂ gave
 42-53% I (R = 4). Cyclization of I with ClCH₂CO₂H in Ac₂O-AcOH gave
 36-46% II. Alkylation of I with BrCH₂CO₂Et and H₂C:CHCN gave 32-46% I (R
 = CH₂CO₂Et, CH₂CH₂CN, resp.).
 IT **131138-89-1P 131138-90-4P**
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation and dehydrogenation of)
 RN 131138-89-1 CAPLUS
 CN Acetamide, N-[4-(4,5-dihydro-5-phenyl-1H-pyrazol-3-yl)phenyl]- (9CI) (CA
 INDEX NAME)



RN 131138-90-4 CAPLUS
 CN Acetamide, N-[4-[5-(4-chlorophenyl)-4,5-dihydro-1H-pyrazol-3-yl]phenyl]-
 (9CI) (CA INDEX NAME)




IT **131138-91-5P 131138-92-6P**
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 131138-91-5 CAPLUS
 CN Acetamide, N-[4-(5-phenyl-1H-pyrazol-3-yl)phenyl]- (9CI) (CA INDEX NAME)



RN 131138-92-6 CAPLUS

CN Acetamide, N-[4-[5-(4-chlorophenyl)-1H-pyrazol-3-yl]phenyl]- (9CI) (CA
INDEX NAME)



L25 ANSWER 63 OF 88 CAPLUS COPYRIGHT 2004 ACS on STN

AN 1990:431810 CAPLUS

DN 113:31810

TI Silver halide color photographic material containing azole compound as cyan coupler

IN Fukunaga, Hiroo; Yamakawa, Kazuyoshi; Furusawa, Genichi

PA Fuji Photo Film Co., Ltd., Japan

SO Jpn. Kokai Tokkyo Koho, 44 pp.

CODEN: JKXXAF

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 01250949	A2	19891005	JP 1988-76403	19880331

PRAI JP 1988-76403 19880331

OS MARPAT 113:31810


AB A Ag halide color photog. material having excellent color reproducibility contains an azole compound [I; R = H, blocking group; Z, Z1, Z2 = (substituted) methine, N, but the substituent \neq OH, acyloxy, sulfonyloxy] as a cyan coupler. A color photog. film having II as a cyan coupler was processed to give images showing excellent color reproducibility and colorfastness on storage at 60° and 70% relative humidity.

IT 127828-91-5 127828-92-6

RL: TEM (Technical or engineered material use); USES (Uses)
(cyan photog. coupler)


RN 127828-91-5 CAPLUS

CN Benzamide, 3-chloro-N-[2-[3-chloro-5-(2-methylpropyl)-1H-pyrazol-4-yl]phenyl]-4-[(dodecylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 127828-92-6 CAPLUS

CN Tetradecanamide, 2-[2-chloro-4-[(3-chloro-4-hydroxyphenyl)sulfonyl]phenoxy]-N-[2-(3-chloro-5-ethyl-1H-pyrazol-4-yl)phenyl]- (9CI) (CA INDEX NAME)



L25 ANSWER 64 OF 88 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 1990:158243 CAPLUS
 DN 112:158243
 TI Preparation of antiarrhythmic 1H-pyrazole-1-alkanamides
 IN Bailey, Denis M.
 PA Sterling Drug Inc., USA
 SO U.S., 15 pp. Cont.-in-part of U.S. Ser. No. 206,246.
 CODEN: USXXAM

DT Patent
 LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 4870095	A	19890926	US 1989-327226	19890322
	IL 86926	A1	19920715	IL 1988-86926	19880630
	AU 8818930	A1	19890119	AU 1988-18930	19880711
	AU 599251	B2	19900712		
	ZA 8804976	A	19890222	ZA 1988-4976	19880711
	ES 2039514	T3	19931001	ES 1988-111051	19880711
	FI 8803315	A	19890114	FI 1988-3315	19880712
	DK 8803881	A	19890116	DK 1988-3881	19880712
	NO 8803114	A	19890116	NO 1988-3114	19880712
	JP 01063573	A2	19890309	JP 1988-174823	19880713

PRAI US 1987-72490 19870713
 US 1988-206246 19880613

OS CASREACT 112:158243; MARPAT 112:158243


AB The title compds. [I, II; R1 = H, alkyl; R2, R3 = H, OH, alkyl, alkoxy, alkylamino, alkylamido, alkylsulfonamido, NO2, NH2, cyano, halo; R4, R5 = H, (hydroxy)alkyl; or R4R5 = straight or branched C2-6 alkylene; R6 = H, OH; R7, R8 = H, OH, alkyl, alkoxy, halo; m = 1,2; A = CH2CH(OH)CH2, (CH2)n; n = 2-8], useful for the treatment of cardiac arrhythmias, are prepared Thus, a solution of 15g Et 4,5-diphenyl-1H-pyrazole-1-acetate in 17 mL 1-(3-aminopropyl)-2-pipecoline was stirred 5 h on a steam bath to give 17.0 g I [R1-R3 = R6-R8 = H, NR4R5 = 2-methyl-1-piperidinyl, A = (CH2)3, m = 1] (III). III at 30 mg/kg i.v. in anesthetized guinea pigs delayed the onset of aconitine HCl-induced arrhythmia including premature ventricular contraction (PVC) 25.9, sustained ventricular contraction (VTACH) 50.5, and sustained ventricular fibrillation (VFIB) 60.0 min vs. control values of 0.97, 1.48, and 3.96 min, resp.

IT **126053-36-9P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of, as antiarrhythmic)

RN 126053-36-9 CAPLUS

CN 1H-Pyrazole-1-acetamide, 4-[4-(acetylamino)phenyl]-N-[3-(diethylamino)propyl]-5-phenyl- (9CI) (CA INDEX NAME)




L25 ANSWER 65 OF 88 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 1990:138120 CAPLUS
 DN 112:138120
 TI Composition containing phenylpyridazinone derivatives for promoting growth and reducing fat in animals
 IN Euler, Klaus; Lechtken, Peter; Kohler, Walter; Hoppe, Peter Paul; Schoener, Franz Josef; Geiss, Karl Heinz; Thyess, Marco
 PA BASF A.-G., Fed. Rep. Ger.
 SO PCT Int. Appl., 40 pp.
 CODEN: PIXXD2
 DT Patent
 LA German
 FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 8903181	A1	19890420	WO 1988-EP905	19881010
	W: US				
	RW: AT, BE, CH, DE, FR, GB, IT, LU, NL, SE				
	DE 3735207	A1	19890427	DE 1987-3735207	19871017
	EP 401219	A1	19901212	EP 1988-909318	19881010
	R: AT, BE, CH, DE, FR, GB, IT, LI, NL, SE				
PRAI	DE 1987-3735207		19871017		
	WO 1988-EP905		19881010		

AB Phenylpyridazinone compds. [I, II, III, IV; R1-R3, R6-R12 = functional groups (e.g., amino-, hydroxy-, halo-), alkyl, aromatic, heterocyclic, alicyclic, heteroalicyclic; X,Y = C, hetero-atoms; A,B,A + B = functional group; R4 = H, Me, CH₂OH; R5 = H; R4 + R5 = Cl-2 alkylidene if A = B = H; M = O, S, substituted amine] are used as supplements in feed for mammals, birds, fish and reptiles where they improve feed utilization (weight gain per unit feed), growth rate, and reduce stored fat. Rats were fed on diets containing 21 of these compds. as supplements in the range 0-100 ppm. Feed utilization efficiency was increased by ≤14% with carcass protein-fat ratios improved by ≤40%. Some compds. were ineffective and others had the reverse effect.


IT **125882-67-9**
 RL: BIOL (Biological study)
 (feed supplement, effects on feed utilization and body-fat content of rats with)
 RN 125882-67-9 CAPLUS
 CN 1-Piperidinepropanamide, N-[4-(4,5-dihydro-5-oxo-1H-pyrazol-3-yl)phenyl]-4-phenyl- (9CI) (CA INDEX NAME)




L25 ANSWER 66 OF 88 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 1989:477898 CAPLUS
 DN 111:77898
 TI Synthesis of some new β -lactams, 4-thiazolidinones, and pyrazolines
 AU Fahmy, A. M.; Hassan, Kh. M.; Khalaf, A. A.; Ahmed, R. A.
 CS Fac. Sci., Assiut Univ., Assiut, Egypt
 SO Revue Roumaine de Chimie (1988), 33(7), 755-61
 CODEN: RRCHAX; ISSN: 0035-3930
 DT Journal
 LA English
 OS CASREACT 111:77898
 AB N-Arylidene-p-aminoacetophenones and/or -p-amino-1-chalcones were converted to a series of β -lactams I, 4-thiazolidinones II (R = p-Cl, p-MeO, p-Me, p-HO, o-HO), and pyrazolines III and IV (R1 = H, p-Cl, p-O2N, p-MeO, p-Me, m-O2N), resp. p-ClCH2CONHC6H4COMe gave p-R2CH2CONHC6H4COCH=CHC6H4R-p (R = H, Cl, NO2, OMe; R1 = piperidino, morpholino), which cyclized with N2H4, PhNHNH2, or (NH2)2CS to give pyrazolines and pyrimidine-2-thiones, resp. II-IV had bactericidal and fungicidal activity, but I was active only against *Penicillium notatum*.
 IT **85791-61-3P 85791-62-4P 115848-69-6P**
115848-70-9P 115848-71-0P 115848-72-1P
115848-90-3P 115848-91-4P 115848-92-5P
115848-93-6P 115848-94-7P 115848-95-8P
115848-96-9P 115848-97-0P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation and microbicidal activity)
 RN 85791-61-3 CAPLUS
 CN Acetamide, N-[4-[1-acetyl-4,5-dihydro-5-(4-methoxyphenyl)-1H-pyrazol-3-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 85791-62-4 CAPLUS
 CN Acetamide, N-[4-[1-acetyl-4,5-dihydro-5-(4-nitrophenyl)-1H-pyrazol-3-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 115848-69-6 CAPLUS
 CN Acetamide, N-[4-(1-acetyl-4,5-dihydro-5-phenyl-1H-pyrazol-3-yl)phenyl]-
 (9CI) (CA INDEX NAME)



RN 115848-70-9 CAPLUS
 CN Acetamide, N-[4-[1-acetyl-5-(4-chlorophenyl)-4,5-dihydro-1H-pyrazol-3-
 yl]phenyl]- (9CI) (CA INDEX NAME)




RN 115848-71-0 CAPLUS
 CN Acetamide, N-[4-[1-acetyl-4,5-dihydro-5-(4-methylphenyl)-1H-pyrazol-3-
 yl]phenyl]- (9CI) (CA INDEX NAME)




RN 115848-72-1 CAPLUS

CN Acetamide, N-[4-[1-acetyl-4,5-dihydro-5-(3-nitrophenyl)-1H-pyrazol-3-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 115848-90-3 CAPLUS

CN 1-Piperidineacetamide, N-[4-(1-acetyl-4,5-dihydro-5-phenyl-1H-pyrazol-3-yl)phenyl]- (9CI) (CA INDEX NAME)




RN 115848-91-4 CAPLUS

CN 1-Piperidineacetamide, N-[4-[1-acetyl-5-(4-chlorophenyl)-4,5-dihydro-1H-pyrazol-3-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 115848-92-5 CAPLUS

CN 1-Piperidineacetamide, N-[4-[1-acetyl-4,5-dihydro-5-(4-nitrophenyl)-1H-pyrazol-3-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 115848-93-6 CAPLUS

CN 1-Piperidineacetamide, N-[4-[1-acetyl-4,5-dihydro-5-(4-methoxyphenyl)-1H-pyrazol-3-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 115848-94-7 CAPLUS


CN 4-Morpholineacetamide, N-[4-(1-acetyl-4,5-dihydro-5-phenyl-1H-pyrazol-3-yl)phenyl]- (9CI) (CA INDEX NAME)




RN 115848-95-8 CAPLUS

CN 4-Morpholineacetamide, N-[4-[1-acetyl-5-(4-chlorophenyl)-4,5-dihydro-1H-pyrazol-3-yl]phenyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 115848-96-9 CAPLUS

CN 4-Morpholineacetamide, N-[4-[1-acetyl-4,5-dihydro-5-(4-nitrophenyl)-1H-pyrazol-3-yl]phenyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 115848-97-0 CAPLUS
CN 4-Morpholineacetamide, N-[4-[1-acetyl-4,5-dihydro-5-(4-methoxyphenyl)-1H-pyrazol-3-yl]phenyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



L25 ANSWER 67 OF 88 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 1989:407397 CAPLUS
 DN 111:7397
 TI Preparation of triphenylpyrazolines as insecticides
 IN Lahm, George Philip
 PA du Pont de Nemours, E. I., and Co., USA
 SO Eur. Pat. Appl., 48 pp.
 CODEN: EPXXDW

DT Patent
 LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 300692	A1	19890125	EP 1988-306478	19880715
	R: ES, GR				
	WO 8900562	A1	19890126	WO 1988-US2335	19880715
	W: AU, BG, BR, DK, HU, JP, KR, SD, SU, US				
	RW: AT, BE, CH, DE, FR, GB, IT, LU, NL, SE				
	AU 8819939	A1	19890213	AU 1988-19939	19880715
	EP 367796	A1	19900516	EP 1988-906671	19880715
	R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
	JP 02504273	T2	19901206	JP 1988-506321	19880715
	CN 1030755	A	19890201	CN 1988-104451	19880716
	US 5006524	A	19910409	US 1990-438467	19900102
PRAI	US 1987-74795		19870717		
	US 1988-199584		19880603		
	WO 1988-US2335		19880715		

OS MARPAT 111:7397

AB The title compds. [I; R1-R3 = halo, cyano, N3, thiocyanato, NO2, R7, OR7, CO2R7, O2CR7, S(O)qR7, CONR7R8, etc.; when m, n or p = 2, R1, R2 or R3, taken together as OCH2O, OCH2CH2O, or CH2CH2O, form an (un)substituted benzo-fused 5- or 6-membered ring; R4 = CO2R9, CONR9R10, SO2NR9R10, etc.; R5 = H, C1-4 alkyl; R6 = H, Me; R7, R9 = H, (un)substituted C≤4 hydrocarbyl, PhCH2; R8, R10 = H, (un)substituted C≤4 hydrocarbyl; R7R8, R9R10 = C4-5 alkylene, CH2CH2OCH2CH2; X = O, S; Y = H, CHO, C≤6 (alkoxy)alkanoyl, haloalkanoyl, (halo)alkylthio, (un)substituted PhS; m, n = 0-5; p = 0-4; q = 0-2] were prepared as insecticides from deoxybenzoins II by a 3-step process. Me3SiCN was refluxed with 4-ClC6H4CHO in CH2Cl2 in the presence of ZnI2 to give 4-ClC6H4CH(CN)OSiMe3 which was converted in 3 steps to II (R2n= 4-Cl, R3p = H, R4 = 4-CO2Me). The latter was converted in 3 steps to I (R1m= 4-F3C, R5 = R6 = Y = H, X = O, R2-R4, n, p unchanged) (III). At 0.55 kg/ha III gave ≥80% kill of several insect larvae, e.g., Spodoptera frugiperda, as well as adult insects, e.g., Anthonomus grandis.


IT **120986-39-2P 120986-40-5P 120986-41-6P**

120986-42-7P

RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of, as insecticide)


RN 120986-39-2 CAPLUS

CN 1H-Pyrazole-1-carboxamide, 3-(4-chlorophenyl)-4,5-dihydro-4-[4-[(methylamino)carbonyl]phenyl]-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 120986-40-5 CAPLUS

CN 1H-Pyrazole-1-carboxamide, N,3-bis(4-chlorophenyl)-4,5-dihydro-4-[4-[(methylamino)carbonyl]phenyl]- (9CI) (CA INDEX NAME)



RN 120986-41-6 CAPLUS

CN 1H-Pyrazole-1-carboxamide, 3-(4-chlorophenyl)-N-(4-fluorophenyl)-4,5-dihydro-4-[4-[(methylamino)carbonyl]phenyl]- (9CI) (CA INDEX NAME)




RN 120986-42-7 CAPLUS


CN 1H-Pyrazole-1-carboxamide, 3-(4-chlorophenyl)-N-(3,4-dichlorophenyl)-4,5-

09/773,736


dihydro-4-[4-[(methyamino)carbonyl]phenyl]- (9CI) (CA INDEX NAME)



L25 ANSWER 68 OF 88 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 1988:492871 CAPLUS
 DN 109:92871
 TI Synthesis of some new β -lactams, 4-thiazolidinones and pyrazolines
 AU Fahmy, A. M.; Hassan, K. M.; Khalaf, A. A.; Ahmed, R. A.
 CS Fac. Sci., Assiut Univ., Assiut, Egypt
 SO Indian Journal of Chemistry, Section B: Organic Chemistry Including
 Medicinal Chemistry (1987), 26B(9), 884-7
 CODEN: IJSBDB; ISSN: 0376-4699
 DT Journal
 LA English
 OS CASREACT 109:92871
 AB Reaction of ClCH_2COCl and $\text{HSCH}_2\text{CO}_2\text{H}$ with $\text{RC}_6\text{H}_4\text{CH:NC}_6\text{H}_4\text{COMe-4}$ ($\text{R} = 4\text{-Cl, 4-OMe, 4-Me, 4-OH, 2-OH}$) gave β -lactam I and thiazolidinones II, resp. $4\text{-R}_1\text{CH:NC}_6\text{H}_4\text{COCH:CHR}_1$ ($\text{R}_1 = \text{Ph, 4-ClC}_6\text{H}_4, 4\text{-O}_2\text{NC}_6\text{H}_4, 4\text{-MeOC}_6\text{H}_4, 4\text{-MeC}_6\text{H}_4, 3\text{-O}_2\text{NC}_6\text{H}_4$) were converted to pyrazolines, e.g. III ($\text{R}_2 = \text{NHAc, N:CHR}_1$). Cyclocondensation of $4\text{-R}_3\text{CH}_2\text{CONHC}_6\text{H}_4\text{COCH:CHR}_1$ ($\text{R}_1 = \text{Ph, 4-ClC}_6\text{H}_4, 4\text{-O}_2\text{NC}_6\text{H}_4, 4\text{-MeOC}_6\text{H}_4$; $\text{R}_3 = \text{piperidino, morpholino}$) with N_2H_4 , PhNHNH_2 and thiourea gave pyrazolines IV and V and pyrimidinethiones VI resp. The newly prepared compds. were tested for antibacterial and antifungal activity and were moderately active.
 IT **85791-61-3P 85791-62-4P 115848-69-6P**
115848-70-9P 115848-71-0P 115848-72-1P
115848-90-3P 115848-91-4P 115848-92-5P
115848-93-6P 115848-94-7P 115848-95-8P
115848-96-9P 115848-97-0P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation and antibacterial and antifungal activity of)
 RN 85791-61-3 CAPLUS
 CN Acetamide, N-[4-[1-acetyl-4,5-dihydro-5-(4-methoxyphenyl)-1H-pyrazol-3-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 85791-62-4 CAPLUS
 CN Acetamide, N-[4-[1-acetyl-4,5-dihydro-5-(4-nitrophenyl)-1H-pyrazol-3-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 115848-69-6 CAPLUS

CN Acetamide, N-[4-(1-acetyl-4,5-dihydro-5-phenyl-1H-pyrazol-3-yl)phenyl]-
(9CI) (CA INDEX NAME)




RN 115848-70-9 CAPLUS

CN Acetamide, N-[4-[1-acetyl-5-(4-chlorophenyl)-4,5-dihydro-1H-pyrazol-3-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 115848-71-0 CAPLUS


CN Acetamide, N-[4-[1-acetyl-5-(4-methylphenyl)-4,5-dihydro-1H-pyrazol-3-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 115848-72-1 CAPLUS
 CN Acetamide, N-[4-[1-acetyl-4,5-dihydro-5-(3-nitrophenyl)-1H-pyrazol-3-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 115848-90-3 CAPLUS
 CN 1-Piperidineacetamide, N-[4-(1-acetyl-4,5-dihydro-5-phenyl-1H-pyrazol-3-yl)phenyl]- (9CI) (CA INDEX NAME)




RN 115848-91-4 CAPLUS
 CN 1-Piperidineacetamide, N-[4-[1-acetyl-5-(4-chlorophenyl)-4,5-dihydro-1H-pyrazol-3-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 115848-92-5 CAPLUS

CN 1-Piperidineacetamide, N-[4-[1-acetyl-4,5-dihydro-5-(4-nitrophenyl)-1H-pyrazol-3-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 115848-93-6 CAPLUS

CN 1-Piperidineacetamide, N-[4-[1-acetyl-4,5-dihydro-5-(4-methoxyphenyl)-1H-pyrazol-3-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 115848-94-7 CAPLUS

CN 4-Morpholineacetamide, N-[4-(1-acetyl-4,5-dihydro-5-phenyl-1H-pyrazol-3-yl)phenyl]- (9CI) (CA INDEX NAME)




RN 115848-95-8 CAPLUS
 CN 4-Morpholineacetamide, N-[4-[1-acetyl-5-(4-chlorophenyl)-4,5-dihydro-1H-pyrazol-3-yl]phenyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 115848-96-9 CAPLUS
 CN 4-Morpholineacetamide, N-[4-[1-acetyl-4,5-dihydro-5-(4-nitrophenyl)-1H-pyrazol-3-yl]phenyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 115848-97-0 CAPLUS
 CN 4-Morpholineacetamide, N-[4-[1-acetyl-4,5-dihydro-5-(4-methoxyphenyl)-1H-pyrazol-3-yl]phenyl]- (9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 2-A




L25 ANSWER 69 OF 88 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 1987:598165 CAPLUS
 DN 107:198165
 TI Synthesis and biological testing of some α -thienyl and α -furyl derivatives
 AU El-Kerdawy, M. M.; El-Emam, A. A.
 CS Fac. Pharm., Univ. Mansoura, Mansoura, Egypt
 SO Journal of the Chemical Society of Pakistan (1987), 9(2), 285-93
 CODEN: JCSPDF; ISSN: 0253-5106
 DT Journal
 LA English
 OS CASREACT 107:198165
 AB Cyclocondensation of furyl chalcone analogs I (X = O, R = Me, R1 = 2-thienyl, C6H4NHAc-4) with R2NHNH2 [R2 = H, Ph, 4-O2NC6H4, 2,4-(O2N)2C6H3] gave pyrazolines II in 45-80% yields. Condensation of II (R2 = Ph, R1 = C6H4NH2-4) with aldehydes, e.g. R3C6H4CHO (R3 = H, 4-MeO, 4-HO, 2-Me2N) gave the corresponding anils, e.g. II (R2 = Ph, R1 = 4-C6H4N:CHC6H4R3) in 40-75% yields. Cyclocondensation of I (X = O, S, R = H, Me, Br, R1 = 2-thienyl, C6H4NHAc-4) with H2NCOCH2CN gave pyridones III (R4 = CN) in 55-60% yields. Alkylation of III (X = S, R = H, R1 = 2-thienyl, R4 = CN) with Grignard reagents gave III (R4 = Ac, COEt, Bz) in 50-75% yields. II [R1 = 2-thienyl, R2 = 2,4-(O2N)2C6H3; R1 = 4-C6H4N:CHC6H3BrOH-5,2, R2 = Ph] were active against Staphylococcus aureus and Candida albicans, resp., and an LD50 study was carried out for II [R1 = 2-thienyl, R2 = 2,4-(O2N)2C6H3].
 IT **111121-65-4P**
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation and acylation of, with acetic anhydride)
 RN 111121-65-4 CAPLUS
 CN Acetamide, N-[4-[4,5-dihydro-5-(5-methyl-2-furanyl)-1H-pyrazol-3-yl]phenyl]- (9CI) (CA INDEX NAME)




IT **111121-73-4P**
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 111121-73-4 CAPLUS
 CN Acetamide, N-[4-[1-acetyl-4,5-dihydro-5-(5-methyl-2-furanyl)-1H-pyrazol-3-yl]phenyl]- (9CI) (CA INDEX NAME)

09/773,736



L25 ANSWER 70 OF 88 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 1987:102210 CAPLUS
 DN 106:102210
 TI Synthesis and some reactions of 2-(α/β -naphthyl)-3,1-benzoxazin-4(H)-ones and 3-amino-2-(β -naphthyl)quinazolin-4(3H)-one.
 AU Mohamed, M. M.; El-Khamary, A. A.; El-Nagdy, S.; Shoshaa, S. W.
 CS Fac. Sci., Ain Shams Univ., Cairo, Egypt
 SO Indian Journal of Chemistry, Section B: Organic Chemistry Including Medicinal Chemistry (1986), 25B(2), 207-11
 CODEN: IJSBDB; ISSN: 0376-4699
 DT Journal
 LA English
 OS CASREACT 106:102210
 AB The title benzoxazinones I (R = 1-naphthyl, 2-naphthyl) have been prepared by the reaction of α - or β -naphthoyl chloride (2 mol) and anthranilic acid (1 mol) in the presence of a catalytic amount of pyridine, and their reactions with amines, formamide and active methylene compds. have been studied. 3-Aminoquinazolinone II (X = O) has been synthesized by the action of hydrazine hydrate on I (R = 2-naphthyl) in n-butanol and its reaction with Ac₂O, aldehydes, esters, and P₂S₅ has been investigated. Cleavage of the C:S bond in the thione II (X = S) with N₂H₄.H₂O and copper bronze has been observed
 IT **106696-40-6P**
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 106696-40-6 CAPLUS
 CN 2-Naphthalenecarboxamide, N-[2-(4,5-dihydro-5-oxo-1H-pyrazol-3-yl)phenyl]-
 (9CI) (CA INDEX NAME)



L25 ANSWER 71 OF 88 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 1986:524288 CAPLUS
 DN 105:124288
 TI Heat-developable photosensitive material
 IN Sato, Kozo; Yabuki, Yoshiharu; Hirai, Hiroyuki; Kawata, Ken
 PA Fuji Photo Film Co., Ltd. , Japan
 SO Eur. Pat. Appl., 78 pp.
 CODEN: EPXXDW

DT Patent
 LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 177033	A2	19860409	EP 1985-112479	19851002
	EP 177033	A3	19861120		
	EP 177033	B1	19880824		
	R: DE, GB, NL				
	JP 61084640	A2	19860430	JP 1984-206833	19841002
	JP 04013704	B4	19920310		
	CA 1256733	A1	19890704	CA 1985-491866	19850930
	US 4657848	A	19870414	US 1985-782811	19851002
PRAI	JP 1984-206833		19841002		


AB A heat-developable photosensitive material is described containing a base precursor of the formula I (R = H, alkyl, cycloalkyl, alkenyl, alkynyl, aralkyl, aryl, heterocyclyl, alkylene, cycloalkylene, alkenylene, alkynylene, aralkylene, arylene, or a divalent heterocyclic group; R1 = H or alkyl group; R2 = alkyl, alkoxy, halogen, acylamino, sulfonylamino, alkylamino, dialkylamino, alkylsulfonyl, arylsulfonyl, CN, carbamoyl, sulfamoyl, or alkoxycarbonyl; Z = CO, CO2, NR3CO, SO2, NR3SO2, PO3R4, or POR, where R3 = H or alkyl and R4 = alkyl; M = alkali metal, alkaline earth metal, quaternary ammonium group or an ammonium group represented by BH where B = organic base; l = 0-3; m, n = 1 or 2. The material provides an image of high d., decreased fog, improved stability under high temperature and high humidity, and good photog. performance. Thus a poly(ethylene terephthalate) support film was coated with a composition containing a Ag(Br,I) emulsion 10, a gelatin dispersion of a coupler 3.5, CH3CONH-p-C6H4C.tplbond.CCO2H.(NH)C(NH2)2 base precursor 0.24, 10% aqueous solution of gelatin 5 g, and a solution of 2 g of 2,6-dichloro-p-aminophenol in 17 mL of H2O. The material was imagewise exposed for 5 s to 2000 lx light and heated for 20 s at 150° to obtain a cyan image with min. d. of 0.16 and a maximum d. of 2.15.

IT 99844-13-0P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation and reaction of)

RN 99844-13-0 CAPLUS

CN Acetamide, N-[4-(4,5-dihydro-5-oxo-1H-pyrazol-3-yl)phenyl]- (9CI) (CA INDEX NAME)



L25 ANSWER 72 OF 88 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 1986:186404 CAPLUS
 DN 104:186404
 TI 2-Heteroaryl-4-aryl-4-pyrazolin-3-ones
 IN Sasse, Klaus; Brandes, Wilhelm; Haenssler, Gerd; Reinecke, Paul; Schmitt, Hans Georg; Paulus, Wilfried
 PA Bayer A.-G. , Fed. Rep. Ger.
 SO Eur. Pat. Appl., 66 pp.
 CODEN: EPXXDW

DT Patent

LA German

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 165448	A2	19851227	EP 1985-105794	19850511
	EP 165448	A3	19880907		
	EP 165448	B1	19911016		

R: AT, BE, CH, DE, FR, GB, IT, LI, NL

	DE 3419127	A1	19851128	DE 1984-3419127	19840523
	DE 3430433	A1	19860227	DE 1984-3430433	19840818
	AT 68493	E	19911115	AT 1985-105794	19850511
PRAI	DE 1984-3419127		19840523		
	DE 1984-3430433		19840818		
	EP 1985-105794		19850511		

AB Fungicidal title compds. [I; R = H, alkyl; R1 = halo, OH, NO2, R3S(O)p, amino, (un)substituted alkyl, alkoxy, condensed carbocycle, heterocycle; R2 = alkoxy, alkylthio, halo, cyano, NO2, CONH2, (un)substituted alkyl, condensed carbocyclo; R3 = (un)substituted alkyl; X, Y, Z = N, CH, CR2; m = 0-5; n = 0-4; p = 0-2] were prepared Thus, HOCH:CPhCO2Et and 2-hydrazinopyrimidine were refluxed in EtOH followed by addition of aqueous

NaOH


and further refluxing to give 63% I (R = H, X = Z = N, Y = CH, m = n = 0). I are more effective fungicides against, e.g., Phytophthora infestans on tomato plants than known agricultural fungicides.

IT **101960-03-6P**

RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of, as agricultural fungicide)

RN 101960-03-6 CAPLUS


CN Acetamide, N-[4-[2,3-dihydro-3-oxo-2-(2-pyridinyl)-1H-pyrazol-4-yl]phenyl]-(9CI) (CA INDEX NAME)



L25 ANSWER 73 OF 88 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 1983:575812 CAPLUS
 DN 99:175812
 TI Herbicidal sulfonamides
 IN Wolf, Anthony David; Rorer, Morris Padgett
 PA du Pont de Nemours, E. I., and Co. , USA
 SO Eur. Pat. Appl., 271 pp.
 CODEN: EPXXDW

DT Patent
 LA English
 FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 83975	A2	19830720	EP 1983-300073	19830106
	EP 83975	A3	19840801		
	EP 83975	B1	19871119		
	R: AT, BE, CH, DE, FR, IT, LI, LU, NL, SE				
	US 4465505	A	19840814	US 1982-428806	19821007
	US 4511392	A	19850416	US 1982-436631	19821029
	AT 30915	E	19871215	AT 1983-300073	19830106
	CA 1239929	A1	19880802	CA 1983-419031	19830106
	US 4606755	A	19860819	US 1984-685026	19841221
	US 4695311	A	19870922	US 1986-861260	19860509
	US 4810282	A	19890307	US 1987-60204	19870610
PRAI	US 1982-337932		19820107		
	US 1982-337934		19820107		
	US 1982-428806		19821007		
	US 1982-436631		19821029		
	EP 1983-300073		19830106		
	US 1984-685026		19841221		
	US 1986-861260		19860509		
OS	CASREACT 99:175812				
AB	Benzenesulfonamides I (R = azolyl, azinyl; R1 = H, F, Cl, Br, Me, CF3, OMe; R2 = H, Me; R3 = substituted pyrimidinyl, triazinyl; X = O, S) (67 compds.) were prepared. Thus, 2-O2NC6H4COME was treated with Me2NCH(OMe)2 to give 2-O2NC6H4COCH:CHNMe2, which was cyclized with NH2OH to the isoxazole II (R4 = NO2). Reduction of the nitro group, diazotization, and reaction with SO2-HCl gave II (R4 = SO2Cl), which was amidated and treated with BuNCO and COCl2 to give II (R4 = SO2NCO). Treatment of the isocyanate with 2-amino-4,6-dimethoxypyrimidine gave III which, at 0.05 kg/ha preemergence, gave total control of e.g., nutsedge.				
IT	87488-79-7P RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent) (preparation and reduction of)				
RN	87488-79-7 CAPLUS				
CN	Acetamide, N-[2-(1-methyl-1H-pyrazol-3-yl)phenyl]- (9CI) (CA INDEX NAME)				



Intermediate

L25 ANSWER 74 OF 88 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 1983:438457 CAPLUS
 DN 99:38457
 TI 1,4-Dihydropyridine derivatives with vasodilating and hypotensive activity
 PA Tokyo Tanabe Co. Ltd., Japan
 SO Fr. Demande, 81 pp.
 CODEN: FRXXBL
 DT Patent
 LA French
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	FR 2511370	A1	19830218	FR 1982-14008	19820811
	FR 2511370	B1	19861024		
	JP 58026882	A2	19830217	JP 1981-125216	19810812
	JP 63021674	B4	19880509		
	JP 58131982	A2	19830806	JP 1982-13398	19820201
	JP 63023193	B4	19880516		
	GB 2108108	A1	19830511	GB 1982-23168	19820811
	GB 2108108	B2	19850807		
	DE 3230400	A1	19830324	DE 1982-3230400	19820812
	DE 3230400	C2	19930225		
	US 4418197	A	19831129	US 1983-457867	19830113
PRAI	JP 1981-125216		19810812		
	JP 1982-13398		19820201		

OS CASREACT 99:38457



AB Pyrazoles I [X = (un)substituted (CH₂)₆; R = O₂NC₆H₄, dihalophenyl; R₁ = alkyl, alkoxyalkyl; R₂ = (un)substituted alkyl, pyridyl, Ph] (119 compds.) were prepared. Thus, I [X = (CH₂)₆, R = 3-O₂NC₆H₄, R₁ = Me, R₂ = 5-Me, II] was obtained in 62.4% yield by treating the tosyloxyhexyl dihydropyridinecarboxylate with 3-methyl-5-pyrazolone. At 3 µg/kg i.v. in dogs II gave a decrease in blood pressure of 14.5 ± 1.3 mmHg for 46.5 ± 2.8 min. and a change in heart rate of 0.8 beats/min.

IT **86419-06-9P**


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (preparation and antihypertensive activity of)

RN 86419-06-9 CAPLUS


CN 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, 6-[[5-[4-(acetylamino)phenyl]-1H-pyrazol-3-yl]oxy]hexyl methyl ester (9CI) (CA INDEX NAME)




L25 ANSWER 75 OF 88 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 1983:197690 CAPLUS
 DN 98:197690
 TI Syntheses and investigations of amino ketones. V. Reactions of
 4'-acetamidochalcones with hydroxylamine and hydrazine
 AU Sykulski, Jerzy; Rokita-Trygubowicz, Teresa
 CS Inst. Fundam. Chem. Sci., Sch. Med., Lodz, 90-145, Pol.
 SO Acta Poloniae Pharmaceutica (1982), 39(1-3), 89-93
 CODEN: APPHAX; ISSN: 0001-6837
 DT Journal
 LA Polish
 OS CASREACT 98:197690
 AB 4'-Acetamidochalcone refluxed with $\text{NH}_2\text{OH} \cdot \text{HCl}$ in EtOH gave I ($\text{R} = \text{R}_1 = \text{R}_2 = \text{H}$) (II). I ($\text{R} = \text{Ac}$, $\text{R}_1 = \text{H}$, $\text{R}_2 = \text{MeO}$ and NO_2) were prepared analogously. II with Ac_2O gave I ($\text{R} = \text{R}_1 = \text{Ac}$, $\text{R}_2 = \text{H}$). A similar acetylation gave rise to the formation of I ($\text{R} = \text{R}_1 = \text{Ac}$, $\text{R}_2 = \text{NO}_2$). Pyrazoline derivs. III ($\text{R}_2 = \text{MeO}$, NO_2 , NHAc , $\text{R}_3 = \text{H}$) were obtained in the reaction of the appropriate aminochalcones with $\text{NH}_2\text{NH}_2 \cdot \text{H}_2\text{O}$ in EtOH; their subsequent acetylation gave the corresponding III ($\text{R}_3 = \text{Ac}$).
 IT **85791-58-8P 85791-59-9P 85791-60-2P**
85791-61-3P 85791-62-4P 85791-63-5P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 85791-58-8 CAPLUS
 CN Acetamide, N-[4-[4,5-dihydro-5-(4-methoxyphenyl)-1H-pyrazol-3-yl]phenyl]-
 (9CI) (CA INDEX NAME)




RN 85791-59-9 CAPLUS
 CN Acetamide, N-[4-[4,5-dihydro-5-(4-nitrophenyl)-1H-pyrazol-3-yl]phenyl]-
 (9CI) (CA INDEX NAME)




RN 85791-60-2 CAPLUS
 CN Acetamide, N,N'-[(4,5-dihydro-1H-pyrazole-3,5-diyl)di-4,1-phenylene]bis-
 (9CI) (CA INDEX NAME)



RN 85791-61-3 CAPLUS
 CN Acetamide, N-[4-[1-acetyl-4,5-dihydro-5-(4-methoxyphenyl)-1H-pyrazol-3-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 85791-62-4 CAPLUS
 CN Acetamide, N-[4-[1-acetyl-4,5-dihydro-5-(4-nitrophenyl)-1H-pyrazol-3-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 85791-63-5 CAPLUS
 CN Acetamide, N,N'-[(1-acetyl-4,5-dihydro-1H-pyrazole-3,5-diyl)di-4,1-

09/773,736

phenylene]bis- (9CI) (CA INDEX NAME)



9

L25 ANSWER 76 OF 88 CAPLUS COPYRIGHT 2004 ACS on STN

AN 1983:179274 CAPLUS

DN 98:179274

TI The ring closure and rearrangement of N-(2-aminobenzoyl)-N-methylhydrazones of β -dicarbonyl compounds

AU Gal, Melinda; Feher, Odon; Tihanyi, Endre; Horvath, Gyula; Jerkovich, Gyula

CS Inst. Drug Res., Budapest, H-1325, Hung.

SO Tetrahedron (1982), 38(19), 2933-8

CODEN: TETRAB; ISSN: 0040-4020

DT Journal

LA English

OS CASREACT 98:179274

AB N-(2-Aminobenzoyl)-N-methylhydrazones of β -dicarbonyl compds.


underwent a variety of cyclization and rearrangement reactions depending on the substituents and the reaction media. MeCOCHRCMe:NNMeCOC6H4NR1R2-o [I; R-R2 = H (II); R = H, R1 = Me, R2 = H, Me] without solvent at 160° or in refluxing tetralin gave the corresponding pyrazoles III. Refluxing II in EtOH/NaOEt gave 79.7% IV. Refluxing I (R = Me, R1 = R2 = H) in EtOH/NaOEt for 1 h gave 24.2% pyrazoloquinolinone V and 40.6% pyrazole VI.

IT 75075-90-0P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent) (preparation and hydrolysis of)


RN 75075-90-0 CAPLUS

CN Acetamide, N-[2-(1,3,4-trimethyl-1H-pyrazol-5-yl)phenyl]- (9CI) (CA INDEX NAME)




Intermediate

L25 ANSWER 77 OF 88 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1981:174968 CAPLUS
DN 94:174968
TI Synthesis of some pyrazolines as schistosomicidal agents
AU Abou Ouf, A. A.; El-Kerdawy, M. M.; Farghaly, A. M.; Moustafa, M. A.
CS Pharm. Chem. Dep., Mansoura Fac. Pharm., Mansoura, Egypt
SO Journal of Drug Research (1979), 11(1-2), 73-80
CODEN: JDGRAX; ISSN: 0368-1866
DT Journal
LA English
AB Condensation of 5-bromo-2-thiophinecarboxaldehyde with RC₆H₄COMe (R = H, 4-Me, 4-AcNH, 2-HO) gave the chalcones I, which cyclized with N₂H₄ to give pyrazolines II (R₁ = H). Acetylation of II (R₁ = H) gave II (R₁ = Ac). IR and NMR spectra of these compds. were recorded, but their schistosomicidal activities were not tested.
IT **77345-09-6P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and acetylation of)
RN 77345-09-6 CAPLUS
CN Acetamide, N-[4-[5-(5-bromo-2-thienyl)-4,5-dihydro-1H-pyrazol-3-yl]phenyl]-(9CI) (CA INDEX NAME)




A large, stylized handwritten mark, possibly a signature or a large 'X', is present in the right margin of the page.


L25 ANSWER 78 OF 88 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 1980:604524 CAPLUS
 DN 93:204524
 TI The ring closure and rearrangement of 1-(2-amino)-benzoyl-1-methylhydrazones of β -dicarbonyl compounds: on the formation and crystal structure of 3a,9a-dihydro-1,3,3a,9a-tetramethyl-4H-pyrazolo[3,4-b]quinolin-4-one
 AU Gal, Melinda; Feher, Odon; Tihanyi, Endre; Horvath, Gyula; Jerkovich, Gyula; Argay, Gyula; Kalman, Alajos
 CS Inst. Drug Res., Budapest, H-1325, Hung.
 SO Tetrahedron Letters (1980), 21(16), 1567-70
 CODEN: TELEAY; ISSN: 0040-4039
 DT Journal
 LA English
 OS CASREACT 93:204524
 AB 2-H₂NC₆H₄CONMeN:CMechRCOME (I; R = H) reacted with NaOEt/EtOH giving pyrazoloquinoline II, whereas on thermolysis pyrazole III (R = COC₆H₄NH₂-2, R₁ = Me) was obtained. I (R = Me) reacted with NaOEt/EtOH giving III (R = Me, R₁ = C₆H₄NHAc-2) and the title pyrazoloquinolinone (IV). The structure of IV was determined by x-ray crystallog. anal. The cyclization mechanism is discussed.
 IT **75075-90-0P**
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 75075-90-0 CAPLUS
 CN Acetamide, N-[2-(1,3,4-trimethyl-1H-pyrazol-5-yl)phenyl]- (9CI) (CA INDEX NAME)




L25 ANSWER 79 OF 88 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 1979:474524 CAPLUS
 DN 91:74524
 TI Syntheses and studies on amino ketones. Part III. Reaction of
 1-(p-acetamidophenyl)butane-1,3-dione with hydrazine
 AU Sykulski, Jerzy; Rokita-Trygubowicz, Teresa
 CS Dep. Org. Chem., Sch. Med., Lodz, 90145, Pol.
 SO Polish Journal of Chemistry (1979), 53(2), 395-401
 CODEN: PJCHDQ; ISSN: 0137-5083
 DT Journal
 LA English
 OS CASREACT 91:74524
 AB The title reaction gave I (R = Ac) or its tautomer. Deacetylation with
 HCl gave I (R = H) or its tautomer. Several ring-acylated derivs. of I (R
 = Ac, H) were prepared
 IT **70958-36-0P**
 RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)
 (preparation and mass spectrum of)
 RN 70958-36-0 CAPLUS
 CN Acetamide, N-[4-[1-(chloroacetyl)-3-methyl-1H-pyrazol-5-yl]phenyl]- (9CI)
 (CA INDEX NAME)



IT **70958-31-5P 70958-33-7P 70958-34-8P**
70958-35-9P 70958-37-1P 70958-38-2P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 70958-31-5 CAPLUS
 CN Acetamide, N-[4-(5-methyl-1H-pyrazol-3-yl)phenyl]- (9CI) (CA INDEX NAME)




RN 70958-33-7 CAPLUS
 CN Acetamide, N-[4-(1-acetyl-3-methyl-1H-pyrazol-5-yl)phenyl]- (9CI) (CA
 INDEX NAME)




RN 70958-34-8 CAPLUS

CN Propanamide, N-[4-[3-methyl-1-(1-oxopropyl)-1H-pyrazol-5-yl]phenyl]- (9CI)
(CA INDEX NAME)




RN 70958-35-9 CAPLUS

CN Acetamide, 2-chloro-N-[4-[1-(chloroacetyl)-3-methyl-1H-pyrazol-5-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 70958-37-1 CAPLUS

CN Acetamide, N-[4-[3-methyl-1-(1-oxopropyl)-1H-pyrazol-5-yl]phenyl]- (9CI)
(CA INDEX NAME)



RN 70958-38-2 CAPLUS
 CN Acetamide, N-[4-(1-benzoyl-3-methyl-1H-pyrazol-5-yl)phenyl]- (9CI) (CA
 INDEX NAME)



L25 ANSWER 80 OF 88 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 1973:58410 CAPLUS
 DN 78:58410
 TI Plant growth regulating 3,5-diphenylpyrazoles
 IN Johnson, Alexander Lawrence; Sweetser, Philip Bliss
 PA du Pont de Nemours, E. I., and Co.
 SO Ger. Offen., 70 pp.
 CODEN: GWXXBX

DT Patent
 LA German

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 2219702	A	19721116	DE 1972-2219702	19720421
	IL 39092	A1	19760229	IL 1972-39092	19720327
	IT 955155	A	19730929	IT 1972-22831	19720407
	AU 7241026	A1	19731018	AU 1972-41026	19720412
	ZA 7202576	A	19730131	ZA 1972-2576	19720417
	ES 401879	A1	19760201	ES 1972-401879	19720418
	CA 982588	A1	19760127	CA 1972-140051	19720419
	BR 7202417	A0	19730503	BR 1972-2417	19720420
	NL 7205441	A	19721024	NL 1972-5441	19720421
	FR 2136595	A5	19721222	FR 1972-14198	19720421
	JP 58011401	B4	19830302	JP 1972-39729	19720421
PRAI	US 1971-136576		19710422		
	US 1972-230508		19720229		


AB About 30 title compds. (e.g. I, Rn = 4-F, 3-MeO, 4-Me, 3-Br, 2,4,6-Me3, 4-Cl, or 2-MeO; R1 = H or Et; R2 = H, Me, or Ac; R3 = OH, OMe, OEt, OPr, OBU, OCH2CH2OH, COSH, CONH2, or CONHBu; R4 = H or Me) were prepared either from phthalic anhydride (or its 4-methyl derivative) and MeCOC6H5-nRn via 2,4-NaO2CR4C6H3COCHNaCOC6H5-nRn and reaction with R2NHNH2 or (in the case of R1 = R2 = R4 = H) by cleavage of II with R3H and optionally Na. I were used against weeds in culture plant fields, e.g. sugar cane, soybean, peanut, or citrus, and for growth regulation of cotton, soybeans, and peanuts.

IT **39785-15-4P**

RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)



RN 39785-15-4 CAPLUS


CN Benzamide, N-(1-methylpropyl)-2-(5-phenyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



L25 ANSWER 81 OF 88 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 1971:498492 CAPLUS
 DN 75:98492
 TI 3,4,5-Triphenylpyrazoles
 AU Comrie, A. M.
 CS Sch. Pharm. Sci., Univ. Strathclyde, Glasgow, UK
 SO Journal of the Chemical Society [Section] C: Organic (1971), (16),
 2807-10
 CODEN: JSOOAX; ISSN: 0022-4952
 DT Journal
 LA English
 AB Benzoin reacted with N₂H₄.HCl in EtOH to give benzil, benzil azine,
 deoxybenzoin, BzH, PhCN, BzOH, BzOEt, desylamine-HCl, 3,4,5-
 triphenylpyrazole (I), and 3,4,5,6-tetraphenylpyridazine and their
 hydrochlorides. N-Alkyl derivs. of I were prepared from the dialkyl
 sulfates, and N-acyl and N-sulfonyl derivs. from the acid and sulfonyl
 chlorides. Nitration of I gave 3,4,5-tris(p-nitrophenyl)pyrazole, and
 bromination gave a mixture of bromo derivs.
 IT **33314-45-3P**
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 33314-45-3 CAPLUS
 CN Acetanilide, 4',4''',4''''-pyrazole-3,4,5-triyltris- (8CI) (CA INDEX
 NAME)

PAGE 1-A





L25 ANSWER 82 OF 88 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 1971:59354 CAPLUS
 DN 74:59354
 TI Photographic product containing a chromogenic coupler
 IN Barr, Charles R.
 PA Eastman Kodak Co.
 SO Fr. Demande, 39 pp.
 CODEN: FRXXBL
 DT Patent
 LA French
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	FR 2011487		19700306		
	GB 1269072			GB	
	US 3620746		19710000	US	
PRAI	US		19680401		

AB A photog. product for recording several images consists of a support on which are coated 2 hydrophilic colloid Ag halide emulsion layers. The 1st layer next to the support is made up of a coarse-grained emulsion sensitive to ≥ 1 portion of the spectrum which upon exposure and development can form in the presence of the oxidation products of a color developer with primary aromatic groups a colored image. The 2nd layer of hydrophilic colloid contains a Ag halide emulsion with finer grains than those of the 1st layer and which is sensitive to a portion of the spectrum different from that of the 1st layer. The 2nd emulsion contains, in addition, (1) a coupler which reacts with the oxidation products of a primary aromatic amine developer so as to form a colored image, which is preferably of a different color from the image formed in the 1st layer and (2) a nondiffusible hydroquinone derivative of general formula I which liberates a developer inhibitor, where Q and Q1 are H or an acyl group which is eliminated in an alkaline medium; R is a heterocyclic radical such as 5-tetrazolyl, 2-benzoxazolyl, 2-benzothiazolyl, or 2-oxadiazolyl; B is a photog. inert group which renders the compound nondiffusible; Q2 is H, SO₃M, or CO₂M where M is H or an alkaline metal. Nondiffusible couplers containing methylenic chains, such as the cyanoacetyl derivs. cyanoacetylcoumarone and cyanoacetylbenzoyl, are used.

IT **32180-71-5**


RL: USES (Uses)

(photographic coupler)


RN 32180-71-5 CAPLUS

CN Butyranilide, 4-(2,4-di-tert-pentylphenoxy)-4'-(3-ethoxy-5-oxo-2-pyrazolin-4-yl)- (8CI) (CA INDEX NAME)


PAGE 1-A




PAGE 2-A



L25 ANSWER 83 OF 88 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 1967:46385 CAPLUS
 DN 66:46385
 TI Synthesis of water soluble hydrazines and 5-pyrazolones
 AU Schindler, Wolfgang
 SO Veroeffentlichungen der Wissenschaftlichen Photo-Laboratorien, Wolfen
 (1965), 10, 277-82
 CODEN: VWPWAI; ISSN: 0372-6975
 DT Journal
 LA German
 AB Butane sultone (28 g.) was added portionwise to 100 g. 60% H₂NNH₂.H₂O (I) and the exothermic reaction cooled with water gave ω-sulfobutyl hydrazine (II), m. 163-5°. II (4.2 g.) boiled in 350 ml. alc. 0.5 hr. with 2.6 g. BzH under reflux gave N-(ω-sulfobutyl)-N'-benzylidenehydrazine, m. 172-4°. Propane sultone (12.2 g.) was added with cooling and stirring to 50 g. 50% I to give 78% ω-sulfopropylhydrazine, m. 195-7°. Thiosemicarbazide (9.1 g.) in 100 ml. 50% MeOH was treated by stirring at room temperature with 14 g. butane sultone. After keeping at least 20 hrs., the solvent was distilled in vacuo. After several days, the clear viscose precipitate was treated with MeOH and boiled briefly to give 53% N1-ω-(sulfobutyl)thiosemicarbazide, m. 195-7°. II (0.02 mole) and the corresponding β-oxo ester (0.02 mole) boiled under reflux in 10-20 ml. AcOH gave III. The following III were prepared (R, m.p., and % yield given): Me, 200-3°, 85; Ph, 262-5°, 54; p-O₂-NC₆H₄ (IV), 280-5°, 23; p-H₂NC₆H₄ (V), >300°, 34 (prepared from IV by reduction with Raney Ni); C₁₇H₃₅, 115-25°, 22; C₆H₄OC₁₈H₃₇-p, 290-5°, 45; C₆H₄NHCOC₁₇H₃₅-p, 238-40°, 35; C₆H₄NHCOC₁₁H₂₃-p, 226-30°, 81. The last two compds. were prepared by heating V and the corresponding acid chloride 2 hrs. in a 2:1 mixture of HC-ONMe₂-C₅H₅N.
 IT **14369-11-0P 14369-12-1P**
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 14369-11-0 CAPLUS
 CN 2-Pyrazoline-1-butanesulfonic acid, 5-oxo-3-(p-stearamidophenyl)- (8CI)
 (CA INDEX NAME)



RN 14369-12-1 CAPLUS
 CN 2-Pyrazoline-1-butanesulfonic acid, 3-(p-lauramidophenyl)-5-oxo- (8CI)
 (CA INDEX NAME)



L25 ANSWER 84 OF 88 CAPLUS COPYRIGHT 2004 ACS on STN

AN 1963:81516 CAPLUS

DN 58:81516

OREF 58:13950g-h,13951a-b

TI Interaction and association of bases and nucleosides in aqueous solutions

AU Ts'o, Paul O. P.; Melvin, Ingelore S.; Olson, Alfred C.

CS California Inst. of Technol.

SO Journal of the American Chemical Society (1963), 85, 1289-96

CODEN: JACSAT; ISSN: 0002-7863

DT Journal

LA Unavailable

AB The molal osmotic coefficients (ϕ) of aqueous purine, uridine, and cytidine in the concentration range of 0.1 to 1.0 molal, and inosine and caffeine

at 0.1 molal, have been determined by thermoelec. measurements of vapor pressure lowering at 25°. The activity coefficients of purine, uridine, and cytidine were calculated. The data indicate that these solutes associate extensively in solution and that the association process does not proceed simply to the dimer stage, but continues to form higher polymers. The results are consistent with a set of association processes which have equal equilibrium consts. for all successive steps. Equilibrium consts. at 25° and standard free energies for association of purine, uridine, and cytidine were found to be 2.1, 0.6, 0.9 molal⁻¹ and -440, 290, 80 cal./mole, resp. The interaction of one base with another base was examined by measuring the increase of solubility of adenine-C14 or thymine-C14 in the presence of varying concns. of a variety of interactants at 25.5° and 38°. The solubility of adenine or thymine was increased by the addition of soluble purine, nucleosides, pyrimidine, or phenol, and was essentially unchanged by the addition of cyclohexanol, adonitol, or urea. The total base-C14 in solution was assumed to be composed of the free base in solution and the H₂O-soluble base-interactant complex. Equilibrium consts.


for these

association processes have been estimated, and they agree semiquant. with the results from measurements of ϕ . The tendency for association and interaction of the free bases and nucleosides in solution can be arranged in the series: purine-purine > purine-pyrimidine > pyrimidine-pyrimidine. The relationship of this finding to the vertical-stacking interaction of the bases in nucleic acids is discussed.


IT **93003-25-9**, Acetanilide, 2'-(1-acetylpyrazol-5-yl)-
(preparation of)

RN 93003-25-9 CAPLUS

CN Acetanilide, 2'-(1-acetylpyrazol-5-yl)- (7CI) (CA INDEX NAME)



L25 ANSWER 85 OF 88 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1963:81515 CAPLUS
DN 58:81515
OREF 58:13950f-g
TI Investigations in heterocycles. XII. The synthesis of pyrazolo[1,5-c]quinazolines
AU DeStevens, George; Halamandaris, Angela; Bernier, Marcel; Blatter, Herbert M.
CS CIBA Pharm. Co., Summit, NJ
SO Journal of Organic Chemistry (1963), 28, 1336-9
CODEN: JOCEAH; ISSN: 0022-3263
DT Journal
LA Unavailable
AB cf. CA 58, 523f. The facile rearrangement of 4-hydroxyquinoline and its derivs. in the presence of excess N2H4.H2O gives rise to 5-(o-aminophenyl)pyrazoles. These compds. in turn serve as intermediates in the synthesis of some new heterocycles, pyrazolo[1,5-c]quinazolines (I). The chemical and spectral properties of these substances are discussed.
IT **93003-25-9**, Acetanilide, 2'-(1-acetylpyrazol-5-yl)- (preparation of)
RN 93003-25-9 CAPLUS
CN Acetanilide, 2'-(1-acetylpyrazol-5-yl)- (7CI) (CA INDEX NAME)



L25 ANSWER 86 OF 88 CAPLUS COPYRIGHT 2004 ACS on STN

AN 1959:56397 CAPLUS

DN 53:56397

OREF 53:10188b-f

TI New antituberculosis agents. XXXVII. Thiosemicarbazones of oxo acids. 3. Thiosemicarbazones of aroylacetaes and their derivatives

AU Belzecki, Czeslaw; Urbanski, Tadeusz

SO Roczniki Chemii (1958), 32, 779-87

CODEN: ROCHAC; ISSN: 0035-7677

DT Journal

LA Unavailable

AB p-RC₆H₄C(:NNHCSNH₂)CH₂CO₂Et were prepared by the method above (R and m.p. given): NO₂ (I), 170-2°; OMe (II), 123-4°; Br (III), 172-3° (all from alc. and all melting with decomposition). 3-C₅H₄NC(:NNHCSNH₂)CH₂CO₂Et (IV), m. 153°, and 4-C₅H₄NC(:NNHCSNH₂)CH₂CO₂Et (V), m. 169-70°, were similarly prepared. Semicarbazones with R = NH₂ (VI), m. 182°, and R = NHAc (VII), m. 152°, were prepared by melting 0.1 mole thiosemicarbazide and 0.1 mole carbonyl compound together, heating at 105-15° until the H₂O was driven off, and working up. I-VII were cyclized by the method of B. and U. (ibid. 30, 781(1956)) to give p-R'C₆H₄C:N.N(CSNH₂).CO.CH₂ (R' and m.p. given): NO₂, 264-8°; NH₂, 224-6°; NHAc, 259-60°; OMe, 165°; Br, 251°; 3-pyridyl, 236°; and 4-pyridyl, 222-3°. The aroylacetic esters reacted with hydrazine to yield p-substituted 3-aryl-5-pyrazolones. When the substituents were NO₂, NH₂, NHAc, OMe, Br, 3-pyridyl, and 4-pyridyl, the m.ps. were 238-9°, 235-6°, 261-3°, 222-3°, 248-9°, 259-60°, and 278-9°, resp. The esters reacted with hydroxylamine to give p-substituted 3-aryl-5-isoxazolones. For the same substituents as above, the corresponding m.ps. were 161-3°, 182°, 190°, 143°, 141-3°, 151-3°, and 199°, resp. The tuberculostatic activity in vitro against M. tuberculosis BCG H37Rv and M. smegmatis was tested for all compds. The most efficient p-substituents in the thiosemicarbazones were OMe and Br, those in the thioformamidoarylpyrazolones were p-BrC₆H₄, and 3-pyridyl. When the thioformamide group was eliminated there was no influence of p-substituents.


IT 99844-13-0, Acetanilide, 4'-(5-oxo-2-pyrazolin-3-yl)-

108801-36-1, 2-Pyrazoline-1-carboxamide, 3-(p-acetamidophenyl)-5-oxothio-

(preparation of)

RN 99844-13-0 CAPLUS


CN Acetamide, N-[4-(4,5-dihydro-5-oxo-1H-pyrazol-3-yl)phenyl]- (9CI) (CA INDEX NAME)



RN 108801-36-1 CAPLUS

CN 2-Pyrazoline-1-carboxamide, 3-(p-acetamidophenyl)-5-oxothio- (6CI) (CA INDEX NAME)

09/773,736



L25 ANSWER 87 OF 88 CAPLUS COPYRIGHT 2004 ACS on STN

AN 1959:9371 CAPLUS

DN 53:9371

OREF 53:1747i,1748a-g

TI Vat dyes

IN Saftien, Karl; Anton, Ernst

PA Badische Anilin- & Soda-Fabrik Akt.-Ges.

DT Patent

LA Unavailable

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 923028		19550131	DE	
AB	<p>Vat dyes of intensive yellow, orange, red, or blue shades of good fastness properties and readily dyed in warm or hot vats, are obtained by mixing the chlorides of dicarboxylic acids of the structure HOOC-AXBCOOH, where A and B stand for the same or different aromatic groups and X for a 5- or 6-membered heterocyclic ring with ≥ 2 C atoms, with amino compds. of the anthraquinone series. For example, a mixture of the dichloride (I) of the 2,5-bis(p-carboxyphenyl)-1,3,4-oxadiazole 24.5, 1-aminoanthraquinone (II) 30.8, and dry PhNO_2 350 parts is heated at 150° for 3 hrs. with good stirring. After cooling, the product is filtered, washed with PhNO_2 and alc., and dried to give yellow needles, soluble in H_2SO_4, dyeing cotton yellow. I is prepared by oxidation of 2,5-bis(p-tolyl)-1,3,4-oxadiazole with chromic acid/glacial AcOH, followed by KMnO_4, and treatment of the intermediate with SOCl_2 in PhNO_2. Similarly are prepared (components, color of product, and color on cotton given):</p> <p>1-amino-5-benzamidoanthraquinone (III), I, yellow-red, reddish yellow; 4-amino-1,9-anthrapyrimidine, I, red-yellow, yellow; Na salt of 1-mercapto-2-aminoanthraquinone, I, yellow-brown, yellow (after treatment with alkaline NaOCl); I, 2-(1,4-diaminoanthraquinonyl)anthra[2,3]thiazole 5,10-dione, deep blue, blue; II, 2,5-bis(4-carboxyphenyl)-1,3,4-thiadiazole dichloride (IV), yellow, reddish yellow; IV, III, yellow-red, reddish yellow; II, 3,6-bis(4-carboxyphenyl)-1,2,4,5-tetrazine (V) and SOCl_2, yellow, yellow; II, the dichloride (VI) of 4,5-bis(4-carboxyphenyl)-4-imidazolin-2-one, red-yellow, yellow; II, the dichloride (VII) of 3,5-bis(4-carboxyphenyl)pyrazole, red-yellow, yellow; III, VII, orange, reddish yellow; II, SOCl_2, and 2,5-bis(4-carboxyphenyl)furan (VIII), orange, red-yellow; VIII, SOCl_2, III, yellow-red, blue-violet; III, SOCl_2, and 2-(p-carboxyphenyl)-5-(p-carboxybiphenyl)-1,3,4-oxadiazole (IX), orange, yellow; III, the m,m'-dicarboxylic acid dichloride isomer (X) of I, orange, yellow; and III, SOCl_2, and 2,5-bis(4-carboxyphenyl)-1,3,4-triazole (XI), red-yellow, yellow. IV is prepared from 2,5-di(p-tolyl)-1,3,4-thiadiazole (obtained by treatment of di(p-tolyl)hydrazine with PS_5) by oxidation with CrO_3 in glacial AcOH, then with KMnO_4 in aqueous Na_2CO_3 solution and by subsequent conversion of the dicarboxylic acid formed into the dichloride with SOCl_2. V is prepared by converting Me p-cyanobenzoate in Et_2O with EtOH and HCl into an intermediate which with $\text{H}_2\text{NNH}_2 \cdot \text{H}_2\text{SO}_4$ and alkali is changed into a V ester from which V is obtained by saponification with alc. KOH. VI is prepared by condensing p-toluoin with urea in glacial AcOH to give 4,5-di(p-tolyl)4-imidazolin-2-one which is converted into the dicarboxylic acid of VI by oxidation with CrO_3/glacial AcOH and KMnO_4. Chlorination with SOCl_2 yields VI. VII is obtained from bis(p-bromobenzoyl)methane which is converted into 3,5-bis(p-bromophenyl)pyrazole with $\text{H}_2\text{NNH}_2 \cdot \text{H}_2\text{O}$. Conversion with CuCN in pyridine yields 3,5-bis(p-cyanophenyl)pyrazole from which, after saponification with dilute</p>				

H₂SO₄, the dicarboxylic acid is obtained giving VII after treatment with SOCl₂. VIII is produced by conversion of 2,5-bis(p-bromophenyl)furan with CuCN into 2,5-bis(p-cyanophenyl)furan and saponification with dilute

H₂SO₄.H₂NNH₂


with 1 mole each of p-toluoyl chloride and p-tolylbenzoyl chloride gives 1-(p-toluoyl)-2-(p-methylphenylbenzoyl)hydrazine which is heated to 300°. The 2-(p-tolyl)-5-(p-methylbiphenyl)-1,3,4-oxadiazole formed is oxidized with CrO₃/glacial AcOH and KMnO₄ to IX. X is obtained by oxidation of 2,5-di(m-tolyl)-1,3,4-oxadiazole with CrO₃/glacial AcOH, reoxidation with KMnO₄, and conversion into the dichloride with SOCl₂. XI is produced from di(p-toluoyl)-1,3,4-triazole which is oxidized to XI with CrO₃/glacial AcOH and KMnO₄.

IT 120579-99-9, Anthraquinone, 1,1'-[pyrazole-3,5-diylbis(p-phenylenecarbonylimino)]bis[5-benzamido- 122316-74-9, Anthraquinone, 1,1'-[pyrazole-3,5-diylbis(p-phenylenecarbonylimino)]di-(preparation of)


RN 120579-99-9 CAPLUS

CN Anthraquinone, 1,1'-[pyrazole-3,5-diylbis(p-phenylenecarbonylimino)]bis[5-benzamido- (6CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 122316-74-9 CAPLUS
 CN Anthraquinone, 1,1'-[pyrazole-3,5-diylbis(p-phenylenecarbonylimino)]di-
 (6CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



L25 ANSWER 88 OF 88 CAPLUS COPYRIGHT 2004 ACS on STN

AN 1958:15814 CAPLUS

DN 52:15814

OREF 52:2866b-h

TI N- and C-Benzoylation of p-aminoacetophenone with methyl benzoate by sodium amide. Synthesis of β -diketones having p-acylamino and p-hydroxy groups

AU Hauser, Charles R.; Eby, Charles J.

CS Duke Univ., Durham, NC

SO Journal of Organic Chemistry (1957), 22, 909-12

CODEN: JOCEAH; ISSN: 0022-3263

DT Journal


LA Unavailable

OS CASREACT 52:15814

AB p-H₂NC₆H₄Ac (I) underwent N-benzoylation with NaNH₂ and BzOMe (II) to give p-benzoylacetophenone (III) which then underwent C-benzoylation with these reagents to give the corresponding β -diketone amide (IV). IV was cyclized with N₂H₄ (V) and CO(NH₂)₂ (VI) to give a pyrazole (VII) and pyrimidol (VIII), resp. Other acylations of ketone amides and the benzoylation of p-HOC₆H₄Ac (IX) were effected to form the corresponding β -diketones. These condensations furnish a significant extension of the Claisen method of synthesis of β -diketones. The mechanism was considered to involve intermediate dianions. I (13.5 g.) left 0.5 hr. with 0.10, 0.30, or 0.40 mole NaNH₂ in 350 ml. liquid NH₃, then during 5 min. 0.10, 0.20, or 0.30 mole II added in an equal volume Et₂O, the mixture stirred 1.5 hr., and the NH₃ removed with simultaneous addition of Et₂O, the mixture from equivalent amts. filtered, the solids triturated with 6N HCl, and dried gave 21.15 g. III, m. 199-201°; 10% unchanged I was recovered. In the expts. with excess NH₂Na and II the crude product was dissolved in hot MeOH and excess saturated aqueous CuAc₂ added, and the resulting

precipitate collected to give the Cu chelate of IV, m. 362° (decomposition). The Cu salt dissolved in concentrated H₂SO₄ and poured on ice gave free IV, m. 184.5-6° (alc.), gave a red test with FeCl₃. Evaporation of the mother liquors gave III. Thus, the yields of III and IV for the above reactions were (equivs. NaNH₂, equivs. II, and % yield of III and IV given): 1, 1, 89, 0; 3, 2, 46, 32; 4, 3, 21, 54. III (12 g.) left 15 min. with 0.15 mole NaNH₂ in 350 ml. NH₃, then treated with 13.6 g. II in Et₂O during 20 min., and left 1 hr., and worked up as above gave 8.9 g. IV. IV (1.7 g.) in 250 ml. MeOH treated dropwise with 4.8 g. V with heating, the heating continued 0.5 hr., the solution treated with 100 ml. H₂O, and cooled gave 1.5 g. 3-p-N-benzamidophenyl-5-phenylpyrazole (VII), m. 247-50°, gave a neg. test with FeCl₃. IV (3.43 g.), 70 ml. alc., and 0.96 g. VI refluxed 8 days with 11 ml. alc. 2.1N HCl gave 58% 4-p-benzamido-6-phenylpyrimidol (VIII).HCl, m. 297-9° (MeOH). NaNH₂ (0.15 mole) in 350 ml. liquid NH₃ with 11.9 g. III treated 20 min. with 10.2 g. EtCO₂Me in 50 ml. Et₂O, the NH₃ immediately replaced with Et₂O, left 24 hrs. at room temperature, and the product separated gave 2.9 g. 1-p-N-benzamidophenylpentane-1,3-dione, needles, m. 170.5-2.0° (95% alc.). p-N-Acetamidoacetophenone (8.85 g.) added to 0.15 mole NaNH₂ in NH₃, followed by 13.6 g. II, and the NH₃ replaced by Et₂O and refluxed 24 hrs. gave 2.85 g. 1-p-N-acetamidophenyl-3-phenylpropane-1,3-dione, m. 162-4° (C₆H₆). Similarly, using EtCO₂Me instead of II gave 13% 1-p-N-acetamidophenylpentane-1,3-dione, m. 135-6.5° (C₆H₆). Similarly, 8.65 g. IX treated in NaNH₂ and NH₃ with 17.3 g. II gave 3.30 g. 1-p-hydroxyphenyl-3-phenylpropane-1,3-dione, m. 154-6° (C₆H₆). Sodiaoacetophenone failed to undergo acylation with Me p-benzamidobenzoate or p-hydroxybenzoate in the presence of excess NaNH₂ under the above conditions.

IT 112248-32-5, Benzanilide, 4'-[5(or 3)-phenylpyrazol-3(or 5)-yl]-
(preparation of)
RN 112248-32-5 CAPLUS
CN Benzanilide, 4'-[5(or 3)-phenylpyrazol-3(or 5)-yl]- (6CI) (CA INDEX NAME)



=> => d his

(FILE 'HOME' ENTERED AT 07:04:03 ON 28 MAY 2004)

FILE 'REGISTRY' ENTERED AT 07:04:08 ON 28 MAY 2004

```

L1          STRUCTURE UPLOADED
L2          0 S L1 SSS SAM
L3          0 S L1 SSS FUL
L4          STRUCTURE UPLOADED
L5          37 S L4 SSS SAM
L6          SCREEN 1839
L7          SCREEN 2016 OR 2026 OR 2039 OR 2040 OR 2045 OR 2047
L8          STRUCTURE UPLOADED
L9          QUE L8 AND L6 NOT L7
L10         14 S L9 SSS SAM
L11         SCREEN 1839
L12         SCREEN 2016 OR 2026 OR 2039 OR 2040 OR 2045 OR 2047
L13         STRUCTURE UPLOADED
L14         QUE L13 AND L11 NOT L12
L15         9 S L14 SSS SAM
L16         1072 S L14 SSS FUL
L17         STRUCTURE UPLOADED
L18         21 S L17 SSS SAM SUB=L16
L19         452 S L17 SSS FUL SUB=L16
L20         STRUCTURE UPLOADED
L21         15 S L20 SSS SAM SUB=L16
L22         350 S L20 SSS FUL SUB=L16
L23         767 S L19 OR L22
L24         305 S L16 NOT L23

```

FILE 'CAPLUS' ENTERED AT 07:27:08 ON 28 MAY 2004

L25 88 S L24


FILE 'CAOLD' ENTERED AT 07:28:39 ON 28 MAY 2004

=> s l24


L26 4 L24

=> d l26 1-4 bib,hitstr


L26 ANSWER 1 OF 4 CAOLD COPYRIGHT 2004 ACS on STN
AN CA58:13950f CAOLD
TI heterocycles - (XII) synthesis of pyrazolo[1,5-c]quinazolines
AU De Stevens, George; Halamandaris, A.; Bernier, M.; Blatter, H. M.
IT **93003-25-9**
RN 93003-25-9 CAOLD
CN Acetanilide, 2'-(1-acetylpyrazol-5-yl)- (7CI) (CA INDEX NAME)



L26 ANSWER 2 OF 4 CAOLD COPYRIGHT 2004 ACS on STN
AN CA53:10187i CAOLD
TI new antituberculosis agents - (XXXVII-XXXVIII) thiosemicarbazones of oxo
acids (2) of aroyl fatty acids, (3) of aroylacetates and their derivs.
AU Belzecki, Czeslaw; Urbanski, T.
IT **99844-13-0 108801-36-1**
RN 99844-13-0 CAOLD
CN Acetamide, N-[4-(4,5-dihydro-5-oxo-1H-pyrazol-3-yl)phenyl]- (9CI) (CA
INDEX NAME)



RN 108801-36-1 CAOLD
CN 2-Pyrazoline-1-carboxamide, 3-(p-acetamidophenyl)-5-oxothio- (6CI) (CA
INDEX NAME)



on SIN

AN CA53:1747i CAOLD

AU Saftien, Karl; Anton, E.

PATENT NO.	KIND	DATE
------------	------	------

IT 120579-99-9 122316-74-9


CN Anthraquinone, 1,1'-[pyrazole-3,5-diylbis(p-phenylenecarbonylimino)]bis[5-benzamido- (6CI) (CA INDEX NAME)

O=C(NC1=CC=C(C=C1)C2=CC=CC=C2C3=CC=CC=C3C(=O)N4C=CC=CC4=O)C(=O)N5C=CC=CC=C5C(=O)N6C=CC=CC=C6C(=O)N7C=CC=CC=C7C(=O)N8C=CC=CC=C8C(=O)N9C=CC=CC=C9C(=O)N10C=CC=CC=C10C(=O)N11C=CC=CC=C11C(=O)N12C=CC=CC=C12C(=O)N13C=CC=CC=C13C(=O)N14C=CC=CC=C14C(=O)N15C=CC=CC=C15C(=O)N16C=CC=CC=C16C(=O)N17C=CC=CC=C17C(=O)N18C=CC=CC=C18C(=O)N19C=CC=CC=C19C(=O)N20C=CC=CC=C20C(=O)N21C=CC=CC=C21C(=O)N22C=CC=CC=C22C(=O)N23C=CC=CC=C23C(=O)N24C=CC=CC=C24C(=O)N25C=CC=CC=C25C(=O)N26C=CC=CC=C26C(=O)N27C=CC=CC=C27C(=O)N28C=CC=CC=C28C(=O)N29C=CC=CC=C29C(=O)N30C=CC=CC=C30C(=O)N31C=CC=CC=C31C(=O)N32C=CC=CC=C32C(=O)N33C=CC=CC=C33C(=O)N34C=CC=CC=C34C(=O)N35C=CC=CC=C35C(=O)N36C=CC=CC=C36C(=O)N37C=CC=CC=C37C(=O)N38C=CC=CC=C38C(=O)N39C=CC=CC=C39C(=O)N40C=CC=CC=C40C(=O)N41C=CC=CC=C41C(=O)N42C=CC=CC=C42C(=O)N43C=CC=CC=C43C(=O)N44C=CC=CC=C44C(=O)N45C=CC=CC=C45C(=O)N46C=CC=CC=C46C(=O)N47C=CC=CC=C47C(=O)N48C=CC=CC=C48C(=O)N49C=CC=CC=C49C(=O)N50C=CC=CC=C50C(=O)N51C=CC=CC=C51C(=O)N52C=CC=CC=C52C(=O)N53C=CC=CC=C53C(=O)N54C=CC=CC=C54C(=O)N55C=CC=CC=C55C(=O)N56C=CC=CC=C56C(=O)N57C=CC=CC=C57C(=O)N58C=CC=CC=C58C(=O)N59C=CC=CC=C59C(=O)N60C=CC=CC=C60C(=O)N61C=CC=CC=C61C(=O)N62C=CC=CC=C62C(=O)N63C=CC=CC=C63C(=O)N64C=CC=CC=C64C(=O)N65C=CC=CC=C65C(=O)N66C=CC=CC=C66C(=O)N67C=CC=CC=C67C(=O)N68C=CC=CC=C68C(=O)N69C=CC=CC=C69C(=O)N70C=CC=CC=C70C(=O)N71C=CC=CC=C71C(=O)N72C=CC=CC=C72C(=O)N73C=CC=CC=C73C(=O)N74C=CC=CC=C74C(=O)N75C=CC=CC=C75C(=O)N76C=CC=CC=C76C(=O)N77C=CC=CC=C77C(=O)N78C=CC=CC=C78C(=O)N79C=CC=CC=C79C(=O)N80C=CC=CC=C80C(=O)N81C=CC=CC=C81C(=O)N82C=CC=CC=C82C(=O)N83C=CC=CC=C83C(=O)N84C=CC=CC=C84C(=O)N85C=CC=CC=C85C(=O)N86C=CC=CC=C86C(=O)N87C=CC=CC=C87C(=O)N88C=CC=CC=C88C(=O)N89C=CC=CC=C89C(=O)N90C=CC=CC=C90C(=O)N91C=CC=CC=C91C(=O)N92C=CC=CC=C92C(=O)N93C=CC=CC=C93C(=O)N94C=CC=CC=C94C(=O)N95C=CC=CC=C95C(=O)N96C=CC=CC=C96C(=O)N97C=CC=CC=C97C(=O)N98C=CC=CC=C98C(=O)N99C=CC=CC=C99C(=O)N100C=CC=CC=C100C(=O)N101C=CC=CC=C101C(=O)N102C=CC=CC=C102C(=O)N103C=CC=CC=C103C(=O)N104C=CC=CC=C104C(=O)N105C=CC=CC=C105C(=O)N106C=CC=CC=C106C(=O)N107C=CC=CC=C107C(=O)N108C=CC=CC=C108C(=O)N109C=CC=CC=C109C(=O)N110C=CC=CC=C110C(=O)N111C=CC=CC=C111C(=O)N112C=CC=CC=C112C(=O)N113C=CC=CC=C113C(=O)N114C=CC=CC=C114C(=O)N115C=CC=CC=C115C(=O)N116C=CC=CC=C116C(=O)N117C=CC=CC=C117C(=O)N118C=CC=CC=C118C(=O)N119C=CC=CC=C119C(=O)N120C=CC=CC=C120C(=O)N121C=CC=CC=C121C(=O)N122C=CC=CC=C122C(=O)N123C=CC=CC=C123C(=O)N124C=CC=CC=C124C(=O)N125C=CC=CC=C125C(=O)N126C=CC=CC=C126C(=O)N127C=CC=CC=C127C(=O)N128C=CC=CC=C128C(=O)N129C=CC=CC=C129C(=O)N130C=CC=CC=C130C(=O)N131C=CC=CC=C131C(=O)N132C=CC=CC=C132C(=O)N133C=CC=CC=C133C(=O)N134C=CC=CC=C134C(=O)N135C=CC=CC=C135C(=O)N136C=CC=CC=C136C(=O)N137C=CC=CC=C137C(=O)N138C=CC=CC=C138C(=O)N139C=CC=CC=C139C(=O)N140C=CC=CC=C140C(=O)N141C=CC=CC=C141C(=O)N142C=CC=CC=C142C(=O)N143C=CC=CC=C143C(=O)N144C=CC=CC=C144C(=O)N145C=CC=CC=C145C(=O)N146C=CC=CC=C146C(=O)N147C=CC=CC=C147C(=O)N148C=CC=CC=C148C(=O)N149C=CC=CC=C149C(=O)N150C=CC=CC=C150C(=O)N151C=CC=CC=C151C(=O)N152C=CC=CC=C152C(=O)N153C=CC=CC=C153C(=O)N154C=CC=CC=C154C(=O)N155C=CC=CC=C155C(=O)N156C=CC=CC=C156C(=O)N157C=CC=CC=C157C(=O)N158C=CC=CC=C158C(=O)N159C=CC=CC=C159C(=O)N160C=CC=CC=C160C(=O)N161C=CC=CC=C161C(=O)N162C=CC=CC=C162C(=O)N163C=CC=CC=C163C(=O)N164C=CC=CC=C164C(=O)N165C=CC=CC=C165C(=O)N166C=CC=CC=C166C(=O)N167C=CC=CC=C167C(=O)N168C=CC=CC=C168C(=O)N169C=CC=CC=C169C(=O)N170C=CC=CC=C170C(=O)N171C=CC=CC=C171C(=O)N172C=CC=CC=C172C(=O)N173C=CC=CC=C173C(=O)N174C=CC=CC=C174C(=O)N175C=CC=CC=C175C(=O)N176C=CC=CC=C176C(=O)N177C=CC=CC=C177C(=O)N178C=CC=CC=C178C(=O)N179C=CC=CC=C179C(=O)N180C=CC=CC=C180C(=O)N181C=CC=CC=C181C(=O)N182C=CC=CC=C182C(=O)N183C=CC=CC=C183C(=O)N184C=CC=CC=C184C(=O)N185C=CC=CC=C185C(=O)N186C=CC=CC=C186C(=O)N187C=CC=CC=C187C(=O)N188C=CC=CC=C188C(=O)N189C=CC=CC=C189C(=O)N190C=CC=CC=C190C(=O)N191C=CC=CC=C191C(=O)N192C=CC=CC=C192C(=O)N193C=CC=CC=C193C(=O)N194C=CC=CC=C194C(=O)N195C=CC=CC=C195C(=O)N196C=CC=CC=C196C(=O)N197C=CC=CC=C197C(=O)N198C=CC=CC=C198C(=O)N199C=CC=CC=C199C(=O)N200C=CC=CC=C200C(=O)N201C=CC=CC=C201C(=O)N202C=CC=CC=C202C(=O)N203C=CC=CC=C203C(=O)N204C=CC=CC=C204C(=O)N205C=CC=CC=C205C(=O)N206C=CC=CC=C206C(=O)N207C=CC=CC=C207C(=O)N208C=CC=CC=C208C(=O)N209C=CC=CC=C209C(=O)N210C=CC=CC=C210C(=O)N211C=CC=CC=C211C(=O)N212C=CC=CC=C212C(=O)N213C=CC=CC=C213C(=O)N214C=CC=CC=C214C(=O)N215C=CC=CC=C215C(=O)N216C=CC=CC=C216C(=O)N217C=CC=CC=C217C(=O)N218C=CC=CC=C218C(=O)N219C=CC=CC=C219C(=O)N220C=CC=CC=C220C(=O)N221C=CC=CC=C221C(=O)N222C=CC=CC=C222C(=O)N223C=CC=CC=C223C(=O)N224C=CC=CC=C224C(=O)N225C=CC=CC=C225C(=O)N226C=CC=CC=C226C(=O)N227C=CC=CC=C227C(=O)N228C=CC=CC=C228C(=O)N229C=CC=CC=C229C(=O)N230C=CC=CC=C230C(=O)N231C=CC=CC=C231C(=O)N232C=CC=CC=C232C(=O)N233C=CC=CC=C233C(=O)N234C=CC=CC=C234C(=O)N235C=CC=CC=C235C(=O)N236C=CC=CC=C236C(=O)N237C=CC=CC=C237C(=O)N238C=CC=CC=C238C(=O)N239C=CC=CC=C239C(=O)N240C=CC=CC=C240C(O=C1C(=O)c2cc(NC(=O)c3ccccc3)ccc2C(=O)c4ccccc41


Page 241

CN Anthraquinone, 1,1'-[pyrazole-3,5-diylbis(p-phenylenecarbonylimino)]di-
(6CI) (CA INDEX NAME)


PAGE 1-A



PAGE 2-A



L26 ANSWER 4 OF 4 CAOLD COPYRIGHT 2004 ACS on STN
AN CA52:2866b CAOLD
TI N- and C-benzoylation of p-aminoacetophenone with Me benzoate by Na
amide-synthesis of β -diketones having p-acylamino and p-hydroxy
groups
AU Hauser, Charles R.; Eby, C. J.
IT **112248-32-5**
RN 112248-32-5 CAOLD
CN Benzanilide, 4'-[5(or 3)-phenylpyrazol-3(or 5)-yl]- (6CI) (CA INDEX NAME)



09/773,736

=> log y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

11.34

830.70

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

0.00

-60.98

STN INTERNATIONAL LOGOFF AT 07:29:06 ON 28 MAY 2004